US 8,906,962 B2Grant

Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

Issue Date:2014-12-09

•29 Claims

Abstract

A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

Metadata

Assignee

Duke University

Inventors

Mitchell A. deLong
John M. McIver
Robert S. Youngquist

Application Information

Application Number:US 14/034,372

Filing Date:2013-09-23

Priority Date:2000-03-31

Art Unit:1628

Classifications

IPC:

A61K31/16A61K31/21A61K31/215A61K31/33A61K31/38A61K31/425A61K31/435A61K31/54A61K31/559A61K8/365A61K8/37A61K8/49A61K31/19A61K31/381A61K31/5575A61Q7/00A61K45/06

Patent Drawings

This patent does not have any drawings.

Description

[0001] This application is a continuation of U.S. patent application Ser. No. 12/535,513, filed Aug. 4, 2009, which is a continuation of U.S. patent application Ser. No. 11/967,423, filed Dec. 31, 2007, now abandoned, which is a continuation of U.S. patent application Ser. No. 11/138,097, filed May 26, 2005, now U.S. Pat. No. 7,388,029, which is a divisional of U.S. patent Ser. No. 09/774,557, filed Jan. 31, 2001, now abandoned, which claims priority to U.S. Provisional Application No. 60/193,645, filed Mar. 31, 2000, all of which are incorporated hereby by reference in their entirety.

FIELD OF THE INVENTION

[0002] This invention relates to compositions and methods for treating hair loss in mammals. More particularly, this invention relates to compositions and methods for arresting or reversing hair loss, or both, and promoting hair growth.

BACKGROUND OF THE INVENTION

[0003] Hair loss is a common problem which is, for example, naturally occurring or chemically promoted through the use of certain therapeutic drugs designed to alleviate conditions such as cancer. Often such hair loss is accompanied by lack of hair re-growth which causes partial or full baldness.

[0004] Hair growth on the scalp does not occur continuously, but rather occurs by a cycle of activity involving alternating periods of growth and rest. This cycle is divided into three main stages; anagen, catagen, and telogen. Anagen is the growth phase of the cycle and is characterized by penetration of the hair follicle deep into the dermis with rapid proliferation of cells which are differentiating to form hair. The next phase is catagen, which is a transitional stage marked by the cessation of cell division, and during which the hair follicle regresses through the dermis and hair growth ceases. The next phase, telogen, is characterized as the resting stage during which the regressed follicle contains a germ with tightly packed dermal papilla cells. At telogen, the initiation of a new anagen phase is caused by rapid cell proliferation in the germ, expansion of the dermal papilla, and elaboration of basement membrane components. When hair growth ceases, most of the hair follicles reside in telogen and anagen is not engaged, thus causing the onset of full or partial baldness.

[0005] Attempts to invoke the re-growth of hair have been made by, for example, the promotion or prolongation of anagen. Currently, there are two drugs approved by the United States Food and Drug Administration for the treatment of male pattern baldness: topical minoxidil (marketed as ROGAINE® by Pharmacia & Upjohn), and oral finasteride (marketed as PROPECIA® by Merck & Co., Inc.). However, the search for efficacious hair growth inducers is ongoing due to factors including safety concerns and limited efficacy.

[0006] The thyroid hormone thyroxine (“T4”) converts to thyronine (“T3”) in human skin by deiodinase I, a selenoprotein. Selenium deficiency causes a decrease in T3 levels due to a decrease in deiodinase I activity; this reduction in T3 levels is strongly associated with hair loss. Consistent with this observation, hair growth is a reported side effect of administration of T4. See, e.g., Berman, “Peripheral Effects of L-Thyroxine on Hair Growth and Coloration in Cattle”, Journal of Endocrinology, Vol. 20, pp. 282-292 (1960); and Gunaratnam, “The Effects of Thyroxine on Hair Growth in the Dog”, J. Small Anim. Pract., Vol. 27, pp. 17-29 (1986). Furthermore, T3 and T4 have been the subject of several patent publications relating to treatment of hair loss. See, e.g., Fischer et al., DE 1,617,477, published Jan. 8, 1970; Mortimer, GB 2,138,286, published Oct. 24, 1984; and Lindenbaum, WO 96/25943, assigned to Life Medical Sciences, Inc., published Aug. 29, 1996.

[0007] Unfortunately, however, administration of T3 or T4, or both, to treat hair loss is often not practicable because these thyroid hormones can induce significant cardiotoxicity. See, e.g., Walker et al., U.S. Pat. No. 5,284,971, assigned to Syntex, issued Feb. 8, 1994 and Emmett et al., U.S. Pat. No. 5,061,798, assigned to Smith Kline & French Laboratories, issued Oct. 29, 1991.

[0008] In an alternative approach, prostaglandins have been proposed to promote hair growth because prostaglandins may have a similar benefit to thyroid hormones, i.e., increasing hair length and changing pigmentation. Naturally occurring prostaglandins (e.g., PGA₂, PGB₂, PGE₁, PGF_2α, and PGI₂) are C-20 unsaturated fatty acids. PGF_2α, the naturally occurring Prostaglandin F analog in humans, is characterized by hydroxyl groups at the C9 and C11 positions on the alicyclic ring, a cis-double bond between C5 and C6, and a trans-double bond between C13 and C14. PGF_2αhas the formula:

[0009]

[0010] Analogs of naturally occurring Prostaglandin F are known in the art. For example, see U.S. Pat. No. 4,024,179 issued to Bindra and Johnson on May 17, 1977; German Patent No. DT-002,460,990 issued to Beck, Lerch, Seeger, and Teufel published on Jul. 1, 1976; U.S. Pat. No. 4,128,720 issued to Hayashi, Kori, and Miyake on Dec. 5, 1978; U.S. Pat. No. 4,011,262 issued to Hess, Johnson, Bindra, and Schaaf on Mar. 8, 1977; U.S. Pat. No. 3,776,938 issued to Bergstrom and Sjovall on Dec. 4, 1973; P. W. Collins and S. W. Djuric, “Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogs”, Chem. Rev., Vol. 93, pp. 1533-1564 (1993); G. L. Bundy and F. H. Lincoln, “Synthesis of 17-Phenyl-18,19,20-Trinorprostaglandins: I. The PG₁Series”, Prostaglandin, Vol. 9 No. 1, pp. 1-4 (1975); W. Bartman, G. Beck, U. Lerch, H. Teufel, and B. Scholkens, “Luteolytic Prostaglandin: Synthesis and Biological Activity”, Prostaglandin, Vol. 17 No. 2, pp. 301-311 (1979); C. Iiljebris, G. Selen, B. Resul, J. Sternschantz, and U. Hacksell, “Derivatives of 17-Phenyl-18,19,20-trinorprostaglandin F_2α. Isopropyl Ester: Potential Antiglaucoma Agents”, Journal of Medicinal Chemistry, Vol. 38, No. 2, pp. 289-304 (1995).

[0011] Prostaglandins in general have a wide range of biological activities. For example, PGE₂has the following properties: a) regulator of cell proliferation, b) regulator of cytokine synthesis, c) regulator of immune responses and d) inducer of vasodilatation. Vasodilatation is thought to be one of the mechanisms of how minoxidil provides a hair growth benefit. In vitro results in the literature also indicate some anti-inflammatory properties of the prostaglandins. c.f.; Tanaka, H. Br J. Pharm., 116, 2298, (1995).

[0012] However, previous attempts at using prostaglandins to promote hair growth have been unsuccessful. Different prostaglandin analogs can bind to multiple receptors at various concentrations with a biphasic effect. Furthermore, administration of naturally occurring prostaglandins can cause side effects such as inflammation, surface irritation, smooth muscle contraction, pain, and bronchoconstriction. Therefore, it is an object of this invention to provide methods for using prostaglandin analogs to grow hair and to provide compositions that promote hair growth in humans and lower animals. It is a further object of this invention to provide a selection of appropriate prostaglandin analogs that will promote hair growth and that do not cause significant undesirable side effects.

SUMMARY OF THE INVENTION

[0013] This invention relates to compositions and methods for treating hair loss. The methods comprise administering the compositions comprising specific prostaglandin analogs that interact strongly with hair-selective receptors, such as the FP receptor. The choice of prostaglandin analog is important because the prostaglandin analogs must selectively activate the FP receptor and not activate any other receptors that would negate the effect of activating the FP receptor. The compositions comprise: component A) the prostaglandin analog, component B) a carrier, and optionally component C) an activity enhancer.

DETAILED DESCRIPTION OF THE INVENTION

[0014] This invention relates to compositions and methods using prostaglandin F analogs (“PGF's”) to treat hair loss in mammals. “Treating hair loss” includes arresting hair loss or reversing hair loss, or both, and promoting hair growth.

[0015] Publications and patents are referred to throughout this disclosure. All U.S. Patents cited herein are hereby incorporated by reference.

[0016] All percentages, ratios, and proportions used herein are by weight unless otherwise specified.

DEFINITION AND USAGE OF TERMS

[0017] The following is a list of definitions for terms, as used herein:

[0018] “Activate” means binding and signal transduction of a receptor.

[0019] “Acyl group” means a monovalent group suitable for acylating a nitrogen atom to form an amide or carbamate, an alcohol to form a carbonate, or an oxygen atom to form an ester group. Preferred acyl groups include benzoyl, acetyl, tert-butyl acetyl, para-phenyl benzoyl, and trifluoroacetyl. More preferred acyl groups include acetyl and benzoyl. The most preferred acyl group is acetyl.

[0020] “Aromatic group” means a monovalent group having a monocyclic ring structure or fused bicyclic ring structure. Monocyclic aromatic groups contain 5 to 10 carbon atoms, preferably 5 to 7 carbon atoms, and more preferably 5 to 6 carbon atoms in the ring. Bicyclic aromatic groups contain 8 to 12 carbon atoms, preferably 9 or 10 carbon atoms in the ring. Aromatic groups are unsubstituted. The most preferred aromatic group is phenyl. Bicyclic aromatic groups include ring systems wherein one ring in the system is aromatic. Preferred bicyclic aromatic groups are ring systems wherein both rings in the system are aromatic. Preferred aromatic rings include naphthyl and phenyl. The most preferred aromatic ring is phenyl.

[0021] “Carbocyclic group” means a monovalent saturated or unsaturated hydrocarbon ring. Carbocyclic groups are monocyclic. Carbocyclic groups contain 4 to 10 carbon atoms, preferably 4 to 7 carbon atoms, and more preferably 5 to 6 carbon atoms in the ring. Carbocyclic groups are unsubstituted. Preferred carbocyclic groups include cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. More preferred carbocyclic groups include cyclohexyl, cycloheptyl, and cyclooctyl. The most preferred carbocyclic group is cycloheptyl. Carbocyclic groups are not aromatic.

[0022] “FP agonist” means a compound that activates the FP receptor.

[0023] “FP receptor” means known human FP receptors, their splice variants, and undescribed receptors that have similar binding and activation profiles as the known human FP receptors. “FP” means the receptor is of the class which has the highest affinity for PGF_2αof all the naturally occurring prostaglandins. FP refers to a known protein.

[0024] “Halogen atom” means F, Cl, Br, or I. Preferably, the halogen atom is F, Cl, or Br; more preferably Cl or F; and most preferably F.

[0025] “Halogenated heterogenous group” means a substituted heterogenous group or a substituted heterocyclic group, wherein at least one substituent is a halogen atom. Halogenated heterogenous groups can have a straight, branched, or cyclic structure. Preferred halogenated heterogenous groups have 1 to 12 carbon atoms, more preferably 1 to 6 carbon atoms, and most preferably 1 to 3 carbon atoms. Preferred halogen atom substituents are Cl and F.

[0026] “Halogenated hydrocarbon group” means a substituted monovalent hydrocarbon group or a substituted carbocyclic group, wherein at least one substituent is a halogen atom. Halogenated hydrocarbon groups can have a straight, branched, or cyclic structure. Preferred halogenated hydrocarbon groups have 1 to 12 carbon atoms, more preferably 1 to 6 carbon atoms, and most preferably 1 to 3 carbon atoms. Preferred halogen atom substituents are Cl and F. The most preferred halogenated hydrocarbon group is trifluoromethyl.

[0027] “Heteroaromatic group” means an aromatic ring containing carbon and 1 to 4 heteroatoms in the ring. Heteroaromatic groups are monocyclic or fused bicyclic rings. Monocyclic heteroaromatic groups contain 5 to 10 member atoms (i.e., carbon and heteroatoms), preferably 5 to 7, and more preferably 5 to 6 in the ring. Bicyclic heteroaromatic rings contain 8 to 12 member atoms, preferably 9 or 10 in the ring. Heteroaromatic groups are unsubstituted. Bicyclic heteroaromatic groups include ring systems in which only one ring is aromatic. Preferred bicyclic heteroaromatic groups are ring systems in which both rings are aromatic. Preferred monocyclic heteroaromatic groups include thienyl, thiazolyl, purinyl, pyrimidyl, pyridyl, and furanyl. More preferred monocyclic heteroaromatic groups include thienyl, furanyl, and pyridyl. The most preferred monocyclic heteroaromatic group is thienyl. Preferred bicyclic heteroaromatic rings include benzothiazolyl, benzothiophenyl, quinolinyl, quinoxalinyl, benzofuranyl, benzimidazolyl, benzoxazolyl, indolyl, and anthranilyl. More preferred bicyclic heteroaromatic rings include benzothiazolyl, benzothiophenyl, and benzoxazolyl.

[0028] “Heteroatom” means an atom other than carbon in the ring of a heterocyclic group or the chain of a heterogeneous group. Preferably, heteroatoms are selected from the group consisting of nitrogen, sulfur, and oxygen atoms. Groups containing more than one heteroatom may contain different heteroatoms.

[0029] “Heterocyclic group” means a saturated or unsaturated ring structure containing carbon and 1 to 4 heteroatoms in the ring. No two heteroatoms are adjacent in the ring, and no carbon in the ring that has a heteroatom bonded to it also has a hydroxyl, amino, or thiol group bonded to it. Heterocyclic groups are not aromatic. Heterocyclic groups are monocyclic. Heterocyclic groups contain 4 to 10 member atoms (i.e., including both carbon atoms and at least 1 heteroatom), preferably 4 to 7, and more preferably 5 to 6 in the ring. Heterocyclic groups are unsubstituted. Preferred heterocyclic groups include piperzyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, and piperdyl.

[0030] “Heterogeneous group” means a saturated or unsaturated chain containing 1 to 18 member atoms (i.e., including both carbon and at least one heteroatom). No two heteroatoms are adjacent. Preferably, the chain contains 1 to 12 member atoms, more preferably 1 to 6. “Lower heterogeneous” means a heterogeneous group having 1 to 6, preferably 1 to 3, member atoms. The chain may be straight or branched. Preferred branched heterogeneous groups have one or two branches, preferably one branch. Preferred heterogeneous groups are saturated. Unsaturated heterogeneous groups have one or more double bonds, one or more triple bonds, or both. Preferred unsaturated heterogeneous groups have one or two double bonds or one triple bond. More preferably, the unsaturated heterogeneous group has one double bond. Heterogeneous groups are unsubstituted.

[0031] “Monovalent hydrocarbon group” means a chain of 1 to 18, preferably 1 to 12, carbon atoms. “Lower monovalent hydrocarbon group” means a monovalent hydrocarbon group having 1 to 6, preferably 1 to 3, carbon atoms. Monovalent hydrocarbon groups may have a straight chain or branched chain structure. Preferred monovalent hydrocarbon groups have one or two branches, preferably 1 branch. Preferred monovalent hydrocarbon groups are saturated. Unsaturated monovalent hydrocarbon groups have one or more double bonds, one or more triple bonds, or combinations thereof. Preferred unsaturated monovalent hydrocarbon groups have one or two double bonds or one triple bond; more preferred unsaturated monovalent hydrocarbon groups have one double bond.

[0032] “Pharmaceutically acceptable” means suitable for use in a human or other mammal.

[0033] “Prostaglandin” means a fatty acid derivative which has a variety of potent biological activities of a hormonal or regulatory nature.

[0034] “Protecting group” is a group that replaces the active hydrogen of a hydroxyl moiety thus preventing undesired side reaction at the hydroxyl moiety. Use of protecting groups in organic synthesis is well known in the art. Examples of protecting groups are found in Chapter 2 Protecting Groups in Organic Synthesis by Greene, T. W. and Wuts, P. G. M., 2^nded., Wiley & Sons, Inc., 1991. Preferred protecting groups include silyl ethers, alkoxymethyl ethers, tetrahydropyranyl, tetrahydrofuranyl, esters, and substituted or unsubstituted benzyl ethers.

[0035] “Safe and effective amount” means a quantity of a prostaglandin high enough to provide a significant positive modification of the subject's condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio).

[0036] “Selective” means having a binding or activation preference for a specific receptor over other receptors which can be quantitated based upon receptor binding or activation assays.

[0037] “Subject” means a living, vertebrate, hair- or fur-bearing animal such as a mammal (preferably human) in need of treatment.

[0038] “Substituted aromatic group” means an aromatic group wherein 1 to 4 of the hydrogen atoms bonded to carbon atoms in the ring have been replaced with other substituents. Preferred substituents include: halogen atoms, cyano groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, aromatic groups, substituted aromatic groups, or any combination thereof. More preferred substituents include halogen atoms, halogenated monovalent hydrocarbon groups, phenyl groups, and phenoxy groups. Preferred substituted aromatic groups include naphthyl. The substituents may be substituted at the ortho, meta, or para position on the ring, or any combination thereof. The preferred substitution pattern on the ring is ortho or meta. The most preferred substitution pattern is ortho.

[0039] “Substituted carbocyclic group” means a carbocyclic group wherein 1 to 4 hydrogen atoms bonded to carbon atoms in the ring have been replaced with other substituents. Preferred substituents include: halogen atoms, cyano groups, monovalent hydrocarbon groups, monovalent heterogeneous groups, substituted monovalent hydrocarbon groups, substituted heterogeneous groups, aromatic groups, substituted aromatic groups, or any combination thereof. More preferred substituents include halogen atoms, halogenated monovalent hydrocarbon groups, phenyl groups, and phenoxy groups.

[0040] “Substituted heteroaromatic group” means a heteroaromatic group wherein 1 to 4 hydrogen atoms bonded to carbon atoms in the ring have been replaced with other substituents. The substituents include halogen atoms, acyl groups, cyano groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, aromatic groups, substituted aromatic groups, heteroaromatic groups, substituted heteroaromatic groups, and any combination thereof. Preferred substituents include halogen atoms, cyano groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, phenyl groups, phenoxy groups, or any combination thereof. More preferred substituents include halogen atoms, halogenated hydrocarbon groups, monovalent hydrocarbon groups, halogenated heterogenous groups, and phenyl groups.

[0041] “Substituted heterocyclic group” means a heterocyclic group wherein 1 to 4 hydrogen atoms bonded to carbon atoms in the ring have been replaced with other substituents. Preferred substituents include: halogen atoms, cyano groups, monovalent hydrocarbon groups, substituted monovalent hydrocarbon groups, heterogeneous groups, substituted heterogeneous groups, aromatic groups, substituted aromatic groups, or any combination thereof. More preferred substituents include halogen atoms, halogenated hydrocarbon groups, phenyl groups, phenoxy groups, or any combination thereof. Substituted heterocyclic groups are not aromatic.

[0042] “Substituted heterogeneous group” means a heterogeneous group, wherein 1 to 4 of the hydrogen atoms bonded to carbon atoms in the chain have been replaced with other substituents. Preferably substituted heterogeneous groups are mono, di, or trisubstituted. Preferred substituents include halogen atoms, hydroxy groups, carboxy groups, aryloxy groups (e.g., phenoxy, chlorophenoxy, tolyloxy, methoxyphenoxy, benzyloxy, alkyloxycarbonylphenoxy, and acyloxyphenoxy), acyloxy groups (e.g., propionyloxy, benzoyloxy, and acetoxy), aromatic groups (e.g., phenyl and tolyl), substituted aromatic groups (e.g., alkoxyphenyl, alkoxycarbonylphenyl, and halophenyl), heterocyclic groups, heteroaromatic groups, substituted heterocyclic groups, and amino groups (e.g., amino, mono- and di-alkylamino having 1 to 3 carbon atoms, methylphenylamino, methylbenzylamino, alkanylamido groups of 1 to 3 carbon atoms, carbamamido, ureido, and guanidino).

[0043] “Substituted monovalent hydrocarbon group” means a monovalent hydrocarbon group wherein 1 to 4 of the hydrogen atoms bonded to carbon atoms in the chain have been replaced with other substituents. Preferred substituted monovalent hydrocarbon groups are mono, di, or trisubstituted. Preferred substituents include halogen atoms; lower monovalent hydrocarbon groups; hydroxy groups; aryloxy groups (e.g., phenoxy, chlorophenoxy, tolyloxy, methoxyphenoxy, benzyloxy, alkyloxycarbonylphenoxy, and acyloxyphenoxy); acyloxy groups (e.g., propionyloxy, benzoyloxy, and acetoxy); carboxy groups; monocyclic aromatic groups; monocyclic heteroaromatic groups; monocyclic carbocyclic groups, monocyclic heterocyclic groups, and amino groups (e.g., amino, mono- and di-alkanylamino groups of 1 to 3 carbon atoms, methylphenylamino, methylbenzylamino, alkanylamido groups of 1 to 3 carbon atoms, carbamamido, ureido, and guanidino).

Prostaglandins Used in the Invention

[0044] This invention relates to the use of prostaglandin F analogs (PGF's) to treat hair loss. Suitable PGF's can have a structure selected from the group consisting of:

[0045]

The PGF can also be selected from the group consisting of pharmaceutically acceptable salts and hydrates of the structures above; biohydrolyzable amides, esters, and imides of the structures above; and optical isomers, diastereomers, and enantiomers of the structures above. Thus, at all stereocenters where stereochemistry is not defined (C₁₁, C₁₂, and C₁₅), both epimers are envisioned. Preferred stereochemistry at all such stereocenters of the compounds of the invention mimic that of naturally occurring PGF_2α. A combination of two or more PGF's can also be used.

[0046] R¹is selected from the group consisting of C(O)OH, C(O)NHOH, C(O)OR³, CH₂OH, S(O)₂R³, C(O)NHR³, C(O)NHS(O)₂R⁴, tetrazole, a cationic salt moiety, a pharmaceutically acceptable amine or ester comprising 2 to 13 carbon atoms, and a biometabolizable amine or ester comprising 2 to 13 atoms. Preferably, R¹is selected from the group consisting of CO₂H, C(O)NHOH, CO₂R³, C(O)NHS(O)₂R⁴, and tetrazole. More preferably, R¹is selected from the group consisting of CO₂H and CO₂R³.

[0047] R²is selected from the group consisting of a hydrogen atom, a lower heterogenous group, and lower monovalent hydrocarbon groups. Preferably, R²is a hydrogen atom.

[0048] R³is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group. Preferably, R³is selected from the group consisting of methyl, ethyl, and isopropyl

[0049] R⁴is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group. Preferably, R⁴is a phenyl group.

[0050] X is divalent. X is selected from the group consisting of —C≡C—, a covalent bond, —CH═C═CH—, —CH═CH—, —CH═N—, —C(O)—, —C(O)Y—, —(CH₂)_n—, wherein n is 2 to 4, —CH₂NH—, —CH₂S—, and —CH₂O—.

[0051] Y is selected from the group consisting of O, S, and NH.

[0052] Z is selected from the group consisting of a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group.

[0053] Preferably, when X is a covalent bond, Z is selected from the group consisting of an aromatic group, a heteroaromatic group, a substituted aromatic group, and a substituted heteroaromatic group. More preferably, when X is a covalent bond, Z is a bicyclic heteroaromatic group.

[0054] Preferably, when X is —C≡C—, Z is a monocyclic aromatic group. More preferably, when X is —C≡C—, Z is selected from the group consisting of furanyl, thienyl, and phenyl.

[0055] Bonds shown as dashed lines in the second structure above indicate that those bonds may optionally be double or triple bonds. For example, when R¹is C(O)OH in the structure:

[0056]

The bond at the C2-C3 position may be a single bond or a double bond. The bond at the C5-C6 position may be a single, double, or triple bond. The bond at the C13-C14 position may be a single, double, or triple bond.

[0057] Examples of PGF's' having the structure:

[0058]

which are suitable for component A) are shown below in Tables 1 and 2.

[0059]

TABLE 1

Examples of Suitable PGF's for Component A)


	13,14-dihydro-16,17-Z-didehyro-17-
	(2-fluorophenyl)-17-trinor PGF_1α



	13,14-dihydro-16,17-E-didehyro-17-
	(2-fluorophenyl)-17-trinor PGF_1α



	13,14-dihydro-E-16,17-didehyro-17-
	phenyl-17-trinor PGF_1α



	13,14-dihydro-E-16,17-didehyro-17-
	(2-fluoro-4-methylphenyl)-17-trinor PGF_1α



	13,14-dihydro-E-16,17-didehyro-17-
	(2,4-dichlorophenyl)-17-trinor PGF_1α



	13,14-dihydro-E-16,17-didehyro-17-
	(2-fluoro-5-chlorophenyl)-17-trinor PGF_1α



	13,14-dihydro-E-16,17-didehyro-17-
	(2,5-difluorophenyl)-17-trinor PGF_1α



	13,14-dihydro-E-16,17-didehyro-17-
	(2-fluoro-3-methoxyphenyl)-17-trinor PGF_1α



	13,14-dihydro-16,17-didehyro-17-(4-
	fluorophenyl)-17-trinor PGF_1α



	13,14-dihydro-E-16,17-didehyro-17-
	(2-fluoro-3-chlorophenyl)-17-trinor PGF_1α



	13,14-dihydro-16,17-didehyro-17-
	(3-fluorophenyl)-17-trinor PGF_1α



	13,14-dihydro-E-16,17-didehyro-17-
	(3-trifluoromethylphenyl)-17-trinor PGF_1α



	13,14-dihydro-16,17,17,18-dienyl-18-
	phenyl-18-dinor PGF_1α



	13,14-dihydro-16,17,17,18-dienyl-18-
	(2,4-difluorophenyl)-18-dinor PGF_1α



	13,14-dihydro-16,17,17,18-dienyl-18-
	(4-methoxyphenyl)-18-dinor PGF_1α



	13,14-dihydro-16,17,17,18-dienyl-
	18-(2-fluorophenyl)-18-dinor PGF_1α



	13,14-dihydro-16,17,17,18-dienyl-
	18-(3-trifluoromethylphenyl)-18-dinor PGF_1α



	13,14-dihydro-16,17-didehydro-17-(2-fluorophenyl)-
	17-trinor PGF_1α 1-hydroxamic acid



	13,14-dihydro-16,17,17,18-dienyl-18-
	phenyl-18-dinor PGF_2α 1-hydroxamic acid



	13,14-dihydro-16-oxo-16-phenyl-16-
	tetranorPGF_1α



	13,14-dihydro-16,17-didehydro-17-3-fluorophenyl-
	17-trinor PGF_1α 1-N-methanesulfonamide



	13,14-dihydro-16-oxo-16-(3,5-
	difluorophenyl)-16-tetranor PGF_1α



	13,14-dihydro-16-oxo-16-(2-furanyl)-
	16-tetranor PGF_1α



	13,14-dihydro-16-oxo-16-(6-fluorobenzo-
	[b]-furanyl-16-(tetranor PGF_1α



	13,14-dihydro-16-oxo16-(2-
	benzothiazolyl)-16-tetranor PGF_1α



	13,14-dihydro-16-oxo-16-(3-chloro-
	5-methylphenyl)-16-tetranor PGF_1α



	13,14-dihydro-16-oxo-16-(2-
	benzo[b]thienyl)-16-tetranor PGF_1α



	13,14-dihydro-16-oxo-16-(3,5-difluorophenyl)-
	16-tetranor PGF_1α 1-hydroxamic acid



	13,14-dihydro-16-oxo-16-(4-methylphenyl)-
	16-tetranor PGF_1α 1-hydroxamic acid



	13,14-dihydro-16-oxo-17-aza-17-
	phenyl-17-trinor PGF_1α



	13,14-dihydro-16-oxo-17-aza-17-(2-
	furyl)-17-trinor PGF_1α



	13,14-dihydro--16-oxo-16-(2-benzo[b]thienyl)-
	16-tretranor PGF_1α 1-N-methanesulfonamide



	13,14-dihydro-16-oxo-17-aza-17-
	(3,4-difluorophenyl)-17-trinor PGF_1α



	13,14-dihydro-16-oxo-17-aza-17-(2-
	fluorophenyl)-17-trinor PGF_1α



	13,14-dihydro-16-oxo-16-phenoxy-16-
	tetranor PGF_1α



	13,14-dihydro-16-oxo-16-(3-
	trifluoromethylphenoxy)-16-tetranor
	PGF_1α



	13,14-dihydro-16-oxo-17-amino-17-
	(3-chlorophenyl)-17-trinor PGF_1α
	1-hydroxamic acid:



	13,14-dihydro-16-oxo-16-(2-
	fluorophenoxy)-16-tetranor PGF_1α



	13,14-dihydro-16-oxo-17-aza-17-
	(3,4-difluorophenyl)-17-trinor
	PGF_1α 1-hydroxamic acid



	13,14-dihydro-16-oxo-17-amino-17-
	phenyl-17-trinor PGF_1α 1-methane
	sulfonamide



	13,14-dihydro-16,17-didehydro-17-
	aza-17-phenyl-17-trinor PGF_1α



	13,14-dihydro-16,17-didehydro-17-
	aza-17-(2-furanyl)-17-trinor PGF_1α



	13,14-dihydro-16,17-didehydro-17-
	aza-17-(3-fluorophenyl)-17-trinor PGF_1α



	13,14-dihydro-16,17-didehydro-17-
	aza-17-(2-fluorophenyl)-17-trinor PGF_1α



	13,14-dihydro-16-oxo-17-aza--17-
	(4-phenylphenyl)-17-trinor PGF_1α



	13,14-dihydro-16,17-didehydro-17-aza-17-
	(2-furanyl)-17-trinor PGF_1α 1-hydroxamic acid



	13,14-dihydro-16,17-didehydro-17-
	aza-17-(3-chlorophenyl)-17-trinor
	PGF_1α 1-hydroxamic acid



	13,14-dihydro-16,17-didehydro-17-
	aza-17-(2-thienyl)-17-trinor PGF_1α
	1-methanesulfonamide

[0060] Where Me in the table above represents a methyl group.

[0061] The PGF's in Table 1 can be prepared using conventional organic syntheses. Preferred syntheses are carried out using reaction schemes 1, 2, and 3. Scheme 1 describes a general reaction scheme for making PGFs wherein X is —CH═CH— (Formula I) or —CH═C═CH— (Formula II). Scheme 2 describes a general reaction scheme for making PGFs wherein X is —C(O)— (Formula III) or —C(O)Y— (Formula IV). Scheme 3 describes a general reaction scheme for making PGFs wherein X is —CH═N— (Formula V).

[0062]

[0063] In Scheme 1, R¹and Z are as defined above. The methyl 7(3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl) heptanoate (S1a) depicted as starting material for Scheme 1 is commercially available (such as from Sumitomo Chemical or Cayman Chemical).

[0064] In Scheme 1, methyl 7-(3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl) heptanoate (S1a) is reacted with a silylating agent and base in a solvent that will allow the silylation to proceed. Preferred silylating agents include tert-butyldimethylsilyl chloride and tert-butyldimethylsilyl trifluoromethanesulphonate. The most preferred silylating agent is tert-butyldimethylsilyl trifluoromethanesulphonate. Preferred bases include triethylamine, trimethylamine, and 2,6-lutidine. More preferred bases include triethylamine and 2,6-lutidine. The most preferred base is 2,6-lutidine. Preferred solvents include halogenated hydrocarbon solvents with dichloromethane being the most preferred solvent. The reaction is allowed to proceed at a temperature of preferably −100° C. to 100° C., more preferably −80° C. to 80° C., and most preferably −70° C. to 23° C.

[0065] The resulting silylated compound is isolated by methods known to one of ordinary skill in the art. Such methods include extraction, solvent evaporation, distillation, and crystallization. Preferably, the silyl ether is purified after isolation by distillation under vacuum.

[0066] The silylated compound is then reacted with the cuprate generated via Grignard formation of the appropriate alkenyl bromide as disclosed, for example, in the following references: H. O. House et. al., “The Chemistry of Carbanions: A Convenient Precursor for the Generation of Lithium Organocuprates”, J. Org. Chem. Vol. 40 (1975) pp. 1460-69; and P. Knochel et. al., “Zinc and Copper Carbenoids as Efficient and Selective a′/d′ Multicoupling Reagents”, J. Amer. Chem. Soc. Vol. 111 (1989) p. 6474-76. Preferred alkenyl bromides include 4-bromo-1-butene, 4-bromo-1-butyne, 4-bromo-2-methyl-1-butene, and 4-bromo-2-ethyl-1-butene. The most preferred alkenyl bromide is 4-bromo-1-butene. Preferred solvents include ethereal solvents, of which diethyl ether and tetrahydrofuran are preferred. The most preferred solvent is tetrahydrofuran. The Grignard reagent is allowed to form at a temperature of 100° C. to 23° C., more preferably 85° C. to 30° C., and most preferably 75° C. to 65° C. The reaction time is preferably 1 to 6 hours, more preferably 2 to 5 hours, and most preferably 3 to 4 hours.

[0067] Once the Grignard reagent is formed, the cuprate is generated from the alkenyl magnesium species. The temperature range for cuprate formation is −100° C. to 0° C. The preferred temperature range is −80° C. to −20° C. The more preferred temperature range is −75° C. to −50° C. The preferred reaction time is 30 minutes to 6 hours, more preferably 45 minutes to 3 hours. The most preferred reaction time is 1 to 1.5 hours.

[0068] The alkene thus formed is isolated by methods known to one of ordinary skill in the art. Such methods include extraction, solvent evaporation, distillation, and crystallization. Preferably, the alkene is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 10% EtOAc/hexanes as the eluent. (EtOAc represents ethyl acetate.)

[0069] The alkene is then reacted with a hydride reducing agent and a polar, protic solvent to give the C-9 alcohol. Preferred reducing agents include lithium aluminum hydride, sodium borohydride, and L-selectride. More preferred reducing agents include sodium borohydride, and L-selectride. The most preferred reducing agent is sodium borohydride. Preferred solvents include methanol, ethanol, and butanol. The most preferred solvent is methanol. The reduction is carried out at a temperature of −100° C. to 23° C. The preferred temperature range is −60° C. to 0° C. The most preferred temperature range is −45° C. to −20° C.

[0070] The resulting alcohol is isolated by methods known to one of ordinary skill in the art. Such methods include extraction, solvent evaporation, distillation, and crystallization. Preferably, the alcohol is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

[0071] The resultant alcohol can be protected as described previously herein. Preferred silylating agents in this case also include tert-butyldimethylsilyl chloride and tert-butyldimethylsilyl trifluoromethanesulfonate. The most preferred silylating agent is tert-butyldimethylsilyl trifluoromethanesulfonate. Preferred bases include triethylamine, trimethylamine, and 2,6-lutidine. More preferred bases include triethylamine and 2,6-lutidine. The most preferred base is 2,6-lutidine. Preferred solvents include halogenated hydrocarbon solvents with dichloromethane being the most preferred solvent. The reaction is allowed to proceed at a temperature of preferably −100° C. to 100° C., more preferably −80° C. to 80° C., and most preferably −70° C. to 23° C.

[0072] The resulting silylated compound, S1b is isolated by methods known to one of ordinary skill in the art. Such methods include extraction, solvent evaporation, distillation, and crystallization. Preferably, the silyl ether is purified after isolation by distillation under vacuum, giving compound S1b.

[0073] The protected alcohol is then treated with a form of osmium and sodium periodate in a solvent in which both are soluble. Preferred forms of osmium include osmium tetraoxide and potassium osmate. Preferred solvent systems include 1:1 mixtures of acetic acid and water and 1:1:2 mixtures of water, acetic acid and THF. (THF represents tetrahydrofuran.) The result of this treatment is the aldehyde, S1c.

[0074] The compound S1c is isolated by methods known to one of ordinary skill in the art. Such methods include extraction, solvent evaporation, distillation, and crystallization. Preferably, S1c is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

[0075] The key intermediate aldehyde depicted as S1c can be reacted with a variety of unsaturated alkenyl anion nucleophiles to provide the C-9 and C-11-protected 13,14-dihydro-prostaglandin F_1αderivatives.

[0076] The resulting compounds can be isolated, but are generally deprotected using techniques known to one of ordinary skill in the art, and optionally, manipulated at C-1 to provide the desired acid derivative at R¹. For example, the condensation of a methyl ester with an amine or a hydroxylamine provides an amide or a hydroxamic acid compound, respectively. After any such manipulation at C-1, the compounds are isolated as the final 13,14-dihydro-15-substituted-15-pentanor prostaglandin F_1αderivative, Formula I.

[0077] Compounds depicted by Formula II can be made directly from intermediate S1c in a manner similar to that for compounds depicted by Formula I substituting the appropriate allene anion. With allene nucleophiles, the reaction is carried out preferably at −80° C. to 0° C., more preferably −80° C. to −20° C., and most preferably −80° C. to −40° C. Preferred bases for the reaction include n-butyl lithium, s-butyl lithium, and t-butyl lithium. The most preferred base is n-butyl lithium. Preferred solvents for the reaction are ether solvents. Preferred solvents include diethyl ether, and tetrahydrofuran. The most preferred solvent is tetrahydrofuran. With heterocyclic nucleophiles, preferred solvents include ethereal solvents. More preferred ethereal solvents include diethyl ether, dibutyl ether and tetrahydrofuran. The most preferred ethereal solvent is tetrahydrofuran. After isolation, similar C-1 manipulations and/or deprotection of the functional groups ensues using techniques known to one of ordinary skill in the art.

[0078]

[0079] In Scheme 2, R¹, Y, and Z are as defined above. The protected alcohol S1b (from Scheme 1) is treated with a hydroborating reagent in an ethereal solvent, followed by oxidative removal of the boron reagent with a suitable oxidant to give a compound of the type S2a. Preferred hydroborating reagents include monochloroborane-dimethylsulfide, diborane, borane-tetrahydrofuran and borane-dimethylsulfide. The most preferred hydroborating reagent is borane-dimethylsulfide. Preferred ethereal solvents include THF and diethyl ether. The most preferred solvent is THF. The reaction is carried out from about 1 to about 24 hours at a temperature of about −20° C. to about +30° C. The preferred temperature range is about 0° C. to about +20° C. The hydroborated product of this reaction may then be oxidatively removed to the alcohol using alkaline hydrogen peroxide (See Boranes in Organic Chemistry, H. C. Brown, Cornell University Press, Ithaca, N.Y. 1972, pp. 321-325), which may then be oxidized to either the aldehyde (W═H) or to the acid (W═OH) using methods known to one of ordinary skill in the art. Alternatively, the hydroborated product may be directly oxidized to the aldehyde or acid by treatment with chromic acid or a Cr(VI) salt. Such salts include pyridinium chlorochromate (PCC) and dichlorochromate. See Brown, H. C.; Kulkarni, Rao, and Patil, Tetrahedron, 1986, 45515. The preferred method is treatment of the hydroborated product with PCC in dichloromethane at room temperature. The result of these manipulations is a compound of the type S2a.

[0080] The compound S2a is isolated by methods known to one of ordinary skill in the art. Such methods include extraction, solvent evaporation, distillation, and crystallization. Preferably, S2a is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent with 0.1% acetic acid added if W═OH.

[0081] The key intermediate aldehyde depicted as S2a can be reacted with a variety unsaturated carbon nucleophiles to provide the C-9 and C-11-protected 13,14-dihydro-16-tetranor prostaglandin F_1αderivatives of Formula III.

[0082] With aromatic and heteroaromatic nucleophiles, the reaction is carried out preferably at −80° C. to 0° C., more preferably −80° C. to −20° C., and most preferably −80° C. to −40° C. Preferred bases for the reaction include n-butyl lithium, s-butyl lithium, lithium diisopropylamide, and t-butyl lithium. The most preferred base is n-butyl lithium. Preferred solvents for the reaction are ether solvents. Preferred solvents include diethyl ether, and tetrahydrofuran. The most preferred solvent is tetrahydrofuran. With heterocyclic nucleophiles, preferred solvents include ethereal solvents. More preferred ethereal solvents include diethyl ether, dibutyl ether and tetrahydrofuran. The most preferred ethereal solvent is tetrahydrofuran.

[0083] The resulting alcohol can be isolated, but is generally oxidized as a crude isolate. The oxidation of benzylic alcohols to benzylic ketones is well known in the art. The preferred reagents to effect this reaction include KMnO₄, MnO₂, chromic acid, Jones' reagent, Collins' reagent, and PCC. The most preferred method is oxidation at room temperature in dichloromethane with PCC for about 4 hours. The ketones are isolated by column chromatography using 20% hexanes/ethyl acetate as solvent. The ester is then removed using standard conditions. See Greene and Wuts, Protecting Groups in Organic Synthesis, Wiley Interscience, NY pp. 224-276. The free acid is then treated with 2.1 equivalents of a strong nitrogen base to effect deprotonation both of the acid and adjacent to the benzylic ketone. Such bases include LDA. This enolate is reacted with a peroxidizing agent which has the effect of oxidizing the compound to deliver the alpha-hydroxy ketone. Such reagents include meta-chloroperoxybenzoic acid, dimethyl dioxirane, Davis' reagent and peracetic acid. The crude product may be isolated or the remaining protecting groups may be removed. At this point manipulation of the acid at C-1 may take place. For example, re-esterifying, making the amide, the hydroxamic acid or the sulfonamide using methods known to one of ordinary skill in the art may be performed to yield compounds according to Formula III.

[0084] Compounds depicted by Formula IV can be made from intermediate S2b. In this case, condensation of the free acid is readily achieved with a variety of alcohols and amines, either by the use of coupling agents such as dicyclohexylcarbodiimide (“DCC”), or by activating the acid with, for example, oxalyl chloride. Following this is the selective removal of the methyl esters as described in Greene and Wuts, Protecting Groups in Organic Synthesis, Wiley Interscience, NY pp. 224-276, and the oxidation of the ester enolates using the same technique described above for the ketone intermediates. Similarly, as described above, the remaining protecting groups are removed and the desired manipulation of C-1 is effected, yielding compounds of Formula IV.

[0085]

[0086] In Scheme 3, R¹and Z are as defined above. The alkene S1b (from Scheme 1) is treated with an osmium salt and with an optional catalyst reoxidant, preferably N-methyl morpholine N-oxide (“NMO”), to give the diol. This diol is isolated by extraction and purified by silica gel chromatography. The diol is then oxidized selectively to the alpha hydroxy aldehyde. This may be accomplished in several ways. For example, a selective oxidant such as DMSO-oxalyl chloride may be used. (“DMSO” represents dimethylsulfoxide.) Alternatively, the primary alcohol may be selectively protected, then the secondary alcohol protected, then the protection on the primary alcohol may then be removed and the alcohol oxidized as described above in Scheme II. However, the preferred method is the addition of a o-bromo-benzyl bromide protecting group, which can be removed with concomitant oxidation by tributyl tin hydride and like reagents. This technique yields compounds of the type S3a, wherein Q=H. From this step follows the condensation of the aldehyde with an amine to form an imine of the type S3b. Appropriate removal of protecting groups and manipulation of C-1 as stated above in Schemes I and II yields compounds of Formula V.

[0087]

TABLE 2

Examples of Suitable PGF's

13,14-dihydro-15-(2-benzothienyl)-15-
pentanor PGF_1α



13,14-dihydro-15-(2-benzothiazolyl)-
15-pentanor PGF_1α



13,14-dihydro-15-(8-fluoro-2-
benzothiazolyl)-15-pentanor PGF_1α



13,14-dihydro-16,17-ynyl-17-(2,3-
difluorophenyl)-17-trinor
PGF_1α



13,14-dihydro-16,17-ynyl-17-(3,4-
difluorophenyl)-17-trinor PGF_1α



13,14-dihydro-16,17-ynyl17-(2,5-
difluorophenyl)-17-trinor PGF_1α



13,14-dihydro-16,17-ynyl-17-(3,5-
difluorophenyl)-17-trinor
PGF_1α



13,14-dihydro-15-(6-fluoro-2-
benzothienyl)-15-pentanor PGF_1α



3,14-dihydro-16,17-ynyl-17-(2,4-
difluorophenyl)-17-trinor PGF_1α



13,14-dihydro-16,17-ynyl-17-(2-
fluoro-4-methylphenyl)-17-trinor
PGF_1α



13,14-dihydro-16,17-ynyl-17-phenyl-
17-trinor PGF_1α isopropyl ester



13,14-dihydro-16,17-ynyl-17-(3-
fluorophenyl)-17-trinor PGF_1α methyl ester



13,14-dihydro-16,17-ynyl-17-(4-
chlorophenyl)-17-trinor
PGF_1α



13,14-dihydro-16,17-ynyl-17-(4-
fluorophenyl)-17-trinor PGF_1α ethyl ester



13,14-dihydro-15-(5-fluoro-2-
benzothiazolyl)-15-pentanor PGF_1α
isopropyl ester



13,14-dihydro-16,17-ynyl-17-(2-
fluorophenyl)-17-trinor PGF_1α methyl
ester



13,14-dihydro-16,17-ynyl-17-(4-
phenyl-phenyl)-17-trinor PGF_1α



13,14-dihydro-16,17-ynyl-17-(2-
chlorophenyl)-17-trinor
PGF_1α



13,14-dihydro-16,17-ynyl-17-(2-
fluorophenyl)-17-trinor
PGF_1α



13,14-dihydro-16,17-ynyl-18-phenyl-
18-dinor PGF_1α



13,14-dihydro-16,17-ynyl-17-(4-
methylphenyl)-17-trinor PGF_1α



13,14-dihydro-15-phenyl-15-pentanor
PGF_1α



13,14-dihydro-15-(4-
trifluoromethylphenyl)-15-pentanor
PGF_1α



13,14-dihydro-16,17-ynyl-18-(2-
fluorophenyl)-18-dinor PGF_1α



13,14-dihydro-15-(4-methylphenyl)-
15-pentanor PGF_1α



13,14-dihydro-15-(3-
trifluoromethylphenyl)-15-pentanor
PGF_1α



13,14-dihydro-15-(2-fluorophenyl)-15-
pentanor PGF_1α



13,14-dihydro-15-(3-chloro-4-fluoro-6-
methylphenyl)-15pentanor PGF_1α



13,14-dihydro-15-(2-chlorophenyl)-15-
pentanor PGF_1α



13,14-dihydro-15-(3,5 difluorophenyl)-
15-pentanor PGF_1α ethyl ester



13,14-dihydro-15-(3-pyridinyl)-15-
pentanor PGF_1α



13,14-dihydro-15-(4-phenylphenyl)-
15-pentanor PGF_1α methyl ester



13,14-dihydro-15-S-(2-fluorophenyl)-
15-pentanor PGF_1α



13,14-dihydro-15-(3-fluoro-4-pyridyl)-
15-pentanor PGF_1α isopropyl ester



13,14-dihydro-15-(benzo(b)thiophen-
5-yl)-15-pentanor PGF_1α



13,14-dihydro-15-S-(2-
fluoronaphthyl)-15-pentanor PGF_1α



13,14-dihydro-15-(6-methylnaphth-
2-yl)-15-pentanor PGF_1α



13,14-dihydro-15-(6-benzothiazol-5-
yl)-15-pentanor PGF_1α



13,14-dihydro-15-(benzofuran-5-yl)-
15-pentanor PGF_1α methyl ester



13,14-dihydro-15-(8-fluoro-2-
naphthyl)-15-pentanor PGF_1α



13,14-dihydro-15-(1-fluoro-3-
trifluoromethyl-2-naphthyl)-15-
pentanor PGF_1α isopropyl ester



13,14-dihydro-15-(5-fluoronaphth-1-
yl)-15-pentanor PGF_1α



13,14-dihydro-15-(8-trifluoromethyl-
2-naphthyl)-15-pentanor PGF_1α



13,14-dihydro-16,17-ynyl-17-(2-
fluorophenyl)-17-trinor PGF_1α 1-
hydroxamic acid



13,14-dihydro-15-(benzothiazolyl)-15-
pentanor PGF_1α 1-hydroxamic acid



13,14-dihydro-15-(4-fluoro-2-benzothienyl)-
15-pentanor PGF_1α 1-hydroxamic acid



13,14-dihydro-15-(2-benzothienyl)-15-pentanor PGF_1α 1-N-
methanesulfonamide

[0088] The PGF's in Table 2 can be prepared by conventional organic syntheses. A preferred synthesis is reaction scheme 4.

[0089]

[0090] In Scheme 4, R¹, R², X, and Z are as defined above. The methyl 7(3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl) heptanoate (S4a) depicted as starting material for Scheme 4 is commercially available (such as from Sumitomo Chemical or Cayman Chemical).

[0091] The C₁₁alcohol of methyl 7-(3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl) heptanoate (S4a) is protected with a suitable protecting group. The most preferred protecting group is a silyl group. In the above Scheme 4, methyl 7-(3-(R)-hydroxy-5-oxo-1-cyclopent-1-yl) heptanoate (S4a) is reacted with a silylating agent and base in a solvent that will allow the silylation to proceed. Preferred silylating agents include tert-butyldimethylsilyl chloride and tert-butyldimethylsilyl trifluoromethanesulphonate. The most preferred silylating agent is tert-butyldimethylsilyl trifluoromethanesulphonate. Preferred bases include triethylamine, trimethylamine, and 2,6-lutidine. More preferred bases include triethylamine and 2,6-lutidine. The most preferred base is 2,6-lutidine. Preferred solvents include halogenated hydrocarbon solvents with dichloromethane being the most preferred solvent. The reaction is allowed to proceed at a temperature of preferably −100° C. to 100° C., more preferably −80° C. to 80° C., and most preferably −70° C. to 23° C.

[0092] The resulting silylated compound is isolated by methods known to those of ordinary skill in the art. Such methods include extraction, solvent evaporation, distillation, and crystallization. Preferably, the silyl ether is purified after isolation by distillation under vacuum.

[0093] The silylated compound is then reacted with the cuprate generated via Grignard formation of the appropriate alkenyl bromide as disclosed, for example, in the following references: H. O. House et. al., “The Chemistry of Carbanions: A Convenient Precursor for the Generation of Lithium Organocuprates”, J. Org. Chem., Vol. 40, pp. 1460-69 (1975); and P. Knochel et. al., “Zinc and Copper Carbenoids as Efficient and Selective a′/d′ Multicoupling Reagents”, J. Amer. Chem. Soc., Vol. 111, p. 6474-76 (1989). Preferred alkenyl bromides include 4-bromo-1-butene, 4-bromo-1-butyne, 4-bromo-2-methyl-1-butene, and 4-bromo-2-ethyl-1-butene. The most preferred alkenyl bromide is 4-bromo-1-butene. Preferred solvents include ethereal solvents, of which diethyl ether and tetrahydrofuran are preferred. The most preferred solvent is tetrahydrofuran. The Grignard reagent is allowed to form at a temperature of 100° C. to 23° C., more preferably 85° C. to 30° C., and most preferably 75° C. to 65° C. The reaction time is preferably 1 to 6 hours, more preferably 2 to 5 hours, and most preferably 3 to 4 hours.

[0094] Once the Grignard reagent is formed, the cuprate is generated from the alkenyl magnesium species. The temperature range for cuprate formation is −100° C. and 0° C.

[0095] The preferred temperature range is −80° C. to −20° C., more preferably −75° C. to −50° C. The preferred reaction time is 30 minutes to 6 hours, more preferably 45 minutes to 3 hours, and most preferably 1 to 1.5 hours.

[0096] The alkene thus formed is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the alkene is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 10% EtOAc/hexanes as the eluent. The alkene is then reacted with a hydride reducing agent and a polar, protic solvent to give the C-9 alcohol. Preferred reducing agents include lithium aluminum hydride, sodium borohydride, and L-selectride. More preferred reducing agents include sodium borohydride, and L-selectride. The most preferred reducing agent is sodium borohydride. Preferred solvents include methanol, ethanol, and butanol. The most preferred solvent is methanol. The reduction is carried out at a temperature between −100° C. and 23° C. The preferred temperature range is −60° C. to 0° C. The most preferred temperature range is −45° C. to −20° C.

[0097] The resulting alcohol is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the alcohol is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

[0098] The resultant alcohol can be protected as described previously herein. Preferred silylating agents in this case also include tert-butyldimethylsilyl chloride and tert-butyldimethylsilyl trifluoromethanesulfonate. The most preferred silylating agent is tert-butyldimethylsilyl trifluoromethanesulfonate. Preferred bases include triethylamine, trimethylamine, and 2,6-lutidine. More preferred bases include triethylamine and 2,6-lutidine. The most preferred base is 2,6-lutidine. Preferred solvents include halogenated hydrocarbon solvents with dichloromethane being the most preferred solvent. The reaction is allowed to proceed at a temperature of preferably −100° C. to 100° C., more preferably −80° C. to 80° C., and most preferably −70° C. to 23° C.

[0099] The resulting silylated compound is isolated by methods known to those of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, the silyl ether is purified after isolation by distillation under vacuum

[0100] The protected or alcohol is then treated with a form of osmium, and sodium periodate in a solvent where they are both soluble. Preferred forms of osmium include osmium tetraoxide and potassium osmate. Preferred solvent systems include 1:1 mixtures of acetic acid and water and 1:1:2 mixtures of water, acetic acid and THF. The result of this treatment is the aldehyde, S4b.

[0101] The compound S4b is isolated by methods known to one of ordinary skill in the art. Such methods include, but are not limited to, extraction, solvent evaporation, distillation, and crystallization. Preferably, S4b is purified by flash chromatography on silica gel (Merck, 230-400 mesh) using 20% EtOAc/hexanes as the eluent.

[0102] The key intermediate aldehyde depicted as S4b can be reacted with a variety unsaturated carbon nucleophiles to provide the C-9 and C-11-protected 13,14-dihydro-16-tetranor prostaglandin F_1α derivatives depicted as S4c.

[0103] With alkyne nucleophiles, the reaction is carried out preferably at −80° C. to 0° C., more preferably −80° C. to −20° C., and most preferably −80° C. to −40° C. Preferred bases for the reaction include n-butyl lithium, s-butyl lithium, t-butyl lithium, and lithium diisopropyl amide (“LDA”). Preferred solvents for the reaction are ether solvents. Preferred solvents include diethyl ether, and tetrahydrofuran. The most preferred solvent is tetrahydrofuran. With heterocyclic nucleophiles, preferred solvents include ethereal solvents. More preferred ethereal solvents include diethyl ether, dibutyl ether and tetrahydrofuran. The most preferred ethereal solvent is tetrahydrofuran.

[0104] The resulting compounds depicted as S4c can then be deprotected using techniques known to one of ordinary skill in the art, and isolated yielding the 13,14-dihydro-15-substituted-15-pentanor prostaglandin F_1α derivatives depicted by Formula VI.

[0105] Compounds depicted by Formula VII can be made directly from the C-9 and C-11-protected 13,14-dihydro-16-tetranor prostaglandin F_1αderivatives depicted as S4c by methods known to one of ordinary skill in the art. For example, the condensation of methyl esters of S4c with amines or hydroxylamine provides compounds depicted by Formula VII. These compounds are isolated by methods known to one of ordinary skill in the art. Such methods include extraction, solvent evaporation, distillation, and crystallization.

[0106] Examples of PGF's having the structure:

[0107]

which are suitable for component A) include: cloprostenol (estrumate), fluprostenol (equimate), tiaprost, alfaprostol, delprostenate, froxiprost, 9-alpha, 11-alpha, 15-alpha-trihydroxy-16-(3-chlorophenoxy)-omega-tetranor-prosta-4-cis-13-trans-dienoic acid, latanoprost and their analogs; and 13,14-dihydro-16-((3-trifluoromethyl)phenoxy)-16-tetranor prostaglandin F_1α, 17-((3-trifluoromethyl)phenyl)-17-trinor-prostaglandin F_2αand its analogs, 13,14-dihydro-18-thienyl-18-dinor prostaglandin F_1α and their analogs. Additional PGF's are also disclosed in CRC Handbook of Eicosanoids: Prostaglandins and Related Lipids, Volume I, Chemical and Biochemical Aspects, Part B. Ed. by Anthony L. Willis, CRC Press, Boca Raton, Table Four, pp. 80-97 (1987) and references therein.

[0108] Preferred PGF's of the present invention are further selective for the FP receptor over an excitatory prostaglandin receptor in a ratio of 1:10, preferably from 1:20, more preferably from 1:50.

Compositions of the Invention

[0109] This invention further relates to a composition for treating hair loss. “Treating hair loss” means arresting hair loss, reversing hair loss, or both, and promoting hair growth. The composition comprises component A) the PGF described above and component B) a carrier. The composition may further comprise component C) one or more optional activity enhancers.

[0110] The composition can be a pharmaceutical or cosmetic composition, administered for treatment or prophylaxis of hair loss. Standard pharmaceutical formulation techniques are used, such as those disclosed in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa. (1990).

[0111] The composition further comprises component B) a carrier. “Carrier” means one or more compatible substances that are suitable for administration to a mammal. Carrier includes solid or liquid diluents, hydrotopes, surface-active agents, and encapsulating substances. “Compatible” means that the components of the composition are capable of being commingled with the PGF's, and with each other, in a manner such that there is no interaction which would substantially reduce the efficacy of the composition under ordinary use situations. Carriers must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the mammal being treated. The carrier can be inert, or it can possess pharmaceutical benefits, cosmetic benefits, or both.

[0112] The choice of carrier for component B) depends on the route by which A) the PGF will be administered and the form of the composition. The composition may be in a variety of forms, suitable, for example, for systemic administration (e.g., oral, rectal, nasal, sublingual, buccal, or parenteral) or topical administration (e.g., local application on the skin, ocular, liposome delivery systems, or iontophoresis). Topical administration directly to the locus of desired hair growth is preferred.

[0113] Carriers for systemic administration typically comprise one or more ingredients selected from the group consisting of a) diluents, b) lubricants, c) binders, d) disintegrants, e) colorants, f) flavors, g) sweeteners, h) antioxidants, j) preservatives, k) glidants, m) solvents, n) suspending agents, o) surfactants, combinations thereof, and others.

[0114] Ingredient a) is a diluent. Suitable diluents include sugars such as glucose, lactose, dextrose, and sucrose; polyols such as propylene glycol; calcium carbonate; sodium carbonate; glycerin; mannitol; sorbitol; and maltodextrin.

[0115] Ingredient b) is a lubricant. Suitable lubricants are exemplified by solid lubricants including silica, talc, stearic acid and its magnesium salts and calcium salts, calcium sulfate; and liquid lubricants such as polyethylene glycol and vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma.

[0116] Ingredient c) is a binder. Suitable binders include polyvinylpyrrolidone; magnesium aluminum silicate; starches such as corn starch and potato starch; gelatin; tragacanth; and cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, methylcellulose, microcrystalline cellulose, and hydroxypropylmethylcellulose; carbomer; providone; acacia; guar gum; and xanthan gum.

[0117] Ingredient d) is a disintegrant. Suitable disintegrants include agar, alginic acid and the sodium salt thereof, effervescent mixtures, croscarmelose, crospovidone, sodium carboxymethyl starch, sodium starch glycolate, clays, and ion exchange resins.

[0118] Ingredient e) is a colorant such as an FD&C dye.

[0119] Ingredient f) is a flavor such as menthol, peppermint, and fruit flavors.

[0120] Ingredient g) is a sweetener such as saccharin and aspartame.

[0121] Ingredient h) is an antioxidant such as butylated hydroxyanisole, butylated hydroxytoluene, and vitamin E.

[0122] Ingredient j) is a preservative such as phenol, alkyl esters of parahydroxybenzoic acid, benzoic acid and the salts thereof, boric acid and the salts thereof, sorbic acid and the salts thereof, chorbutanol, benzyl alcohol, thimerosal, phenylmercuric acetate and nitrate, nitromersol, benzalkonium chloride, cetylpyridinium chloride, methyl paraben, and propyl paraben. Particularly preferred are the salts of benzoic acid, cetylpyridinium chloride, methyl paraben and propyl paraben, and sodium benzoate.

[0123] Ingredient k) is a glidant such as silicon dioxide.

[0124] Ingredient m) is a solvent, such as water, isotonic saline, ethyl oleate, alcohols such as ethanol, glycerin, glycols (e.g., polypropylene glycol and polyethylene glycol), and buffer solutions (e.g., phosphate, potassium acetate, boric carbonic, phosphoric, succinic, malic, tartaric, citric, acetic, benzoic, lactic, glyceric, gluconic, glutaric and glutamic).

[0125] Ingredient n) is a suspending agent. Suitable suspending agents include AVICEL® RC-591 from FMC Corporation of Philadelphia, Pa. and sodium alginate.

[0126] Ingredient o) is a surfactant such as lecithin, polysorbate 80, sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene monoalkyl ethers, sucrose monoesters, lanolin esters, and lanolin ethers. Suitable surfactants are known in the art and commercially available, e.g., the TWEENS® from Atlas Powder Company of Wilmington, Del.

[0127] Compositions for parenteral administration typically comprise A) 0.1 to 10% of a PGF and B) 90 to 99.9% of a carrier comprising a) a diluent, and m) a solvent. Preferably, component a) is propylene glycol and m) is ethanol or ethyl oleate.

[0128] Compositions for oral administration can have various dosage forms. For example, solid forms include tablets, capsules, granules, and bulk powders. These oral dosage forms comprise a safe and effective amount, usually at least 5%, and preferably from 25% to 50%, of A) the PGF. The oral dosage compositions further comprise B) 50 to 95% of a carrier, preferably 50 to 75%.

[0129] Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed. Tablets typically comprise A) the PGF, and B) a carrier comprising ingredients selected from the group consisting of a) diluents, b) lubricants, c) binders, d) disintegrants, e) colorants, f) flavors, g) sweeteners, k) glidants, and combinations thereof. Preferred diluents include calcium carbonate, sodium carbonate, mannitol, lactose and cellulose. Preferred binders include starch, gelatin, and sucrose. Preferred disintegrants include alginic acid, and croscarmelose. Preferred lubricants include magnesium stearate, stearic acid, and talc. Preferred colorants are the FD&C dyes, which can be added for appearance. Chewable tablets preferably contain g) sweeteners such as aspartame and saccharin, or f) flavors such as menthol, peppermint, and fruit flavors.

[0130] Capsules (including time release and sustained release formulations) typically comprise A) the PGF, and B) a carrier comprising one or more a) diluents disclosed above in a capsule comprising gelatin. Granules typically comprise A) the PGF, and preferably further comprise k) glidants such as silicon dioxide to improve flow characteristics.

[0131] The selection of ingredients in the carrier for oral compositions depends on secondary considerations like taste, cost, and shelf stability, which are not critical for the purposes of this invention. One skilled in the art can optimize appropriate ingredients without undue experimentation.

[0132] The solid compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that A) the PGF is released in the gastrointestinal tract at various times to extend the desired action. The coatings typically comprise one or more components selected from the group consisting of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, acrylic resins such as EUDRAGIT® coatings (available from Rohm & Haas G.M.B.H. of Darmstadt, Germany), waxes, shellac, polyvinylpyrrolidone, and other commercially available film-coating preparations such as Dri-Klear, manufactured by Crompton & Knowles Corp., Mahwah, N.J. or OPADRY® manufactured by Colorcon, Inc., of West Point, Pa.

[0133] Compositions for oral administration can also have liquid forms. For example, suitable liquid forms include aqueous solutions, emulsions, suspensions, solutions reconstituted from non-effervescent granules, suspensions reconstituted from non-effervescent granules, effervescent preparations reconstituted from effervescent granules, elixirs, tinctures, syrups, and the like. Liquid orally administered compositions typically comprise A) the PGF and B) a carrier comprising ingredients selected from the group consisting of a) diluents, e) colorants, and f) flavors, g) sweeteners, j) preservatives, m) solvents, n) suspending agents, and o) surfactants. Peroral liquid compositions preferably comprise one or more ingredients selected from the group consisting of e) colorants, f) flavors, and g) sweeteners.

[0134] Other compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms. Such compositions typically comprise one or more of soluble filler substances such as a) diluents including sucrose, sorbitol and mannitol; and c) binders such as acacia, microcrystalline cellulose, carboxymethylcellulose, and hydroxypropylmethylcellulose. Such compositions may further comprise b) lubricants, e) colorants, f) flavors, g) sweeteners, h) antioxidants, and k) glidants.

[0135] The compositions may further comprise component C) an optional activity enhancer. Component C) is preferably selected from the group consisting of i) hair growth stimulants (other than the PGF) and ii) penetration enhancers.

[0136] Component i) is an optional hair growth stimulant. Component i) is exemplified by vasodilators, antiandrogens, cyclosporins, cyclosporin analogs, antimicrobials, anti-inflammatories, thyroid hormones, thyroid hormone derivatives, and thyroid hormone analogs, non-selective prostaglandin agonists or antagonists, retinoids, triterpenes, combinations thereof, and others. “Non-selective prostaglandin” agonists and antagonists differ from component A) in that they do not selectively activate the FP receptor, and they may activate other receptors.

[0137] Vasodilators such as potassium channel agonists including minoxidil and minoxidil derivatives such as aminexil and those described in U.S. Pat. Nos. 3,382,247, 5,756,092, 5,772,990, 5,760,043, 5,466,694, 5,438,058, 4,973,474, and cromakalin and diazoxide can be used as optional hair growth stimulants in the composition.

[0138] Examples of suitable antiandrogens include 5-α-reductase inhibitors such as finasteride and those described in U.S. Pat. No. 5,516,779, and in Nane et al., Cancer Research 58, “Effects of Some Novel Inhibitors of C17,20-Lyase and 5α-Reductase in vitro and in vivo and Their Potential Role in the Treatment of Prostate Cancer,” as well as cyproterone acetate, azelaic acid and its derivatives and those compounds described in U.S. Pat. No. 5,480,913, flutamide, and those compounds described in U.S. Pat. Nos. 5,411,981, 5,565,467, and 4,910,226.

[0139] Antimicrobials include selenium sulfide, ketoconazole, triclocarbon, triclosan, zinc pyrithione, itraconazole, asiatic acid, hinokitiol, mipirocin and those described in EPA 0,680,745, clinacycin hydrochloride, benzoyl peroxide, benzyl peroxide and minocyclin.

[0140] Examples of suitable anti-inflammatories include glucocorticoids such as hydrocortisone, mometasone furoate and prednisolone, nonsteroidal anti-inflammatories including cyclooxygenase or lipoxygenase inhibitors such as those described in U.S. Pat. No. 5,756,092, and benzydamine, salicylic acid, and those compounds described in EPA 0,770,399, published May 2, 1997, WO 94/06434, published Mar. 31, 1994, and FR 2,268,523, published Nov. 21, 1975.

[0141] 3,5,3′-Triiodothyronine is an example of a suitable thyroid hormone.

[0142] Examples of suitable non-selective prostaglandins agonists and antagonists include compounds such as those described in WO 98/33497, Johnstone, published Aug. 6, 1998, WO 95/11003, Stjernschantz, published Apr. 27, 1995, JP 97-100091, Ueno and JP 96-134242, Nakamura.

[0143] Suitable retinoids include isotretinoin, acitretin, and tazarotene.

[0144] Other optional hair growth stimulants for component i) include benzalkonium chloride, benzethonium chloride, phenol, estradiol, chlorpheniramine maleate, chlorophyllin derivatives, cholesterol, salicylic acid, cysteine, methionine, red pepper tincture, benzyl nicotinate, D,L-menthol, peppermint oil, calcium pantothenate, panthenol, castor oil, prednisolone, resorcinol, chemical activators of protein kinase C, glycosaminoglycan chain cellular uptake inhibitors, inhibitors of glycosidase activity, glycosaminoglycanase inhibitors, esters of pyroglutamic acid, hexosaccharic acids or acylated hexosaccharic acids, aryl-substituted ethylenes, N-acylated amino acids, flavinoids, ascomycin derivatives and analogs, histamine antagonists such as diphenhydramine hydrochloride, triterpenes such as oleanolic acid and ursolic acid and those described in U.S. Pat. Nos. 5,529,769, 5,468,888, 5,631,282, and 5,679,705, JP 10017431, WO 95/35103, JP 09067253, WO 92/09262, JP 62093215, and JP 08193094; saponins such as those described in EP 0,558,509 to Bonte et al., published Sep. 8, 1993 and WO 97/01346 to Bonte et al, published Jan. 16, 1997, proteoglycanase or glycosaminoglycanase inhibitors such as those described in U.S. Pat. Nos. 5,015,470, 5,300,284, and 5,185,325, estrogen agonists and antagonists, pseudoterins, cytokine and growth factor promoters, analogs or inhibitors such as interleukin1 inhibitors, interleukin-6 inhibitors, interleukin-10 promoters, and tumor necrosis factor inhibitors, vitamins such as vitamin D analogs and parathyroid hormone antagonists, Vitamin B12 analogs and panthenol, interferon agonists and antagonists, hydroxyacids such as those described in U.S. Pat. No. 5,550,158, benzophenones, and hydantoin anticonvulsants such as phenyloin, and combinations thereof.

[0145] Other additional hair growth stimulants are described in JP 09-157,139 to Tsuji et al., published Jun. 17, 1997; EP 0277455 A1 to Mirabeau, published Aug. 10, 1988; WO 97/05887 to Cabo Soler et al., published Feb. 20, 1997; WO 92/16186 to Bonte et al., published Mar. 13, 1992; JP 62-93215 to Okazaki et al., published Apr. 28, 1987; U.S. Pat. No. 4,987,150 to Kurono et al., issued Jan. 22, 1991; JP 290811 to Ohba et al., published Oct. 15, 1992; JP 05-286,835 to Tanaka et al., published Nov. 2, 1993, FR 2,723,313 to Greff, published Aug. 2, 1994, U.S. Pat. No. 5,015,470 to Gibson, issued May 14, 1991, U.S. Pat. No. 5,559,092, issued Sep. 24, 1996, U.S. Pat. No. 5,536,751, issued Jul. 16, 1996, U.S. Pat. No. 5,714,515, issued Feb. 3, 1998, EPA 0,319,991, published Jun. 14, 1989, EPA 0,357,630, published Oct. 6, 1988, EPA 0,573,253, published Dec. 8, 1993, JP 61-260010, published Nov. 18, 1986, U.S. Pat. No. 5,772,990, issued Jun. 30, 1998, U.S. Pat. No. 5,053,410, issued Oct. 1, 1991, and U.S. Pat. No. 4,761,401, issued Aug. 2, 1988.

[0146] The most preferred activity enhancers are minoxidil and finasteride, most preferably minoxidil.

[0147] Component ii) is a penetration enhancer that can be added to all of the compositions for systemic administration. The amount of component ii), when present in the composition, is typically 1 to 5%. Examples of penetration enhancers include 2-methyl propan-2-ol, propan-2-ol, ethyl-2-hydroxypropanoate, hexan-2,5-diol, polyoxyethylene(2) ethyl ether, di(2-hydroxypropyl)ether, pentan-2,4-diol, acetone, polyoxyethylene(2) methyl ether, 2-hydroxypropionic acid, 2-hydroxyoctanoic acid, propan-1-ol, 1,4-dioxane, tetrahydrofuran, butan-1,4-diol, propylene glycol dipelargonate, polyoxypropylene 15 stearyl ether, octyl alcohol, polyoxyethylene ester of oleyl alcohol, oleyl alcohol, lauryl alcohol, dioctyl adipate, dicapryl adipate, di-isopropyl adipate, di-isopropyl sebacate, dibutyl sebacate, diethyl sebacate, dimethyl sebacate, dioctyl sebacate, dibutyl suberate, dioctyl azelate, dibenzyl sebacate, dibutyl phthalate, dibutyl azelate, ethyl myristate, dimethyl azelate, butyl myristate, dibutyl succinate, didecyl phthalate, decyl oleate, ethyl caproate, ethyl salicylate, isopropyl palmitate, ethyl laurate, 2-ethyl-hexyl pelargonate, isopropyl isostearate, butyl laurate, benzyl benzoate, butyl benzoate, hexyl laurate, ethyl caprate, ethyl caprylate, butyl stearate, benzyl salicylate, 2-hydroxypropanoic acid, 2-hydroxyoctanoic acid, dimethyl sulphoxide, N,N-dimethyl acetamide, N,N-dimethyl formamide, 2-pyrrolidone, 1-methyl-2-pyrrolidone, 5-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, phosphine oxides, sugar esters, tetrahydrofurfural alcohol, urea, diethyl-m-toluamide, 1-dodecylazacyloheptan-2-one, omega three fatty acids and fish oils, and combinations thereof.

[0148] In a preferred embodiment of the invention, the PGF's are topically administered. Topical compositions that can be applied locally to the skin may be in any form including solutions, oils, creams, ointments, gels, lotions, shampoos, leave-on and rinse-out hair conditioners, milks, cleansers, moisturizers, sprays, skin patches, and the like. Topical compositions comprise: component A) the PGF described above and component B) a carrier. The carrier of the topical composition preferably aids penetration of the PGF's into the skin to reach the environment of the hair follicle. Topical compositions preferably further comprise C) one or more of the optional activity enhancers described above.

[0149] The exact amounts of each component in the topical composition depend on various factors. The amount of component A) depends on the IC₅₀of the PGF selected. “IC₅₀” means inhibitory concentration 50^thpercentile. The amount of component A) added to the topical composition is:
IC₅₀×10⁻²≧% of component A)≧IC₅₀×10⁻³,
where IC₅₀is expressed in nanomolar units. For example, if the IC₅₀of the PGF is 1 nM, the amount of component A) will be 0.001 to 0.01%. If the IC₅₀of the PGF is 10 nM, the amount of component A) will be 0.01 to 0.1%. If the IC₅₀of the PGF is 100 nM, the amount of component A) will be 0.1 to 1.0%. If the IC₅₀of the PGF is 1000 nM, the amount of component A) will be 1.0 to 10%, preferably 1.0 to 5%. If the amount of component A) is outside the ranges specified above (i.e., either higher or lower), efficacy of the treatment may be reduced. IC₅₀can be calculated according to the method in Reference Example 1, below. One skilled in the art can calculate IC₅₀without undue experimentation.

[0150] The topical composition preferably further comprises 1 to 20% component C), and a sufficient amount of component B) such that the amounts of components A), B), and C), combined equal 100%. The amount of B) the carrier employed in conjunction with the PGF is sufficient to provide a practical quantity of composition for administration per unit dose of the compound. Techniques and compositions for making dosage forms useful in the methods of this invention are described in the following references: Modern Pharmaceutics, Chapters 9 and 10, Banker & Rhodes, eds. (1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms, 2^ndEd., (1976).

[0151] Component B) the carrier may comprise a single ingredient or a combination of two or more ingredients. In the topical compositions, component B) is a topical carrier. Preferred topical carriers comprise one or more ingredients selected from the group consisting of water, alcohols, aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, polypropylene glycol-2 myristyl propionate, dimethyl isosorbide, combinations thereof, and the like. More preferred carriers include propylene glycol, dimethyl isosorbide, and water.

[0152] The topical carrier may comprise one or more ingredients selected from the group consisting of q) emollients, r) propellants, s) solvents, t) humectants, u) thickeners, v) powders, and w) fragrances in addition to, or instead of, the preferred topical carrier ingredients listed above. One skilled in the art would be able to optimize carrier ingredients for the topical compositions without undue experimentation.

[0153] Ingredient q) is an emollient. The amount of ingredient q) in the topical composition is typically 5 to 95%. Suitable emollients include stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, propane-1,2-diol, butane-1,3-diol, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, sesame oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petrolatum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate, polydimethylsiloxane, and combinations thereof. Preferred emollients include stearyl alcohol and polydimethylsiloxane.

[0154] Ingredient r) is a propellant. The amount of ingredient r) in the topical composition is typically 5 to 95%. Suitable propellants include propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide, and combinations thereof.

[0155] Ingredient s) is a solvent. The amount of ingredient s) in the topical composition is typically 5 to 95%. Suitable solvents include water, ethyl alcohol, methylene chloride, isopropanol, castor oil, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethylsulfoxide, dimethyl formamide, tetrahydrofuran, and combinations thereof. Preferred solvents include ethyl alcohol.

[0156] Ingredient t) is a humectant. The amount of ingredient t) in the topical composition is typically 5 to 95%. Suitable humectants include glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, gelatin, and combinations thereof. Preferred humectants include glycerin.

[0157] Ingredient u) is a thickener. The amount of ingredient u) in the topical composition is typically 0 to 95%.

[0158] Ingredient v) is a powder. The amount of ingredient v) in the topical composition is typically 0 to 95%. Suitable powders include chalk, talc, fullers earth, kaolin, starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetra alkyl ammonium smectites, trialkyl aryl ammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate, and combinations thereof.

[0159] Ingredient w) is a fragrance. The amount of ingredient w) in the topical composition is typically 0.001 to 0.5%, preferably 0.001 to 0.1%.

[0160] Component C) the optional activity enhancer is as described above. Any of the i) hair growth stimulants and ii) penetration enhancers may be added to the topical compositions. Preferably, the topical composition comprises 0.01 to 15% of component i) the optional hair growth stimulant. More preferably, the composition comprises 0.1 to 10%, and most preferably 0.5 to 5% of component i). Preferably, the topical composition comprises 1 to 5% of component ii).

[0161] In an alternative embodiment of the invention, topical pharmaceutical compositions for ocular administration are prepared by conventional methods. Topical pharmaceutical compositions for ocular administration typically comprise A) a PGF, B) a carrier, such as purified water, and one or more ingredients selected from the group consisting of y) sugars such as dextrans, particularly dextran 70, z) cellulose or a derivative thereof, aa) a salt, bb) disodium EDTA (Edetate disodium), and cc) a pH adjusting additive.

[0162] Examples of z) cellulose derivatives suitable for use in the topical pharmaceutical composition for ocular administration include sodium carboxymethyl cellulose, ethyl cellulose, methyl cellulose, and hydroxypropylmethylcellulose. Hydroxypropylmethylcellulose is preferred.

[0163] Examples of aa) salts suitable for use in the for use in the topical pharmaceutical composition for ocular administration include sodium chloride, potassium chloride, and combinations thereof.

[0164] Examples of cc) pH adjusting additives include HCl or NaOH in amounts sufficient to adjust the pH of the topical pharmaceutical composition for ocular administration to 7.2-7.5.

[0165] This invention further relates to a method for darkening hair, thickening hair, and reversing hair graying. The method comprises applying the topical composition for treating hair loss to hair, to skin in the locus of hair, or both. For example, the topical composition may be applied to hair growing on the scalp or eyelashes. The topical composition can be, for example, a cosmetic composition prepared as described above. An example of a composition that may be applied to eyelashes is a mascara. The PGF may be added to mascara compositions known in the art, such as the mascara described in U.S. Pat. No. 5,874,072, which is hereby incorporated by reference. The mascara further comprises dd) a water-insoluble material, ee) a water-soluble, film-forming polymer, ff) a wax, o) a surfactant, gg) a pigment, and s) a solvent.

[0166] Ingredient dd) is a water-insoluble material selected from the group consisting of acrylate copolymers; styrene/acrylate/methacrylate copolymers; acrylic latex; styrene/acrylic ester copolymer latex; polyvinylacetate latex; vinyl acetate/ethylene copolymer latex; styrene/butadiene copolymer latex; polyurethane latex; butadiene/acrylonitrile copolymer latex; styrene/acrylate/acrylonitrile copolymer latex; and mixtures thereof, wherein the acrylate copolymers, and the styrene/acrylate/methacrylate copolymers additionally comprise ammonia, propylene glycol, a preservative and a surfactant.

[0167] Ingredient ee) is a water-soluble, film-forming polymer. Ingredient ee) is selected from the group consisting of vinyl alcohol/poly(alkyleneoxy)acrylate, vinyl alcohol/vinyl acetate/poly-(alkyleneoxy)acrylate, polyethylene oxide, polypropylene oxide, acrylates/octyl-acrylamide copolymers and mixtures thereof.

[0168] Ingredient ff) is a wax. “Wax” means a lower-melting organic mixture or compound of high molecular weight, solid at room temperature and generally similar in composition to fats and oils except that they contain no glycerides. Some are hydrocarbons, others are esters of fatty acids and alcohols. Waxes useful in this invention are selected from the group consisting of animal waxes, vegetable waxes, mineral waxes, various fractions of natural waxes, synthetic waxes, petroleum waxes, ethylenic polymers, hydrocarbon types such as Fischer-Tropsch waxes, silicone waxes, and mixtures thereof wherein the waxes have a melting point between 55 and 100° C.

[0169] Ingredient o) is surfactant, as described above. Ingredient o) in the mascara is preferably a surfactant having an HLB from 3 to 15. Suitable surfactants include those disclosed in the C.T.F.A. Cosmetic Ingredient Handbook, pp. 587-592 (1992); Remington's Pharmaceutical Sciences, 15th ed., pp. 335-337 (1975); and McCutcheon's Volume 1, Emulsifiers & Detergents, North American Edition, pp. 236-239 (1994).

[0170] Ingredient gg) is a pigment. Suitable pigments include inorganic pigments, organic lake pigments, pearlescent pigments, and mixtures thereof. Inorganic pigments useful in this invention include those selected from the group consisting of rutile or anatase titanium dioxide, coded in the Color Index under the reference CI 77,891; black, yellow, red and brown iron oxides, coded under references CI 77,499, 77,492 and, 77,491; manganese violet (CI 77,742); ultramarine blue (CI 77,007); chromium oxide (CI 77,288); chromium hydrate (CI 77,289); and ferric blue (CI 77,510); and mixtures thereof.

[0171] The organic pigments and lakes useful in this invention include those selected from the group consisting of D&C Red No. 19 (CI 45,170), D&C Red No. 9 (CI 15,585), D&C Red No. 21 (CI 45,380), D&C Orange No. 4 (CI 15,510), D&C Orange No. 5 (CI 45,370), D&C Red No. 27 (CI 45,410), D&C Red No. 13 (CI 15,630), D&C Red No. 7 (CI 15,850), D&C Red No. 6 (CI 15,850), D&C Yellow No. 5 (CI 19,140), D&C Red No. 36 (CI 12,085), D&C Orange No. 10 (CI 45,425), D&C Yellow No. 6 (CI 15,985), D&C Red No. 30 (CI 73,360), D&C Red No. 3 (CI 45,430), and the dye or lakes based on Cochineal Carmine (CI 75,570), and mixtures thereof.

[0172] The pearlescent pigments useful in this invention include those selected from the group consisting of the white pearlescent pigments such as mica coated with titanium oxide, bismuth oxychloride, colored pearlescent pigments such as titanium mica with iron oxides, titanium mica with ferric blue, chromium oxide and the like, titanium mica with an organic pigment of the above-mentioned type as well as those based on bismuth oxychloride and mixtures thereof.

[0173] Ingredient s) is a solvent described above, preferably water.

[0174] The amount of A) the PGF added to the mascara is as described above for topical compositions.

[0175] The PGF's may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.

[0176] Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines. A preferred formulation for topical delivery of the present compounds uses liposomes as described in Dowton et al., “Influence of Liposomal Composition on Topical Delivery of Encapsulated Cyclosporin A: I. An in vitro Study Using Hairless Mouse Skin”, S.T.P. Pharma Sciences, Vol. 3, pp. 404-407 (1993); Wallach and Philippot, “New Type of Lipid Vesicle: Novasome®”, Liposome Technology, Vol. 1, pp. 141-156 (1993); Wallach, U.S. Pat. No. 4,911,928, assigned to Micro-Pak, Inc., issued Mar. 27, 1990; and Weiner et al., U.S. Pat. No. 5,834,014, assigned to The University of Michigan and Micro-Pak, Inc., issued Nov. 10, 1998 (with respect to Weiner et al., with a compound as described herein administered in lieu of, or in addition to, minoxidil).

[0177] The PGF's may also be administered by iontophoresis. See, e.g., Internet site www.unipr.it/arpa/dipfarm/erasmus/erasml4.html; Banga et al., “Hydrogel-based Iontotherapeutic Delivery Devices for Transdermal Delivery of Peptide/Protein Drugs”, Pharm. Res., Vol. 10 (5), pp. 697-702 (1993); Ferry, “Theoretical Model of Iontophoresis Utilized in Transdermal Drug Delivery”, Pharmaceutical Acta Helvetiae, Vol 70, pp. 279-287 (1995); Gangarosa et al., “Modern Iontophoresis for Local Drug Delivery”, Int. J. Pharm., Vol. 123, pp. 159-171 (1995); Green et al., “Iontophoretic Delivery of a Series of Tripeptides Across the Skin in vitro”, Pharm. Res., Vol 8, pp. 1121-1127 (1991); Jadoul et al., “Quantification and Localization of Fentanyl and TRH Delivered by Iontophoresis in the Skin”, Int. J. Pharm., Vol. 120, pp. 221-8 (1995); O'Brien et al., “An Updated Review of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy”, Drugs, Vol. 37, pp. 233-309 (1989); Parry et al., “Acyclovir Biovailability in Human Skin”, J. Invest. Dermatol., Vol. 98 (6), pp. 856-63 (1992); Santi et al., “Drug Reservoir Composition and Transport of Salmon Calcitonin in Transdermal Iontophoresis”, Pharm. Res., Vol 14 (1), pp. 63-66 (1997); Santi et al., “Reverse Iontophoresis—Parameters Determining Electroosmotic Flow: I. pH and Ionic Strength”, J. Control. Release, Vol. 38, pp. 159-165 (1996); Santi et al., “Reverse Iontophoresis—Parameters Determining Electroosmotic Flow: II. Electrode Chamber Formulation”, J. Control. Release, Vol. 42, pp. 29-36 (1996); Rao et al., “Reverse Iontophoresis: Noninvasive Glucose Monitoring in vivo in Humans”, Pharm. Res., Vol. 12 (12), pp. 1869-1873 (1995); Thysman et al., “Human Calcitonin Delivery in Rats by Iontophoresis”, J. Pharm. Pharmacol., Vol. 46, pp. 725-730 (1994); and Volpato et al., “Iontophoresis Enhances the Transport of Acyclovir through Nude Mouse Skin by Electrorepulsion and Electroosmosis”, Pharm. Res., Vol. 12 (11), pp. 1623-1627 (1995).

[0178] The PGF's may be included in kits comprising a PGF, a systemic or topical composition described above, or both; and information, instructions, or both that use of the kit will provide treatment for hair loss in mammals (particularly humans). The information and instructions may be in the form of words, pictures, or both, and the like. In addition or in the alternative, the kit may comprise a PGF, a composition, or both; and information, instructions, or both, regarding methods of application of the PGF or composition, preferably with the benefit of treating hair loss in mammals.

Methods of the Invention

[0179] This invention further relates to a method for treating hair loss in mammals. The method comprises administering to a mammal (preferably a human) suffering from hair loss, a PGF described above. For example, a mammal diagnosed with alopecia including male pattern baldness and female pattern baldness can be treated by the methods of this invention. Preferably, a systemic or topical composition comprising A) the PGF and B) a carrier is administered to the mammal. More preferably, the composition is a topical composition comprising A) the PGF, B) the carrier, and C) an optional activity enhancer.

[0180] The dosage of the PGF administered depends on the method of administration. For systemic administration, (e.g., oral, rectal, nasal, sublingual, buccal, or parenteral), typically, 0.5 mg to 300 mg, preferably 0.5 mg to 100 mg, more preferably 0.1 mg to 10 mg, of a PGF described above is administered per day. These dosage ranges are merely exemplary, and daily administration can be adjusted depending on various factors. The specific dosage of the PGF to be administered, as well as the duration of treatment, and whether the treatment is topical or systemic are interdependent. The dosage and treatment regimen will also depend upon such factors as the specific PGF used, the treatment indication, the efficacy of the compound, the personal attributes of the subject (such as, for example, weight, age, sex, and medical condition of the subject), compliance with the treatment regimen, and the presence and severity of any side effects of the treatment.

[0181] For topical administration (e.g., local application on the skin, ocular, liposome delivery systems, or iontophoresis), the topical composition is typically administered once per day. The topical compositions are administered daily for a relatively short amount of time (i.e., on the order of weeks). Generally, 6 to 12 weeks is sufficient. The topical compositions are preferably leave-on compositions. In general, the topical composition should not be removed for at least several hours after administration.

[0182] In addition to the benefits in treating hair loss, the inventors have surprisingly found that the PGF's in the compositions and methods of this invention also darken and thicken hair and may reverse hair graying. This invention further relates to a method for darkening and thickening hair. The method comprises applying the topical composition for treating hair loss to growing hair and skin in the locus of the growing hair. In a preferred embodiment of the invention, the topical composition, such as the mascara composition described above, is applied to eyelashes.

EXAMPLES

[0183] These examples are intended to illustrate the invention to those skilled in the art and should not be interpreted as limiting the scope of the invention set forth in the claims.

Reference Example 1

Radioligand Binding Assay

[0184] IC₅₀of a PGF can be determined relative to PGF_2αusing the Radioligand Binding Assay. As a control, the IC₅₀for PGF_2αitself should be no lower than 1.0 nM and no higher than 5.0 nM.

[0185] In this assay, COS-7 cells are transiently transfected with the hFP recombinant plasmid using LipofectAMINE Reagent. Forty-eight hours later, the tranfected cells are washed with Hank's Balanced Salt Solution (HBSS, without CaCl₂, MgCl₂, MgSO₄, or phenol red). The cells are detached with versene, and HBSS is added. The mixture is centrifuged at 200 g for 10 minutes, at 4° C. to pellet the cells. The pellet is resuspended in Phosphate-Buffered Saline-EDTA buffer (PBS; 1 mM EDTA; pH 7.4; 4° C.). The cells are disrupted by nitrogen cavitation (Parr model 4639), at 800 psi, for 15 minutes at 4° C. The mixture is centrifuged at 1000 g for 10 minutes at 4° C. The supernatant is centrifuged at 100,000 g for 60 minutes at 4° C. The pellet is resuspended to 1 mg protein/mL TME buffer (50 mM Tris; 10 mM MgCl₂; 1 mM EDTA; pH 6.0; 4° C.) based on protein levels measured using the Pierce BCA Protein Assay kit. The homogenate is mixed for 10 seconds using a Kinematica POLYTRON® (available from KINEMATICA AG, Luzernerstrassel47A CH-6014 Littau, Switzerland). The membrane preparations are then stored at −80° C., until thawed for assay use.

[0186] The receptor competition binding assays are developed in a 96 well format. Each well contains 100 g of hFP membrane, 5 nM (3H) PGF2, and the various competing compounds in a total volume of 200 L. The plates are incubated at 23° C. for 1 hour. The incubation is terminated by rapid filtration using the Packard Filtermate 196 harvester through Packard UNIFILTER® GF/B filters (available from Packard Instrument Co., Inc. of Downers Grove Ill.) pre-wetted with TME buffer. The filter is washed four times with TME buffer. Packard Microscint 20, a high efficiency liquid scintillation cocktail, is added to the filter plate wells and the plates remain at room temperature for three hours prior to counting. The plates are read on a Packard TOPCOUNT® Microplate Scintillation Counter (also available from Packard Instrument Co., Inc.)

Reference Example 2

Telogen Conversion Assay

[0187] PGF's are tested for their potential to grow hair using the Telogen Conversion Assay. The Telogen Conversion Assay measures the potential of a PGF to convert mice in the resting stage of the hair growth cycle (“telogen”), to the growth stage of the hair growth cycle (“anagen”).

[0188] Without intending to be limited by theory, there are three principal phases of the hair growth cycle: anagen, catagen, and telogen. It is believed that there is a longer telogen period in C3H mice (Harlan Sprague Dawley, Inc., Indianapolis, Ind.) from approximately 40 days of age until about 75 days of age, when hair growth is synchronized. It is believed that after 75 days of age, hair growth is no longer synchronized. Wherein about 40 day-old mice with dark fur (brown or black) are used in hair growth experiments, melanogenesis occurs along with hair (fur) growth wherein the topical application of hair growth inducers are evaluated. The Telogen Conversion Assay herein is used to screen PGF's for potential hair growth by measuring melanogenesis.

[0189] Three groups of 44 day-old C3H mice are used: a vehicle control group, a positive control group, and a test PGF group, wherein the test PGF group is administered a PGF used in the method of this invention. The length of the assay is 24 days with 15 treatment days (wherein the treatment days occur Mondays through Fridays). Day 1 is the first day of treatment. A typical study design is shown in Table 3 below. Typical dosage concentrations are set forth in Table 3, however the skilled artisan will readily understand that such concentrations may be modified.

[0190]

TABLE 3

Assay Parameters
Group	Animal		Concen-	Application	Length of
#	#	Compound	tration	volume	Study

1	1-10	Test	0.01% in	400 μL topical	26 days
		Compound	vehicle**
2	11-20	Positive	0.01% in	400 μL topical	26 days
		Control	vehicle**
		(T3)*
3	21-30	Vehicle**	N/A	400 μL topical	26 days

*T3 is 3,5,3′-triiodothyronine.
**The vehicle is 60% ethanol, 20% propylene glycol, and 20% dimethyl isosorbide (commercially available from Sigma Chemical Co., St. Louis, MO).

[0191] The mice are treated topically Monday through Friday on their lower back (base of tail to the lower rib). A pipettor and tip are used to deliver 400 μL to each mouse's back. The 400 μL application is applied slowly while moving hair on the mouse to allow the application to reach the skin.

[0192] While each treatment is being applied to the mouse topically, a visual grade of from 0 to 4 will be given to the skin color in the application area of each animal. As a mouse converts from telogen to anagen, its skin color will become more bluish-black. As indicated in Table 4, the grades 0 to 4 represent the following visual observations as the skin progresses from white to bluish-black.

[0193]

TABLE 4

Evaluation Criteria
Visual Observation	Grade

Whitish Skin Color	0
Skin is light gray (indication of initiation of anagen)	1
Appearance of Blue Spots	2
Blue Spots are aggregating to form one large blue area	3
Skin is dark blue (almost black) with color covering majority of	4
treatment area (indication of mouse in full anagen)

Example 1

13,14-dihydro-15-(2-benzathiozolyl)pentanor Prostaglandin F1α, having the structure

[0194]

was tested according to the method Reference Example 1. 13,14-dihydro-15-(2-benzathiozolyl)pentanor Prostaglandin F_1α grew hair and had IC₅₀of 45 nM.

Comparative Example 1

[0195] Latanoprost, having the structure:

[0196]

was tested according to the method Reference Example 1. Latanoprost was active at 0.01% and 0.1%. Grades representing the average animal score on day 26 are reported in Table 5.

[0197] However, latanoprost is nonselective. Although latanoprost does not negate the effect of activating the FP receptor, latanoprost also activates the EP₁receptor, which which results in the side effect of causing pain.

Example 2

[0198] Fluprostenol Methyl Ester having the structure:

[0199]

was tested according to the method Reference Example 1. Fluprostenol grew hair at 0.01% and 0.1%. Grades representing the average animal score on day 26 are reported in Table 5.

[0200]

TABLE 5

Grades
Example	PGF	0.01%	0.1%

Comparative Example 1	latanaprost	0.71	2.9
Example 2	fluprostenol methyl ester	3.9	2.6

Comparative Example 2

[0201] A composition containing 0.01% of a T3 compound was prepared and tested according to the method of Reference Example 1. The T3 compound grew hair.

Example 3

[0202] Compositions for topical administration are made, comprising:

[0203]


Component	3-1	3-2	3-3


PGF (wt %)	0.019	0.027	0.045
IC₅₀the PGF (nM)	19	27	45
Ethanol (wt %)	59.988	59.983	59.973
Propylene Glycol (wt %)	19.996	19.995	19.991
Dimethyl Isosorbide (wt %)	19.996	19.995	19.991

The PGFs in the compositions are as follows:

[0204]


	Sample	PGF

	3-1

	3-2

	3-3

A human male subject suffering from male pattern baldness is treated by a method of this invention. Specifically, for 6 weeks, one of the above compositions is daily administered topically to the subject to induce hair growth.

Example 4

[0205] A composition for topical administration is made according to the method of Dowton et al., “Influence of Liposomal Composition on Topical Delivery of Encapsulated Cyclosporin A: I. An in vitro Study Using Hairless Mouse Skin”, S.T.P. Pharma Sciences, Vol. 3, pp. 404-407 (1993), using a PGF in lieu of cyclosporin A and using the NOVASOME® 1 (available from Micro-Pak, Inc. of Wilmington, Del.) for the non-ionic liposomal formulation.

[0206] A human male subject suffering from male pattern baldness is treated each day with the above composition. Specifically, for 6 weeks, the above composition is administered topically to the subject.

Example 5

[0207] Shampoos are made, comprising:

[0208]


Component	Ex. 5-1	Ex. 5-2	Ex. 5-3	Ex. 5-4

Ammonium Lauryl Sulfate	11.5%	11.5%	9.5%	7.5%
Ammonium Laureth Sulfate	4%	3%	2%	2%
Cocamide MEA	2%	2%	2%	2%
Ethylene Glycol Distearate	2%	2%	2%	2%
Cetyl Alcohol	2%	2%	2%	2%
Stearyl Alcohol	1.2%	1.2%	1.2%	1.2%
Glycerin	1%	1%	1%	1%
Polyquaternium 10	0.5%	0.25%	—	—
Polyquaternium 24	—	—	0.5%	0.25%
Sodium Chloride	0.1%	0.1%	0.1%	0.1%
Sucrose Polyesters of	3%	3%	—	—
Cottonate Fatty Acid
Sucrose Polyesters of	2%	3%	—	—
Behenate Fatty Acid
Polydimethyl Siloxane	—	—	3%	2%
Cocaminopropyl Betaine	—	1%	3%	3%
Lauryl Dimethyl Amine Oxide	1.5%	1.5%	1.5%	1.5%
Decyl Polyglucose	—	—	1%	1%
DMDM Hydantoin	0.15%	0.15%	0.15%	0.15%
PGF having IC₅₀of 19 nM	—	0.019%	0.019%	—
PGF having IC₅₀of 45 nM	0.045%	—	—	0.045%
Minoxidil			3%	2%
Phenoxyethanol	0.5%	0.5%	0.5%	0.5%
Fragrance	0.5%	0.5%	0.5%	0.5%
Water	q.s.	q.s.	q.s.	q.s.

The PGF having IC₅₀of 19 nM is the same as that in Example 3-1.
The PGF having IC₅₀of 45 nM is the same as that in Example 3-3.

[0209] A human subject suffering from male pattern baldness is treated by a method of this invention. Specifically, for 12 weeks, a shampoo described above is used daily by the subject.

Example 6

[0210] A mascara composition is prepared. The composition comprises:

[0211]


Component	% W/W

WATER, DEIONIZED, USP	q.s
BLACK 1080 MICRONIZED TYPE	10.000
GLYCERYL MONOSTEARATE (2400 TYPE)	8.500
C18-36 ACID TRIGLYCERIDE	5.500
STEARIC ACID, TRIPLE PRESSED, LIQUID	4.000
ETHYL ALCOHOL SD 40-B, 190 PROOF/SERIAL #:	4.000
BEESWAX WHITE, FLAKES	3.250
SHELLAC, NF	3.000
LECITHIN, GRANULAR (TYPE 6450)	2.500
TRIETHANOLAMINE 99% - TANK	2.470
PARAFFIN WAX	2.250
PARAFFIN WAX 118/125	2.250
CARNAUBA WAX, NF	2.000
POTASSIUM CETYL PHOSPHATE	1.000
PHENOXYETHANOL	0.800
OLEIC ACID NF	0.750
DL-PANTHENOL	0.350
PVP/VA COPOLYMER	0.250
METHYLPARABEN, NF	0.200
DIAZOLIDINYL UREA	0.200
SIMETHICONE	0.200
ETHYLPARABEN NF	0.150
PENTAERYTHRITYL HYDROGENATED ROSINATE	0.150
PROPYLPARABEN, NF	0.100
TRISODIUM EDTA	0.100
PGF having IC₅₀of 19 nM	0.019

The PGF is the same as that used in Example 3-1.
A human female subject applies the composition each day. Specifically, for 6 weeks, the above composition is administered topically to the subject to darken and thicken eyelashes.

Example 7

[0212] Pharmaceutical compositions in the form of tablets are prepared by conventional methods, such as mixing and direct compaction, formulated as follows:

[0213]


	Ingredient	Quantity (mg per tablet)


	PGF	0.5
	Microcrystalline Cellulose	100
	Sodium Starch Glycollate	30
	Magnesium Stearate	3

[0214] The PGF is the same as that used in Example 3-3.

[0215] The above composition is administered orally to a subject once daily for 6 to 12 weeks to promote hair growth.

Example 8

[0216] Pharmaceutical compositions in liquid form are prepared by conventional methods, formulated as follows:

[0217]


	Ingredient	Quantity

	PGF	0.1 mg
	Phosphate buffered physiological saline	10 ml
	Methyl Paraben	0.05 ml

[0218] The PGF is the same as that used in Example 3-3.

[0219] 1.0 ml of the above composition is administered subcutaneously once daily at the site of hair loss for 6 to 12 weeks to promote hair growth.

Example 9

[0220] A topical pharmaceutical composition is prepared by conventional methods and formulated as follows:

[0221]


	Ingredient	Amount (wt %)


	PGF	0.004
	Dextran 70	0.1
	Hydroxypropyl methylcellulose	0.3
	Sodium Chloride	0.77
	Potassium chloride	0.12
	Disodium EDTA (Edetate disodium)	0.05
	Benzalkonium chloride	0.01
	HCL and/or NaOH	pH 7.2-7.5
	Purified water	q.s. to 100%

[0222] The PGF is the same as that used in Example 3-3.

[0223] The above composition is administered ocularly to a subject once per day for 6 to 12 weeks to promote eyelash growth.

EFFECTS OF THE INVENTION

[0224] The compositions and methods herein provide a cosmetic benefit with respect to hair growth and appearance in subjects desiring such treatment.

Claims

What is claimed is:

1. A method of growing hair, wherein the method comprises topically applying to mammalian skin a safe and effective amount of a composition comprising:

A) an active ingredient selected from the group consisting of a prostaglandin F analog of the following structure:

and pharmaceutically acceptable salts thereof;

wherein R¹is selected from the group consisting of C(O)NHOH, CH₂OH, S(O)₂R³, C(O)NHR³, C(O)NHS(O)₂R⁴, and tetrazole;

R²is selected from the group consisting of a hydrogen atom, a lower heterogeneous group, and a lower monovalent hydrocarbon group;

R³is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;

R⁴is selected from the group consisting of a monovalent hydrocarbon group, a heterogeneous group, a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted monovalent hydrocarbon group, a substituted heterogeneous group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group;

X is selected from the group consisting of —CC—, a covalent bond, —CH═C═CH—, —CH═CH—, —CH═N—, —C(O)—, —C(O)Y—, —(CH₂)_n—, wherein n is 2 to 4, —CH₂NH—, —CH₂S—, and —CH₂O—;

Y is selected from the group consisting of a sulfur atom, an oxygen atom, and NH; and

Z is selected from the group consisting of a carbocyclic group, a heterocyclic group, an aromatic group, a heteroaromatic group, a substituted carbocyclic group, a substituted heterocyclic group, a substituted aromatic group, and a substituted heteroaromatic group.

2. The method of claim 1, wherein R¹is selected from the group consisting of C(O)NHOH, C(O)NHR³, and C(O)NHS(O)₂R⁴, and tetrazole.

3. The method of claim 1, wherein R²is a hydrogen atom.

4. The method of claim 1, wherein R³is selected from the group consisting of methyl, ethyl, and isopropyl.

5. The method of claim 1, wherein Z is an aromatic ring.

6. The method of claim 1, wherein the composition is a topical composition in a form selected from the group consisting of solutions, oils, creams, ointments, gels, lotions, shampoos, leave-on and rinse-out hair conditioners, milks, cleansers, moisturizers, sprays, and skin patches.

7. The method of claim 1, wherein the composition is a topical composition further comprising B) a carrier, wherein the carrier is selected from the group consisting of water, alcohols, aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, dimethyl isosorbide, polypropylene glycol, 2 myristyl propionate, and combinations thereof.

8. The method of claim 1, wherein the composition further comprises C) an activity enhancer selected from the group consisting of i) a hair growth stimulant, ii) a penetration enhancer, and combinations thereof.

9. The method of claim 8, wherein component i) is selected from the group vasodilator, an antiandrogen, a cyclosporin, a cyclosporin analog, an antimicrobial, an anti-inflammatory, a thyroid hormone, a thyroid hormone derivative, and a thyroid hormone analog, a non-selective prostaglandin agonist, a non-selective prostaglandin antagonist, a retinoid, a triterpene, and combinations thereof.

10. The method of claim 8, wherein component ii) is selected from the group consisting of 2-methyl propan-2-ol, propan-2-ol, ethyl-2-hydroxypropanoate, hexan-2,5-diol, polyoxyethylene(2) ethyl ether, di(2-hydroxypropyl) ether, pentan-2,4-diol, acetone, polyoxyethylene(2) methyl ether, 2-hydroxypropionic acid, 2-hydroxyoctanoic acid, propan-1-ol, 1,4-dioxane, tetrahydrofuran, butan-1,4-diol, propylene glycol dipelargonate, polyoxypropylene 15 stearyl ether, octyl alcohol, polyoxyethylene ester of oleyl alcohol, oleyl alcohol, lauryl alcohol, dioctyl adipate, dicapryl adipate, di-isopropyl adipate, di-isopropyl sebacate, dibutyl sebacate, diethyl sebacate, dimethyl sebacate, dioctyl sebacate, dibutyl suberate, dioctyl azelate, dibenzyl sebacate, dibutyl phthalate, dibutyl azelate, ethyl myristate, dimethyl azelate, butyl myristate, dibutyl succinate, didecyl phthalate, decyl oleate, ethyl caproate, ethyl salicylate, isopropyl palmitate, ethyl laurate, 2-ethyl-hexyl pelargonate, isopropyl isostearate, butyl laurate, benzyl benzoate, butyl benzoate, hexyl laurate, ethyl caprate, ethyl caprylate, butyl stearate, benzyl salicylate, 2-hydroxypropanoic acid, 2-hydroxyoctanoic acid, dimethyl sulphoxide, N,N-dimethyl acetamide, N,N-dimethyl formamide, 2-pyrrolidone, 1-methyl-2-pyrrolidone, 5-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, phosphine oxides, sugar esters, tetrahydrofurfural alcohol, urea, diethyl-m-toluamide, 1-dodecylazacyloheptan-2-one, and combinations thereof.

11. The method of claim 1, wherein the composition is a topical composition locally administered on the skin once per day.

12. The method of claim 11, wherein the composition is administered once per day for 6 to 12 weeks.

13. The method of claim 1, wherein the composition is topically applied directly to the locus of desired hair growth.

14. The method of claim 1, wherein the prostaglandin F analog is selective for an FP receptor over an excitatory prostaglandin receptor in a ratio of at least 1:10.

15. The method of claim 1, wherein the prostaglandin F analog is selective for an FP receptor over an excitatory prostaglandin receptor in a ratio of at least 1:20.

16. The method of claim 1, wherein the prostaglandin F analog is selective for an FP receptor over an excitatory prostaglandin receptor in a ratio of at least 1:50.

17. A method of growing hair, wherein the method comprises topically applying to mammalian skin a safe and effective amount of a composition comprising:

A) an active ingredient selected from the group consisting of a prostaglandin F analog of the following structure:

and pharmaceutically acceptable salts thereof;

wherein R¹is selected from the group consisting of C(O)NHOH, C(O)NHR³, C(O)NHS(O)₂R⁴and tetrazole;

R²is a hydrogen atom;

R³is methyl, ethyl or isopropyl;

R⁴is phenyl;

X is selected from the group consisting of —C≡C—, a covalent bond, —CH═C═CH—, —CH═CH—, —CH═N—, —C(O)—, —C(O)Y—, and —(CH₂)_n—, wherein n is 2 to 4;

Y is selected from the group consisting of a sulfur atom, an oxygen atom, and NH; and

18. The method of claim 17, wherein Z is an aromatic ring.

19. The method of claim 17, wherein the composition is a topical composition in a form selected from the group consisting of solutions, oils, creams, ointments, gels, lotions, shampoos, leave-on and rinse-out hair conditioners, milks, cleansers, moisturizers, sprays, and skin patches.

20. The method of claim 17, wherein the composition is a topical composition further comprising B) a carrier, wherein the carrier is selected from the group consisting of water, alcohols, aloe vera gel, allantoin, glycerin, vitamin A and E oils, mineral oil, propylene glycol, dimethyl isosorbide, polypropylene glycol, 2 myristyl propionate, and combinations thereof.

21. The method of claim 17, wherein the composition further comprises C) an activity enhancer selected from the group consisting of i) a hair growth stimulant, ii) a penetration enhancer, and combinations thereof.

22. The method of claim 21, wherein component i) is selected from the group vasodilator, an antiandrogen, a cyclosporin, a cyclosporin analog, an antimicrobial, an anti-inflammatory, a thyroid hormone, a thyroid hormone derivative, and a thyroid hormone analog, a non-selective prostaglandin agonist, a non-selective prostaglandin antagonist, a retinoid, a triterpene, and combinations thereof.

23. The method of claim 21, wherein component ii) is selected from the group consisting of 2-methyl propan-2-ol, propan-2-ol, ethyl-2-hydroxypropanoate, hexan-2,5-diol, polyoxyethylene(2) ethyl ether, di(2-hydroxypropyl) ether, pentan-2,4-diol, acetone, polyoxyethylene(2) methyl ether, 2-hydroxypropionic acid, 2-hydroxyoctanoic acid, propan-1-ol, 1,4-dioxane, tetrahydrofuran, butan-1,4-diol, propylene glycol dipelargonate, polyoxypropylene 15 stearyl ether, octyl alcohol, polyoxyethylene ester of oleyl alcohol, oleyl alcohol, lauryl alcohol, dioctyl adipate, dicapryl adipate, di-isopropyl adipate, di-isopropyl sebacate, dibutyl sebacate, diethyl sebacate, dimethyl sebacate, dioctyl sebacate, dibutyl suberate, dioctyl azelate, dibenzyl sebacate, dibutyl phthalate, dibutyl azelate, ethyl myristate, dimethyl azelate, butyl myristate, dibutyl succinate, didecyl phthalate, decyl oleate, ethyl caproate, ethyl salicylate, isopropyl palmitate, ethyl laurate, 2-ethyl-hexyl pelargonate, isopropyl isostearate, butyl laurate, benzyl benzoate, butyl benzoate, hexyl laurate, ethyl caprate, ethyl caprylate, butyl stearate, benzyl salicylate, 2-hydroxypropanoic acid, 2-hydroxyoctanoic acid, dimethyl sulphoxide, N,N-dimethyl acetamide, N,N-dimethyl formamide, 2-pyrrolidone, 1-methyl-2-pyrrolidone, 5-methyl-2-pyrrolidone, 1,5-dimethyl-2-pyrrolidone, 1-ethyl-2-pyrrolidone, phosphine oxides, sugar esters, tetrahydrofurfural alcohol, urea, diethyl-m-toluamide, 1-dodecylazacyloheptan-2-one, and combinations thereof.

24. The method of claim 17, wherein the composition is a topical composition locally administered on the skin once per day.

25. The method of claim 24, wherein the composition is administered once per day for 6 to 12 weeks.

26. The method of claim 17, wherein the composition is topically applied directly to the locus of desired hair growth.

27. The method of claim 17, wherein the prostaglandin F analog is selective for an FP receptor over an excitatory prostaglandin receptor in a ratio of at least 1:10.

28. The method of claim 17, wherein the prostaglandin F analog is selective for an FP receptor over an excitatory prostaglandin receptor in a ratio of at least 1:20.

29. The method of claim 17, wherein the prostaglandin F analog is selective for an FP receptor over an excitatory prostaglandin receptor in a ratio of at least 1:50.

Patent Citations (407)

Patent	Date	Inventor	Cited By
US3382247(A)	1968-05-01	Anthony	Applicant
US3435053(A)	1969-03-01	Beal et al.	Applicant
US3524867(A)	1970-08-01	Beal et al.	Applicant
US3598858(A)	1971-08-01	Bergstrom et al.	Applicant
US3636120(A)	1972-01-01	Pike	Applicant
US3644363(A)	1972-02-01	Kim	Applicant
US3691216(A)	1972-09-01	Bergstrom et al.	Applicant
US3706789(A)	1972-12-01	Bergstrom et al.	Applicant
US3723427(A)	1973-03-01	Susi	Applicant
US3776938(A)	1973-12-01	Bergstrom et al.	Applicant
US3776939(A)	1973-12-01	Bergstrom et al.	Applicant
US3798275(A)	1974-03-01	Finch et al.	Applicant
US3839409(A)	1974-10-01	Bergstrom et al.	Applicant
US3852337(A)	1974-12-01	Bergstrom et al.	Applicant
US3882241(A)	1975-05-01	Phariss	Applicant
US3882245(A)	1975-05-01	DuCharme	Applicant
US3896156(A)	1975-07-01	Beal et al.	Applicant
US3928588(A)	1975-12-01	Robert	Applicant
US3931282(A)	1976-01-01	Muchowski et al.	Applicant
US3934013(A)	1976-01-01	Poulsen	Applicant
US3966792(A)	1976-06-01	Hayashi et al.	Applicant
US3974213(A)	1976-08-01	Hess et al.	Applicant
US3984424(A)	1976-10-01	Schaff	Applicant
US3984455(A)	1976-10-01	Beal et al.	Applicant
US3985791(A)	1976-10-01	Muchowski et al.	Applicant
US4004020(A)	1977-01-01	Skuballa et al.	Applicant
US4005133(A)	1977-01-01	Morozowich	Applicant
US4011262(A)	1977-03-01	Hess et al.	Applicant
US4018812(A)	1977-04-01	Hayashi et al.	Applicant
US4024179(A)	1977-05-01	Bindra et al.	Applicant
US4051238(A)	1977-09-01	Sokolowski	Applicant
US4061671(A)	1977-12-01	Beck et al.	Applicant
US4073934(A)	1978-02-01	Skuballa et al.	Applicant
US4089885(A)	1978-05-01	Husbands	Applicant
US4105854(A)	1978-08-01	Gibson	Applicant
US4116989(A)	1978-09-01	Nelson	Applicant
US4123441(A)	1978-10-01	Johnson	Applicant
US4128577(A)	1978-12-01	Nelson	Applicant
US4128720(A)	1978-12-01	Hayashi et al.	Applicant
US4139619(A)	1979-02-01	Chidsey, III	Applicant
US4152527(A)	1979-05-01	Hess et al.	Applicant
US4154950(A)	1979-05-01	Nelson	Applicant
US4158667(A)	1979-06-01	Axen	Applicant
US4171331(A)	1979-10-01	Biddlecom et al.	Applicant
US4206151(A)	1980-06-01	Grudzinskas	Applicant
US4217360(A)	1980-08-01	Vorbruggen et al.	Applicant
US4225507(A)	1980-09-01	Sih	Applicant
US4225508(A)	1980-09-01	Sih	Applicant
US4268522(A)	1981-05-01	Eggler et al.	Applicant
US4284646(A)	1981-08-01	Vorbruggen et al.	Applicant
US4296504(A)	1981-10-01	Lawson	Applicant
US4311707(A)	1982-01-01	Birnbaum et al.	Applicant
US4489092(A)	1984-12-01	Vorbruggen et al.	Applicant
US4499293(A)	1985-02-01	Johnson et al.	Applicant
US4543353(A)	1985-09-01	Faustini et al.	Applicant
US4596812(A)	1986-06-01	Chidsey, III et al.	Applicant
US4599353(A)	1986-07-01	Bito	Applicant
US4621100(A)	1986-11-01	Lund et al.	Applicant
US4704386(A)	1987-11-01	Mueller	Applicant
US4757089(A)	1988-07-01	Epstein	Applicant
US4812457(A)	1989-03-01	Narumiya et al.	Applicant
US4883819(A)	1989-11-01	Bito	Applicant
US4889845(A)	1989-12-01	Ritter et al.	Applicant
US4912235(A)	1990-03-01	Cooper et al.	Applicant
US4952581(A)	1990-08-01	Bito et al.	Applicant
US4968812(A)	1990-11-01	Wang et al.	Applicant
US5001153(A)	1991-03-01	Ueno	Applicant
US5041439(A)	1991-08-01	Kasting et al.	Applicant
US5063057(A)	1991-11-01	Spellman et al.	Applicant
US5166178(A)	1992-11-01	Ueno et al.	Applicant
US5194429(A)	1993-03-01	Ueno	Applicant
US5212324(A)	1993-05-01	Ueno et al.	Applicant
US5219885(A)	1993-06-01	Frolich et al.	Applicant
US5280018(A)	1994-01-01	Ritter et al.	Applicant
US5288754(A)	1994-02-01	Woodward et al.	Applicant
US5296504(A)	1994-03-01	Stjernschantz et al.	Applicant
US5302617(A)	1994-04-01	Ueno	Applicant
US5312832(A)	1994-05-01	Chan	Applicant
US5321128(A)	1994-06-01	Stjernschantz et al.	Applicant
US5332730(A)	1994-07-01	Chan	Applicant
US5340813(A)	1994-08-01	Klein et al.	Applicant
US5352708(A)	1994-10-01	Woodward et al.	Applicant
US5409911(A)	1995-04-01	Tyler et al.	Applicant
US5422368(A)	1995-06-01	Stjernschantz	Applicant
US5422369(A)	1995-06-01	Stjernschantz	Applicant
US5422371(A)	1995-06-01	Liao et al.	Applicant
US5426115(A)	1995-06-01	Ueno et al.	Applicant
US5431881(A)	1995-07-01	Palacios	Applicant
US5458883(A)	1995-10-01	Epstein	Applicant
US5464868(A)	1995-11-01	Frolich et al.	Applicant
US5480900(A)	1996-01-01	DeSantis, Jr. et al.	Applicant
US5500230(A)	1996-03-01	Nathanson	Applicant
US5508303(A)	1996-04-01	Isogaya et al.	Applicant
US5510383(A)	1996-04-01	Bishop	Applicant
US5516652(A)	1996-05-01	Abramovitz et al.	Applicant
US5567079(A)	1996-10-01	Felder	Applicant
US5576315(A)	1996-11-01	Hallinan et al.	Applicant
US5578618(A)	1996-11-01	Stjernschantz et al.	Applicant
US5578640(A)	1996-11-01	Hanson	Applicant
US5578643(A)	1996-11-01	Hanson	Applicant
US5587391(A)	1996-12-01	Burk	Applicant
US5605814(A)	1997-02-01	Abramovitz et al.	Applicant
US5605931(A)	1997-02-01	Hanson	Applicant
US5607978(A)	1997-03-01	Woodward et al.	Applicant
US5627208(A)	1997-05-01	Stjernschantz et al.	Applicant
US5641494(A)	1997-06-01	Cauwenbergh	Applicant
US5658897(A)	1997-08-01	Burk	Applicant
US5663203(A)	1997-09-01	Ekerdt et al.	Applicant
US5665773(A)	1997-09-01	Klimko et al.	Applicant
US5670506(A)	1997-09-01	Leigh et al.	Applicant
US5681850(A)	1997-10-01	Frolich et al.	Applicant
US5688819(A)	1997-11-01	Woodward et al.	Applicant
US5698733(A)	1997-12-01	Hellberg et al.	Applicant
US5703108(A)	1997-12-01	Cameron et al.	Applicant
US5716609(A)	1998-02-01	Jain et al.	Applicant
US5719140(A)	1998-02-01	Chandrakumar et al.	Applicant
US5741810(A)	1998-04-01	Burk	Applicant
US5759789(A)	1998-06-01	Abramovitz et al.	Applicant
US5770759(A)	1998-06-01	Ueno et al.	Applicant
US5773472(A)	1998-06-01	Stjernschantz	Applicant
US5792851(A)	1998-08-01	Schuster et al.	Applicant
US5834498(A)	1998-11-01	Burk	Applicant
US5840847(A)	1998-11-01	Abramovitz et al.	Applicant
US5849791(A)	1998-12-01	Stjernschantz et al.	Applicant
US5863948(A)	1999-01-01	Epstein et al.	Applicant
US5869281(A)	1999-02-01	Abramovitz et al.	Applicant
US5877211(A)	1999-03-01	Woodward	Applicant
US5885766(A)	1999-03-01	Mahe et al.	Applicant
US5885974(A)	1999-03-01	Danielov	Applicant
US5889052(A)	1999-03-01	Klimko et al.	Applicant
US5892099(A)	1999-04-01	Maruyama et al.	Applicant
US5958723(A)	1999-09-01	Abramovitz et al.	Applicant
US5972965(A)	1999-10-01	Taniguchi et al.	Applicant
US5973002(A)	1999-10-01	Frolich et al.	Applicant
US5977173(A)	1999-11-01	Wos et al.	Applicant
US5985597(A)	1999-11-01	Ford-Hutchinson et al.	Applicant
US5990346(A)	1999-11-01	Kataoka et al.	Applicant
US5994397(A)	1999-11-01	Selliah et al.	Applicant
US6013823(A)	2000-01-01	Mamarella et al.	Applicant
US6025375(A)	2000-02-01	Taniguchi et al.	Applicant
US6025392(A)	2000-02-01	Selliah et al.	Applicant
US6030959(A)	2000-02-01	Tremont et al.	Applicant
US6030999(A)	2000-02-01	Stjemschantz et al.	Applicant
US6031001(A)	2000-02-01	Stjemschantz et al.	Applicant
US6031079(A)	2000-02-01	Ford-Hutchinson et al.	Applicant
US6037364(A)	2000-03-01	Burk	Applicant
US6037368(A)	2000-03-01	Podos et al.	Applicant
US6043264(A)	2000-03-01	Ohtake et al.	Applicant
US6048895(A)	2000-04-01	Wos et al.	Applicant
US6107338(A)	2000-08-01	Wos et al.	Applicant
US6110969(A)	2000-08-01	Tani et al.	Applicant
US6121253(A)	2000-09-01	Han et al.	Applicant
US6124344(A)	2000-09-01	Burk	Applicant
US6126957(A)	2000-10-01	Epstein	Applicant
US6160129(A)	2000-12-01	Burk	Applicant
US6169111(B1)	2001-01-01	Zinke et al.	Applicant
US6232344(B1)	2001-05-01	Feng	Applicant
US6262105(B1)	2001-07-01	Johnstone	Applicant
US6372730(B1)	2002-04-01	deLong et al.	Applicant
US6403649(B1)	2002-06-01	Woodward et al.	Applicant
US6410780(B1)	2002-06-01	deLong et al.	Applicant
US6441047(B2)	2002-08-01	DeSantis, Jr.	Applicant
US6444840(B1)	2002-09-01	deLong et al.	Applicant
US6451859(B1)	2002-09-01	deLong et al.	Applicant
US6534082(B1)	2003-03-01	Epstein	Applicant
US6548535(B2)	2003-04-01	Garcia et al.	Applicant
US6586463(B2)	2003-07-01	deLong et al.	Applicant
US6716876(B2)	2004-04-01	Burk	Applicant
US6894175(B1)	2005-05-01	DeLong et al.	Applicant
US7045634(B2)	2006-05-01	Krauss et al.	Applicant
US7070768(B2)	2006-07-01	Krauss	Applicant
US7074942(B2)	2006-07-01	deLong	Applicant
US7115659(B2)	2006-10-01	DeLong	Applicant
US7157590(B2)	2007-01-01	Gutman et al.	Applicant
US7288029(B1)	2007-10-01	Lyon	Applicant
US7320967(B2)	2008-01-01	Michelet et al.	Applicant
US7388029(B2)	2008-06-01	deLong et al.	Applicant
US7407987(B2)	2008-08-01	deLong et al.	Applicant
US7521530(B2)	2009-04-01	Peri et al.	Applicant
US7589233(B2)	2009-09-01	Chandran	Applicant
US8541466(B2)	2013-09-01	deLong et al.	Applicant
US8618086(B2)	2013-12-01	deLong et al.	Applicant
US8623918(B2)	2014-01-01	deLong et al.	Applicant
US8722739(B2)	2014-05-01	deLong et al.	Applicant
US2001/0047025(A1)	2001-11-01	Garcia et al.	Applicant
US2002/0013294(A1)	2002-01-01	deLong et al.	Applicant
US2002/0037914(A1)	2002-03-01	deLong et al.	Applicant
US2002/0044953(A1)	2002-04-01	Michelet et al.	Applicant
US2002/0045659(A1)	2002-04-01	Michelet et al.	Applicant
US2002/0052414(A1)	2002-05-01	Bernard et al.	Applicant
US2002/0146439(A1)	2002-10-01	deLong et al.	Applicant
US2002/0172693(A1)	2002-11-01	deLong et al.	Applicant
US2003/0083381(A1)	2003-05-01	Kumagai et al.	Applicant
US2003/0147823(A1)	2003-08-01	Woodward et al.	Applicant
US2003/0165549(A1)	2003-09-01	Bernard et al.	Applicant
US2003/0191173(A1)	2003-10-01	Garcia et al.	Applicant
US2003/0199590(A1)	2003-10-01	Cagle	Applicant
US2004/0082013(A1)	2004-04-01	Regan	Applicant
US2004/0157912(A1)	2004-08-01	Old et al.	Applicant
US2004/0167190(A1)	2004-08-01	Stjernschantz et al.	Applicant
US2004/0171596(A1)	2004-09-01	Prokai et al.	Applicant
US2005/0058614(A1)	2005-03-01	Krauss	Applicant
US2005/0112075(A1)	2005-05-01	Hwang et al.	Applicant
US2006/0106078(A1)	2006-05-01	Krauss et al.	Applicant
US2006/0121069(A1)	2006-06-01	deLong et al.	Applicant
US2006/0135609(A1)	2006-06-01	Toone et al.	Applicant
US2006/0247214(A1)	2006-11-01	deLong et al.	Applicant
US2007/0004620(A1)	2007-01-01	Jabbour et al.	Applicant
US2007/0161699(A1)	2007-07-01	Epstein et al.	Applicant
US2007/0254920(A1)	2007-11-01	deLong et al.	Applicant
US2007/0282006(A1)	2007-12-01	Woodward et al.	Applicant
US2008/0070988(A1)	2008-03-01	Woodward et al.	Applicant
US2008/0096240(A1)	2008-04-01	Woodward et al.	Applicant
US2008/0103184(A1)	2008-05-01	deLong et al.	Applicant
US2009/0018204(A1)	2009-01-01	Brinkenhoff	Applicant
US2009/0203659(A1)	2009-08-01	Woodward et al.	Applicant
US2014/0031423(A1)	2014-01-01	deLong et al.	Applicant
US2014/0099268(A1)	2014-04-01	deLong et al.	Applicant
BE746615	1970-07-01		Applicant
CA1339132	1997-07-01		Applicant
CA2401731	2001-10-01		Applicant
DE1801750	1969-07-01		Applicant
DE1617477	1970-01-01		Applicant
DE2255731	1973-05-01		Applicant
DE2355731	1974-05-01		Applicant
DE2409460	1974-08-01		Applicant
DE2460990	1974-12-01		Applicant
DE2365101	1975-07-01		Applicant
DE2460990	1976-07-01		Applicant
DE2605584	1976-08-01		Applicant
DE2605242	1976-09-01		Applicant
DE2517771	1976-10-01		Applicant
DE2737808	1978-03-01		Applicant
EP170258	1986-02-01		Applicant
EP249194	1986-06-01		Applicant
EP295092	1988-12-01		Applicant
EP308135	1989-03-01		Applicant
EP342003	1989-11-01		Applicant
EP572014	1993-01-01		Applicant
EP639563	1995-02-01		Applicant
EP648488	1995-04-01		Applicant
EP1008588	1998-02-01		Applicant
EP857718	1998-08-01		Applicant
EP1016660	1998-09-01		Applicant
EP911321	1999-04-01		Applicant
EP925787	1999-06-01		Applicant
EP970697	1999-09-01		Applicant
EP947500	1999-10-01		Applicant
EP1267807	2003-01-01		Applicant
EP1267806	2005-12-01		Applicant
FR2108027	1971-09-01		Applicant
FR2182928	1973-12-01		Applicant
FR2239458	1975-02-01		Applicant
FR2314712	1977-01-01		Applicant
FR2730811	1995-02-01		Applicant
GB1236227	1971-06-01		Applicant
GB1251750	1971-10-01		Applicant
GB1285371	1972-08-01		Applicant
GB1285372	1972-08-01		Applicant
GB1324737	1973-07-01		Applicant
GB1409841	1975-11-01		Applicant
GB1456512	1976-11-01		Applicant
GB1456513	1976-11-01		Applicant
GB1456514	1976-11-01		Applicant
GB1456838	1976-11-01		Applicant
GB1542569	1979-03-01		Applicant
GB1545411	1979-05-01		Applicant
GB2025413	1980-01-01		Applicant
GB2048254	1980-12-01		Applicant
GB2330307	1999-04-01		Applicant
JP49-069636	1974-07-01		Applicant
JP49-075558	1974-07-01		Applicant
JP49-093342	1974-09-01		Applicant
JP49-100071	1974-09-01		Applicant
JP49-101356	1974-09-01		Applicant
JP49-102647	1974-09-01		Applicant
JP50-95269	1975-07-01		Applicant
JP50-142539	1975-11-01		Applicant
JP50-157344	1975-12-01		Applicant
JP51-086449	1976-07-01		Applicant
JP52-5744	1977-01-01		Applicant
JP52-012919	1977-01-01		Applicant
JP52-053841	1977-04-01		Applicant
JP53-028160	1978-03-01		Applicant
JP58-029710	1983-02-01		Applicant
JP60-032763	1985-02-01		Applicant
JP61-218510	1986-09-01		Applicant
JP63-211231	1988-09-01		Applicant
JP2022226	1990-01-01		Applicant
JP3-034934	1991-02-01		Applicant
JP3-83925	1991-04-01		Applicant
JP3-83926	1991-04-01		Applicant
JP4-300833	1992-10-01		Applicant
JP5-331025	1993-12-01		Applicant
JP9-295921	1997-11-01		Applicant
JP10-251225	1998-09-01		Applicant
JP10-287532	1998-10-01		Applicant
JP2003180399	2003-07-01		Applicant
WO86/00616	1986-01-01		Applicant
WO89/03384	1989-04-01		Applicant
WO90/02553	1990-03-01		Applicant
WO92/02495	1992-02-01		Applicant
WO94/08585	1994-04-01		Applicant
WO95/00552	1995-01-01		Applicant
WO95/11003	1995-04-01		Applicant
WO95/11033	1995-04-01		Applicant
WO95/18102	1995-07-01		Applicant
WO95/19165	1995-07-01		Applicant
WO95/19964	1995-07-01		Applicant
WO96/10407	1996-04-01		Applicant
WO96/36599	1996-11-01		Applicant
WO97/03973	1997-02-01		Applicant
WO97/09049	1997-03-01		Applicant
WO97/15319	1997-05-01		Applicant
WO97/23223	1997-07-01		Applicant
WO97/23225	1997-07-01		Applicant
WO97/23226	1997-07-01		Applicant
WO97/29735	1997-08-01		Applicant
WO97/31895	1997-09-01		Applicant
WO97/39754	1997-10-01		Applicant
WO98/00100	1998-01-01		Applicant
WO98/12175	1998-03-01		Applicant
WO98/13016	1998-04-01		Applicant
WO98/19680	1998-05-01		Applicant
WO98/20880	1998-05-01		Applicant
WO98/20881	1998-05-01		Applicant
WO98/21180	1998-05-01		Applicant
WO98/21181	1998-05-01		Applicant
WO98/21182	1998-05-01		Applicant
WO98/27976	1998-07-01		Applicant
WO98/28264	1998-07-01		Applicant
WO98/33497	1998-08-01		Applicant
WO98/39293	1998-09-01		Applicant
WO98/47515	1998-10-01		Applicant
WO98/50024	1998-11-01		Applicant
WO98/53809	1998-12-01		Applicant
WO98/57930	1998-12-01		Applicant
WO98/57942	1998-12-01		Applicant
WO98/58911	1998-12-01		Applicant
WO99/02165	1999-01-01		Applicant
WO99/12550	1999-03-01		Applicant
WO99/12551	1999-03-01		Applicant
WO99/12552	1999-03-01		Applicant
WO99/12553	1999-03-01		Applicant
WO99/12554	1999-03-01		Applicant
WO99/12555	1999-03-01		Applicant
WO99/12556	1999-03-01		Applicant
WO99/12557	1999-03-01		Applicant
WO99/12558	1999-03-01		Applicant
WO99/12559	1999-03-01		Applicant
WO99/12560	1999-03-01		Applicant
WO99/12561	1999-03-01		Applicant
WO99/12563	1999-03-01		Applicant
WO99/12895	1999-03-01		Applicant
WO99/12896	1999-03-01		Applicant
WO99/12897	1999-03-01		Applicant
WO99/12898	1999-03-01		Applicant
WO99/12899	1999-03-01		Applicant
WO99/19300	1999-04-01		Applicant
WO99/21562	1999-05-01		Applicant
WO99/22731	1999-05-01		Applicant
WO99/25357	1999-05-01		Applicant
WO99/25358	1999-05-01		Applicant
WO99/30675	1999-06-01		Applicant
WO99/30718	1999-06-01		Applicant
WO99/32441	1999-07-01		Applicant
WO99/32640	1999-07-01		Applicant
WO99/32641	1999-07-01		Applicant
WO99/33794	1999-07-01		Applicant
WO99/47497	1999-09-01		Applicant
WO99/50241	1999-10-01		Applicant
WO99/50242	1999-10-01		Applicant
WO99/61029	1999-12-01		Applicant
WO99/64621	1999-12-01		Applicant
WO99/65303	1999-12-01		Applicant
WO99/65527	1999-12-01		Applicant
WO/02450	2000-01-01		Applicant
WO/03736	2000-01-01		Applicant
WO/03980	2000-01-01		Applicant
WO/04898	2000-02-01		Applicant
WO/04899	2000-02-01		Applicant
WO/07627	2000-02-01		Applicant
WO/09557	2000-02-01		Applicant
WO/13664	2000-03-01		Applicant
WO/15608	2000-03-01		Applicant
WO/16760	2000-03-01		Applicant
WO/51971	2000-09-01		Applicant
WO/51979	2000-09-01		Applicant
WO/51980	2000-09-01		Applicant
WO/54810	2000-09-01		Applicant
WO1/10873	2001-02-01		Applicant
WO1/74307	2001-10-01		Applicant
WO1/74313	2001-10-01		Applicant
WO1/74314	2001-10-01		Applicant
WO1/74315	2001-10-01		Applicant
WO2/067901	2002-09-01		Applicant
WO2/096868	2002-12-01		Applicant
WO3/051822	2003-06-01		Applicant
WO3/066008	2003-08-01		Applicant
WO3/077910	2003-09-01		Applicant
WO2006/047466	2006-05-01		Applicant
WO2006/106311	2006-10-01		Applicant
WO2007/123818	2007-11-01		Applicant
WO2007/127639	2007-11-01		Applicant
WO2009/011744	2009-01-01		Applicant
WO2010/096123	2010-08-01		Applicant
WO2010/108012	2010-09-01		Applicant

Non-Patent Literature (564)

U.S. Appl. No. 11/174,420, filed Jul. 1, 2005, deLong et al.Applicant
U.S. Appl. No. 90/009,430, filed Mar. 15, 2009, Woodward.Applicant
U.S. Appl. No. 90/009,431, filed Mar. 10, 2009, Johnstone.Applicant
Canadian Office Response from Reissue Board in Application No. 2,401,731 dated Nov. 25, 2013.Applicant
Chinese Patent Office Action dated Feb. 7, 2014 (12 pages) for Chinese Application No. 201010193487.1, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315) filed Mar. 30, 2011 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
“Agents for Glaucoma,” Journal of the American Pharmaceutical Association, New Drugs of 2001, http://www.edscape.com/viewarticle/436631—22 (2007) 4 pages.Applicant
“Bimatoprost (ophthalmic)” Medlineplus, Health information online (Jul. 24, 2001) 4 pages, www.nlm.nih.gov/medlineplus/druginfor/uspdi/500295.Applicant
“Phase III lumigan—AGN 192024—data presented at American Academy of Ophthalmology,” Business Wire (Oct. 23, 2000) 3 pages.Applicant
Abramovitz, M. et al., “Cloning and expression of a cDNA for the human prostanoid FP receptor,” J. Biol. Chem. (1994) 269:2632-2636.Applicant
Abramovitz, M. et al., “The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs,” Biochimica et Biophysica Acta (2000) 1483(2):285-293.Applicant
ADIS, Adisinsight: ZD-6416, AstraZeneca (United Kingdom) Mar. 27, 2000, 1 page.Applicant
AGN-192024, Pharmaprojects, HB4 S1G (2006).Applicant
Allergan Clinical Study Report, Study No. 192024-008, “A multicenter, double-masked, unevenly randomized, parallel, active-controlled three-month study (with treatment extended to one year) of the safety and efficacy of once-daily or twice-daily administered AGN 192024 0.03% ophthalmic solution compared with twice-daily administered timolol 0.5% ophthalmic solution in subjects with glaucoma or ocular hypertension,” (Aug. 1, 2000), vol. 1 of 32, 356 pages.Applicant
Allergan Clinical Study Report, Study No. 192024-009, “A multicenter, double-masked, randomized, parallel, 3-month study (with treatment extended to 1 year) of the safety and efficacy of AGN 192024 0.03% ophthalmic solution administered once-daily or twice-daily compared with Timolol 0.5% ophthalmic solution administered twice-daily in subjects with glaucoma or ocular hypertension” (Aug. 2, 2000) 34 pages.Applicant
Allergan Clinical Study Report, Study No. 192024-010-01, “A multi-center, investigator-masked, randomized, parallel study of the safety and efficacy of AGN 192024 0.03% ophthalmic solution compared with Latanoprost 0.005% ophthalmic solution administered once-daily in subjects with glaucoma or ocular hypertension” (May 9, 2001) 38 pages.Applicant
Allergan Press Release, “Phase III Lumigan? (AGN 192024) data presented at American Academy of Ophthalmology,” Mar. 1, 2000, 5 pages.Applicant
Alm et al., “Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning,” Ophthalmology (1995) 102(12):1743-1752.Applicant
Alm, A. et al., “Phase III latanoprost studies in Scandanavia, the United Kingdom and the United States,” Surv. Ophthalmol. (1997) 41(Suppl 2):5105-S110.Applicant
Alm, A. et al., “Uveoscleral outflow—a review,” Exp. Eye Res. (2009) 88(4):760-768, Epub Jan. 3, 2009.Applicant
Alm, A., “The potential of prostaglandin derivates in glaucoma therapy; prostaglandins and derivates,” Curr. Opin. Opthalmol. (1993) 4(11):44-50.Applicant
Al-Sereiti, M.R., et al., “Pharmacology of Rosemary (Rosmarinus officinalis Linn.) and Its Therapeutic Potentials,” Indian Journal of Experimental Biology, vol. 37, Feb. 1999, pp. 124-130.Applicant
Anonymous, “Alprostadil (nexmed):Alprox-TD, Befar, Femprox, Prostaglandin E1 (nexmed),” Drugs R&D (1999) 2(6):413-414.Applicant
Audoly, L.P. et al., “Identification of specific EP receptors responsible for the hemodynamic effects of PGE2,” Am. J. Physiol. (1999) 46(3):H924-930.Applicant
Badawy, S.I. et al., “Salt selection for pharmaceutical compounds,” Adeyeye, J. editor, Preformulation in Solid Dosage Form Development, Informa Healthcare (2008) Chapter 2.3, 63-80.Applicant
Bartman, W., et al., “Leutolytic Prostaglandins Synthesis and Biological Activity”, Prostaglandins, vol. 17, No. 2, pp. 301-311, 1979.Applicant
Bastin, R.J. et al., “Salt selection and optimisation procedures for pharmaceutical new chemical entities,” Organic Process R&D (2000) 4(5):427-435.Applicant
Bean, G.W., “Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences,” Survey of Ophthalmology (2008) 53(1):569-84.Applicant
Berge, S.M. et al., “Pharmaceutical salts,” J. Pharm. Sci. (1997) 66(1):1-19.Applicant
Berglund, B.A. et al., “Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils,” Adv. Exp. Med. Biol. (1999) 469:527-533.Applicant
Bialer, M. et al., “Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers,” Eur. J. Clin. Pharma. (1984) 27:501-503.Applicant
Bito, L., “A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond,” The Proctor Lecture (2001) 42(6):1126-1133.Applicant
Bito, L.Z. et al., “Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of psotaglandins to cat or rhesus monkey eyes,” Invest. Ophthalmol. Vis. Sci. (1983) 24(3):312-319.Applicant
Bito, L.Z. et al., “The ocular pharma-cokinetics of eicosanoids and their derivatives,” Exp. Eye Res. (1987) 44:217-226.Applicant
Bockaert, J. et al., “Molecular tinkering of G protein-coupled receptors: an evolutionary success,” Eur. Molecular Biol. Org. (1999) 18:1723-1729.Applicant
Brandt, J.D. et al., “Comparison of once-or twice-daily bimatoprost with twice-daily timolol in pateints with elevated IPO. A three month clinical tril,” Ophthalmology (2001) 108(6):1023-1031.Applicant
Brown, M.M. et al., “Improper topical self-administration of ocular medication among patients with glaucoma,” Can. J. Ophthal. (1984) 19(1):2-5.Applicant
Brubaker, R.F. et al., “Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics,” Am. J. Opthal. (2001) 131(1):19-24.Applicant
Buck, F. et al., “Characterization of N- and C-terminal deletion mutants of the rat serotonin HT2 receptor in Xenopus laevis oocytes,” Biochem. Biophys. Res. Comm. (1991) 178, 1421-1428.Applicant
Bundy, G. L., and Lincoln, F. H., “Synthesis of 17-Phenyl-18, 19, 20-Trinoprostaglandins 1. The PG, Series,” Prostaglandins, vol. 9, No. 1, (Jan. 1975), pp. 1-4.Applicant
Cadet, P. et al., “Molecular identification and functional expression of mu3, a novel alternatively apliced variant of the human mu opiate receptor gene,” J. Immunol. (2003) 170(10):5118-5123.Applicant
Camras, C.B. et al. “Bimatoprost, the prodrug of a prostaglandin analogue,” Br. J. Ophthalmol. (2008) 92:862-863.Applicant
Camras, C.B. et al., “Latanoprost, a prostaglandin analog, for glaucoma therapy,” Ophthalmology (1996) 103(11):1916-1924.Applicant
Camras, C.B. et al., “Multiple dosing of prostaglandin F2alpha or epinephrine on cynomolgus monkey eyes,” Invest. Ophthalmol. Vis. Sci. (1987) 28(3):463-469.Applicant
Camras, C.B. et al., “Multiple dosing of prostaglandin F2alpha or epinephrine on cynomolgus monkey eyes,” Invest. Ophthalmol. Vis. Sci. (1987) 28(6):921-926.Applicant
Camras, C.B. et al., “Multiple dosing of prostaglandin F2alpha or epinephrine on cynomolgus monkey eyes,” Invest. Ophthalmol. Vis. Sci. (1988) 29(9):1428-1436.Applicant
Camras, C.B. et al., “Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits,” Invest. Ophthal & Vis. Sci. (1977) 16, 1125-1134.Applicant
Camras, C.B. et al., “Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2alpha,” Curr. Eye Res. (1981) 1(4):205-209.Applicant
Camras, C.B., “Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma,” Ophthalmology (1996) 103(1):138-147.Applicant
Camras, C.B., “Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery,” American Academy of Ophthalmology (2004) 2193-2198.Applicant
Cantor, L.B. et al., “Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract,” Br. J. Ophthalmol. (2007) 91:629-632.Applicant
Cantor, L.B., “Reply—bimatoprost, the prodrug of a prostaglandin analogue,” Br. J. Ophthalmol. (2008) 92:863-864.Applicant
CAS RN 155206-00-1 (May 20, 1994).Applicant
Cayatte, A.J. et al., “The thromboxane A2 receptor antagonist S18886 decreases atheroschlerotic lesions and serum intracellular adhesion molecule-1 in the Apo E knockout mouse,” Circulation (1998) 96:115.Applicant
Center for Drug Evaluation and Research, “Medical Officer's Review of NDA, Application No. 21-275,” Mar. 14, 2001; 120-day safety update Jan. 23, 2001; Mar. 2, 2001; Sep. 18, 2000, 63 pages.Applicant
Chen, J. et al., “AGN 191129: a neutral prostaglandin F-2 alpha (PGF2a) analog that lacks the mitogenic and uterotonic effects typical of FP receptor agonists,” IOVS (1999) 40:3562-B420, p. S675.Applicant
Chen, J. et al., “Replacement of the carboxylic acid group of prostaglandin F2alpha (PGH2alpha) with certain non-ionizable substituents results in pharmacologically unique ocular hypotensive agents,” 11th International Conference Advances Prostaglandins and Leuotremic Res. Basic Sci. & New Clinical Applications—Abstract book (2000) 48.Applicant
Chen, J. et al., “Structure-based dissociation of a type I polyketide synthase module,” Chem. Biol. (2007) 14, 784-792.Applicant
Chen, J. et al., “Studies on the pharmacology of prostamide F2alpha a naturally occurring substance,” Br. J. Pharm. (2001) 133, 63p.Applicant
Chen, J. et al., “Studies using isolated uterine and other preparations show Bimatoprost and prostanoid FP agents have different activity profiles,” Br. J. Pharm. (2005) 144, 493-501.Applicant
Chowdhury, U.R. et al., “Proteome analysis of human aqueous humor,” Biochem. Mol. Biol. (2010) 51(10):4921-4931.Applicant
Chrai, S.S. et al., “Drop size and initial dosing frequency problems of topically applied ophthalmic drugs,” J. Pharm. Sci. (1974) 63:333-338.Applicant
Chyun, Y.S. et al., “Stimulation of bone formation by prostaglandin E2,” Prostaglandins (1984) 27:97-103.Applicant
Ciruela, F. et al., “Immunologicla identification of A1 adenosine receptors in brain cortex,” J. Neurosci. Res. (1995) 42, 818-828.Applicant
Clissold, D., “The potential for prostaglandin pharmaceuticals,” Spec. Publ.-R. Soc. Chem. (1999) 244:115-129.Applicant
Coleman, R.A. et al., “Prostanoids and their receptors,” Comprehensive Med. Chem., Membranes and Receptors (1990) 3:643-714.Applicant
Coleman, R.A. et al., “VIII. International Union of Pharmacology. Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes,” Pharmacol. Rev. (1994) 46(2):205-229.Applicant
Collins, P.W. et al., “Synthesis of therapeutically useful prostaglandin and prostacyclin analogs,” Chem. Rev. (1993) 93:1533-1564.Applicant
Colombe, L. et al., “Prostanoid receptors in anagen human hair follicles,” Exp. Derm. (2007) 17:63-72.Applicant
Corsini, A. et al., “(5Z)-Carbacyclin discriminates between prostacyclin receptors coupled to adenylate cyclase in vascular smooth muscle and platelets,” Br. J. Pharmacol. (1987) 90:255-261.Applicant
Crowston, J.G. et al., “Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice,” Invest. Ophthal. Vis. Sci. (2005) 46:4571-4577.Applicant
Cummings, J. et al., “Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development,” Biochem. Pharmacol. (1998) 56:405-414.Applicant
Cyr, C. et al., “Prolonged desensitization of the human endothelin a receptor in Xenopus oocytes,” J. Biol. Chem. (1993) 268, 26071-26074.Applicant
Darnell, J. et al., “Cell-to-cell signaling: hormones and receptors,” Mol. Cell. Biol. (1990) 738-743.Applicant
Davies, S.S., “Hydrolysis of bimatoprost (lumigan) to its free acid by ocular tissue in vitro,” J. Ocular Pharm. Thera. (2003) 19(1):45-54.Applicant
Dean, T.R. et al., “Improvement of optic nerve head blood flow after one-week topical treatment with travoprost (AL-06221) in the rabbit,” IOVS (1999) 40(4):2688-B563, p. S509.Applicant
Del Toro, F. et al., “Characterization of prostaglandin E2 receptors and their role in 24,25-(OH)2D2-mediated effects on resting zone chondrocytes,” J. Cell Physiol. (2000) 182(2):196-208.Applicant
Delong, M.A., “Prostaglandin receptor ligands: recent patent activity,” Drugs (2000) 3(9):1039-1052.Applicant
Depperman, W.J., Jr., “Up-to-date scalp tonic,” New Eng. J. Med. (1970) 283(2):1115.Applicant
Dirks, M. et al., “Efficacy and safety of the ocular hyotensive lipid 192024 in patients with elevated IOP: a 30-day comparison with Latanoprost,” Invest. Opthal. Visual Sci. (2000) 41(4):2737-B983.Applicant
Draelos, Z.D., “Special considerations in eye cosmetics,” Clinics in Dermatology (2001) 19, 424-430.Applicant
DuBiner, H. et al., “Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost,” Survey of Ophthal. (2001) 45(S4):S353-S360.Applicant
Easthope, S.E. et al., “Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension,” Drugs Aging (2002) 19(3):231-248.Applicant
Eisenberg, D.L. et al., “A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension,” Drug Safety (1999) 20(6):505-514.Applicant
Ellis, C. K., et al., “Metabolism of Prostaglandin D2 in the Monkey,” J. of Biological Chem., vol. 254, No. 10, pp. 4152-4163 (1979).Applicant
Ernst, O.P. et al., “Mutation of the fourth cytoplasmic loop of Rhodopsin affects binding of transducin and peptides derived from the carboxyl-terminal sequences of transducin α and γ subunits,” J. Biol. Chem. (2000) 275, 1937-1943.Applicant
Fagot, D. et al., “Mitogenic signaling by prostaglandins in chemically transformed mouse fibroblasts: comparison with phorbol esters and insulin,” Endocrinology (1993) 132(4):1729-1734.Applicant
Fall, P. M., et al “Inhibition of Collagen Synthesis by Prostaglandins in the Immortalized Rat Osteoblastic Cell Line Pyla: Structure-Activity Relations and Signal Transduction Mechanisms,” J. Bone Miner. Res. (1994) 9:1935-1943 (abstract).Applicant
Fan, T. et al., “A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of μand δ opioid receptor hetero-oligomers,” J. biol. Chem. (2005) 280, 38478-38488.Applicant
Faulkner, R., “Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of Lumigan® or Travatan®,” J. Ocular Pharm. Thera. (2010) 26(2):147-156.Applicant
FDA Consumer Magazine, “New Drugs for Glaucoma” (May-Jun. 2001) 35(3), 4.Applicant
FDA Consumer, “New drugs for glaucoma (Lumigan and Travatan)” May 2001, available at http://www.highbeam.com/doc/1G1-75608860.html/print.Applicant
FDA Eye Cosmetic Safety at http://www.fda.gov/cosmetics/productandingredientsafety/productinformation/ucm137241.htm, (Aug. 1, 2001) 2 pages.Applicant
FDA Label for Approved NDA 22-184—Lumigan 0.01% and Lumigan 0.03% (Aug. 31, 2010) 5 pages.Applicant
FDA Press Release, “FDA News” of Mar. 16, 2001 entitled “FDA approves two new intraocular pressure lowering drugs for the management of glaucoma,” 2 pages.Applicant
Fiscella, R.G., “Peek into the drug pipeline,” Review of Optometery Online, Jan. 15, 2001, pp. 1-5.Applicant
Fitzpatrick, F. A., “Separation of Prostaglandins and Thromboxanes by Gas Chromatography with Glass Capillary Columns,” Analytical Chemistry, vol. 50, No. 1, pp. 47-52, 1978.Applicant
Fletcher, D.G. et al., “Synthesis and biological acivity of 16, 17-configurationally-ridig-17-aryl 18, 19, 20-trinorprostaglandins,” Prostaglandins (1976) 12(4):493-500.Applicant
Flisiak, R. et al., “Effect of misoprostol on the course of viral hepatitis B,” Hepato-Gastroenterology (1997) 44(17):1419-1425.Applicant
Fowler, C.J., “The contribution of cydooxygenase-2 to endocannabinoid metabolism and action,” Br. J. Pharmacol. (2007) 152:594-601.Applicant
Frenkel, R.E. et al., “Evaluation of circadian control of intraocular pressure after a single drop of bimatoprost 0.03% or travoprost 0.004%,” Curr. Med. Res. Opin. (2008) 24(4):919-923, epub Feb. 8, 2008.Applicant
Funk, C.D. et al., “Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype,” J. Biol. Chem. (1993) 268:26767-26772.Applicant
Gandolfi, S.A. et al., “Effect of Bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to Latanoprost,” Ophthal. (2003) 110:609-613.Applicant
Gandolfini, S. et al., “Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension,” Adv. In Therapy (2001) 18(3):110-121.Applicant
Garadi, R. et al., “Travoprost: a new once-daily dosed prostaglandin for the reduction of elevated intraocular pressure,” IOVS (1999) 40(4):4378-B181, p. S831.Applicant
Garza, L.A. et al., “Prostaglandin 02 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia,” Sci. Transl. Med. (2012) 4:1-11.Applicant
Gaynes, B.I. et al., “Topical ophthalmic NSAIDs: a discussion with focus on Nepfenac ophthalmic suspension,” Clin. Ophthal. (2008) 2, 355-368.Applicant
Geng, L. et al., “Topical or systemic 16,16 dm-prostaglandin E2 or WR-2721 (WR-1065) protects mice and alopecia after fractionated irradiation,” Int. J. Radiat. Biol. (1992) 61(4):533-537.Applicant
Geng, L., Malkinson, F.D., Hanson, W.R., “Misoprostol, A PGE1 Analog that is Radioprotective for Murine Intestine and Hair, Induces Widely Different Cytokinetic Changes in these Tissues,” Journal of Investigative Dermatology, 1996, vol. 106, No. 4, p. 858.Applicant
Gerth, J. et al., “Drug makers reap profits on tax-backed research,” New York Times, Apr. 23, 2000, 10 pages.Applicant
Giuffre, G., “The effects of prostaglandin F2alpha in the human eye,” Graefe's Arch. Clin. Exp. Ophthalmol. (1985) 222:139-141.Applicant
Glaucoma Foundation, Treatment update, New drug approved by Food and Drug Administration. Unoprostone isopropyl ophthalmic solution, 15%, Eye to Eye Newsletter, (Fall 2000) 11, p. 10.Applicant
Griffin, B.W. et al., “AL-8810: a novel prostaglandin F2a analog with selective antagonist effects at the prostaglandin F2a (FP) receptor,” J. Pharmacol. Exp. Ther. (1999) 290(3):1278-1284.Applicant
Gupta, R. et al., “Evaluating eye drop instillation technique in glaucoma patients,” J. Glaucoma (2012) 21:189-192.Applicant
Haj-Yehia, A. et al., “Structure-pharmacokinetic rleationships in a series of short fatty acid amides that possess anticonvulsant activity,” J. Pharm. Sci. (1990) 79, 719-24.Applicant
Hall, A., Smith, W. H. T., “Clinprost Teijin,” Current Opinion in Cardiovascular, Pulmonary & Renal Investigation Drugs, 1999, 1(5), pp. 605-610.Applicant
Hallinan, E.A. et al., “Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs,” J. Med. Chem. (1996) 39:609-613.Applicant
Hanson, W.R. et al., “16,16 dm prostaglandin 2 protects from acute radiation-induced alopecia in mice,” Clin. Res. (1988) 36(6):906a.Applicant
Hanson, W.R. et al., “Misoprostol, a PGE1 Analog that is Radioprotective for Murine Intestine and Hair, Induces Widely Different Cytokinetic Changes in these Tissues,” J. Invest. Dermatol. (1996) 106(4):858.Applicant
Hanson, W.R. et al., “Subcutaneous or topical administration of 16,16 dimethyl prostaglandin E2 protects from radiation-induced alopecia in mice,” Int. J. Radiat. Oncol. Biol. Phys. (1992) 23(2):333-337.Applicant
Hartke, J.R. et al., “Prostanoid FP agonists build bone in the ovariectomized rat,” J. Bone Min. Res. (1999) 14(T326):S207.Applicant
Hayashi, M. et al., “Prostaglandin Analogues Possessing Antinidatory Effects. 1. Modification of the ω Chain,” J. Med. Chem. (1980) 23(5):519-524.Applicant
Hecker, M. et al., “Studies on the interaction of minoxidil with prostacyclin synthase in-vitro,” Biochem. Pharmacol. (1988) 37(17):3363-3365.Applicant
Hellberg, M.R. et al., “Identification and characteristics of the ocular hypotensive efficacy of Travoprost, a potent and selective prostaglandin receptor agonist and AL-6598, a DP prostaglandin receptor agonist,” Surv. Ophthal. (2002) 47:S13-33.Applicant
Hellberg, M.R. et al., “The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyltrinor PGF2a by human and rabbit ocular tissue,” J. Ocular Pharmacol. Ther. (2003) 19:97-103.Applicant
Higginbotham, E.J. et al., “One-year randomized study comparing bimatoprost and timololin in glaucoma and ocular hypertension,” Arch. Ophthal. (2002) 120(10):1286-1293.Applicant
Hirata, T. et al., “Prostanoid receptors,” Chem. Rev. (2011) 111(10):6209-6230.Applicant
Ho, N.F.H., “Physical model approach to the design of drugs with improved intestinal absorption,” in Design of Biopharmaceutical Properties Through Prodrugs and Analogs, Roche ed, (1977) Chapter 8, pp. 136, 177-182.Applicant
Hoen, P.A.C. et al., “mRNA degradation controls differentiation state-dependent differences in transcript and splice variant abundance,” Nuc. Acids Res. (2010) 39, 556-566.Applicant
Honohan, T. et al., “Duration of the activity of the acid, methyl ester and amide of an orally active platelet aggregation inhibitory prostanoid in the rat,” Prost. (1980) 19(1):139-153.Applicant
Honohan, T. et al., “Hydrolysis of an orally active platelet inhibitory prostanoid amide in the plasma of several species,” Prostaglandins (1980) 19(1):123-138.Applicant
Hori, H. et al., “The thickness of human scalp: normal and bald,” J. Invest. Derm. (1972) 58, 396-399.Applicant
Hosoda, M. et al., “Do glaucoma patients use eye drops correctly?” J. Glaucoma (1995) 4:202-206.Applicant
Houssay, A.B. et al., “Effects of prostaglandins upon hair growth in mice,” Acta Physiol. Let. Am. (1976) 266(3):186-191.Applicant
Huang, A. et al., “Different modes of inhibition of increase in cytosolic calcium and aggregation of rabbit platelets by two thromboxane A2 antagonists,” Asia Pacific Journal of Pharmacology (1994) 9:163-171.Applicant
Hulan, H.W. et al., “The development of dermal lesions and alopecia in male rats fed grapeseed oil,” Can. J. Physiol. Pharmacol. (1976) 54(1):1-6.Applicant
Hulan, H.W. et al., “The effect of long-chain monoenes on prostaglandin E2 synthesis by rat skin,” Lipids (1977) 12(7):604-609.Applicant
Hwang, K. et al., “Thickness of Korean upper eyelid skin at different levels,” J. Craniofacial Surgery (2006) 17, 54-56.Applicant
Ichhpujani, P. et al., “Comparison of human ocular distribution of dimatoprost and latanoprost,” J. Ocular Pharm. Thera. (2012) 28:134-145.Applicant
Ichikawa, E.A. et al., “Molecular aspects of the structures and functions of the prostaglandin E receptors,” J. Lipid Mediators Cell Signaling (1996) 14:83-87.Applicant
Inoue, H., “Thromboxane A2 receptor antagonists,” Farumashia (1996) 32(1):1221-1225 (no English translation available).Applicant
Jakobsson, P.J. et al., “Membrane-associated proteins in elcosanoid and glutathione metabolism (MAPEG)—a widespread protein superfamily,” Am J. Resp. Crit. Care Med. (2000) 161:S20-S24.Applicant
Jimenez De Asua, L. et al., “The stimulation of the initiation of DNA synthesis and cell division in Swiss mouse 3T3 cells by prostaglandin F2alpha requires specific functional groups in the molecule,” J. Biol. Chem. (1983) 256(14):8774-8780.Applicant
Jimenez, J.J. et al., “Stimulated monocyte-conditioned media protect for cytosine arabinoside-induced alopecia in rat,” Clin. Res. (1990) 38(4):973a.Applicant
Johnstone, M.A. et al., “Prostaglandin-induced hair growth,” Surv. Ophth. (2002) 47(1):S185-202.Applicant
Johnstone, M.A., “Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost,” Amer. J. Ophthal. (1997) 544-547.Applicant
Johnstone, M.A., Brief latanoprost Rx induces hypertrichosis, IOVS (1998) 39(4):1180-B61.Applicant
Joost, P. et al., “Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands,” Genome Biol. (2002) 3(11):0063.1-16.Applicant
Jordan, B.A. et al., “G-protein coupled receptor heterodimerization modulates receptor function,” Nature (1999) 399(6737):697-700.Applicant
Karim, S.M.M. et al., “Prostaglandins and human respiratory tract smooth muscle: structure activity relationship,” Adv. Prostaglandin Thromboxane Res. (1980) 7:969-980.Applicant
Kass, M.A. et al., “Madarosis in chronic epinephrine therapy,” Arch. Ophthal. (1972) 88:429-431.Applicant
Kaufman, P.L., “Effects of intracamerally infused prostaglandins on outflow facility in cynomolgus monkey eyes with intact or retrodisplaced ciliary muscle,” Exp. Eye Res. (1986) 43:819-827.Applicant
Kaupmann, K. et al., “GABA(B)-receptor subtypes assemble into functional heteromeric complexes,” Nature (1998) 396, 683-687.Applicant
Ke, T-L et al., “Nepafanac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation,” Inflammation (2000) 24, 371-384.Applicant
Kelly, C.R et al., “Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone an dother analogs via endogenous mouse, rat and cloned human Fp prostaglandin receptors,” J. Pharm. Exp. Ther. (2003) 304(1):238-245.Applicant
Kende, et, al., “Prostaglandin Phosphonic Acids Through Homolytic Halodecarboxylation of Prostaglandins Flα and F2α,” Tetrahedron Letters, vol. 40, pp. 8189-8192 (1999).Applicant
Kerstetter, J.R. et al., “Prostaglandin F2 alpha- 1 -isopropylester lowers intraocular pressure without decreasing aqueous humor flow,” Am. J. Ophthalmology (1988) 105:30-34.Applicant
Kiriyama, M. et al., “Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells,” Br. J. Pharm. (1997) 122:217-224.Applicant
Kluender, H.C. et al., “The Synthesis of Diethylphosphonoprostaglandin Analogs” Prostaglandins and Medicine (1979) 2(6):441-444.Applicant
Kobilka, B.K. et al., “Chimeric alpha2-, beta2-adrenergic receptors: delineration of domains in volved in effector coupling and ligand binding specificity,” Science (1988) 240:1310-1316.Applicant
Kolker, A.E., Discussion, Ophthalmology (2001) 108(6):1032.Applicant
Krauss, A.H.P. et al., “Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin-F2-alpha,” Br. J. Pharmacol. (1996) 117(6):1171-1180.Applicant
Kvedar, J.C. et al., “Topical minoxidil in the treatment of male pattern alopecia,” Pharmacotherapy (1987) 7(6):191-197.Applicant
La Du, B.N., “Pharmacogenetics: defective enzymes in relation to reactions to drugs,” Ann. Rev. Med. (1972) 23, 453-468.Applicant
Lachgar, S. et al., “Effect of VEGF and minoxidil on the production of arachidonic acid metabolites by cultured hair, dermal papilla cells,” Eur. J. Dermatol. (1996) 6(5):365-368.Applicant
Lachgar, S. et al., “Hair dermal papilla cell metabolism is influenced by minoxidil,” Fundam. Clin. Pharmacol. (1997) 11(2):178.Applicant
Lachgar, S. et al., “Modulation by minoxidil and VEGF of the production of inflammatory mediators by hair follicle dermal papilla cells,” J. Invest. Derm. (1995) 104(1):161.Applicant
Lardy, C. et al., “Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl) sulfonyl]amino] methyl] cyclopentyl] methyl] benzeneacetate,” Arzneim.-Forsch./Drug Res. (1994) 44(11):1196-1202.Applicant
Latisse (Bimatoprost Ophthalmic Solution) 0.03% Label (2001).Applicant
Lederer, C.M. et al., “Drop size of commercial glaucoma medications,” Am. J. Ophthal. (1986) 101:691-694.Applicant
Lee, P.-Y. et al., “The effect of prostaglandin F2alpha on intraocular pressure in mormotensive human subjects,” Invest. Ophthalmol. Vis. Sci. (1988) 29(10):1474-1477.Applicant
Lee, V.H.L. et al., “Improved ocular drugs delivery with prodrugs,” in Prodrugs: Topical and Ocular Drug Delivery, Marcel Dekker, New York (1992) 221-297.Applicant
Lee, V.H.L. et al., “Review: topical ocular drug delivery: recent developments and future challenges,” J. Ocular Pharm. (1986) 2:67-108.Applicant
Letter from Bernadette Attinger at Sandoz Inc. To the General Counsels at Allergan, Inc. and Duke University regarding Notice of Certification Under 21 USC Sect. 355(j)(2)(b) of Federal Food, Drug and Cosmetic Act) and 21 CFR Sect. 314.95, regarding Sandoz Inc.'s ANDA 202719, dated Mar. 3, 2011 (21 pages).Applicant
Letter from Bernice Tao at Apotex, Inc. to the General Counsels at Allergan, Inc. and Duke University regarding “Apotex Bimatoprost Topical Solution 0.03% Paragraph IV Certification—U.S. Patent Nos. 7,351,404 and 7,388,029” (Jul. 26, 2010) 49 pages.Applicant
Letter from Joanne Curri at Hi-Tech Pharmacal Co., Inc. to Duke University regarding Abbreviated New Drug Application in Accordance with Section 505(j)(2)(b) of the Food, Drug and Cosmetic Act dated Jun. 29, 2011 (22 pages)Applicant
Letter from Joyce Delgaudio at Watson Laboratories, Inc. to the General Counsels at Allergan, Inc. and Duke University regarding Notification of Certification for U.S. Patent Nos. 7,351,404; 7,388,029; 8,038,988; and 8,101,161 Pursuant to §505(j)(2)(B)(iv) of the Federal Food, Drug, and Cosmetic Act dated Feb. 28, 2012 (42 pages), redacted.Applicant
Liang, Y. et all., “Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor varian complexes,” Br. J. Pharmacol. (2008) 154:1079-1093.Applicant
Liljebris, C., Selen, G., Resul, B. Stjernschantz, J., and Hacksell, U., “Derivatives of 17-Phenyl-18, 19, 20 Trinorprostaglan F2a Isopropyl Ester: Potential Antiglaucoma Agents,” Journal of Medicinal Chemistry, vol. 38, No. 2, (1995), pp. 289-304.Applicant
Ling, G. et al., “16,16 dm prostaglandin E2 protects mice from fractionated radiation-induced alopecia,” Clin. Res. (1990) 38(3):858a.Applicant
Lumigan (Bimatoprost Opthalmic Solution) 0.03% Package Insert, Mar. 2001.Applicant
Lumigan 6-month phase 3 data presented at American Glaucoma Society Meeting, Mar. 2, 2001, Business Wire, 3 pages.Applicant
Lundy, M.W. et al., “Restoration of cancellous architecture and increased bone strength in aged osteopenic rats treated with fluprostenol, ”J. Bone Min. Res. (1999) 1(4)SA368:S401.Applicant
Maddox, Y.T. et al., “Amide and L-amino derivatives of F prostaglandins as prostaglandin antagonists,” Nature (1978) 273:549-552.Applicant
Maggio, R. et al., “Reconsitution of functional muscarinic receptors by co-expression of amino- and carboxyl-terminal receptor fragments,” Fed. Eur. Biochem. Soc. Left. (1993) 319, 195-200.Applicant
Malkinson, F.D. et al., “Prostaglandins protect against murine hair injury produced by ionizing radiation or doxorubicin,” J. Invest. Dermatol. (1993) 101(1, Suppl):135S-137S.Applicant
Mansberger, S.L. et al., “Eyelash formation secondary to latanoprost treatment in a patient with alopecia,” Arch. Ophthalmol. (2000) 118:718-719.Applicant
Maruyama, T. et al., “EP1 receptor antagonists suppress tactile allodynia in rats,” Prostaglandins Lipid Mediat. (1999) 59:217.Applicant
Matias et al., “Prostaglandin ethanolamides (Prostamides): in vitro pharmacology and metabolism,” J. Pharm. Exp. Thera. (2004) 309:745-757.Applicant
Matsumura, H., “Prostaglandins and Sleep,” Saishin No to Shinkai Kagaku Shiritzu 10, 1998, pp. 79-89 (no English translation available).Applicant
Maw, G.N., “Pharmacological therapy for the treatment of erectile dysfunction,” Annu. Rep. Med. Chem. (1999) 34:71-80.Applicant
Maxey, K.M., “The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist,” Survey of Ophthalmology (2002) 47(1):S34-40.Applicant
McCullough, P.A., “Ridogrel,”Current Opinion in Anti-inflammatory & Immunomodulatory Investigation Drugs (1999) 1(3):265-276.Applicant
Mentlein, R. et al., “Hydrolysis of ester- and amide-type drugs by purified isoenzymes of nonspecific carboxylesterase from rat liver,” Biochem. Pharm. (1984) 33:1243-1248.Applicant
Michelet, J.F. et al., “Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulation effect,” J. Invest. Dermatol. (1997) 108(2):205-209.Applicant
Mihele, D., “The Testing of the Hepatoprotective Action of Some New Synthetic Prostaglandins,” Farmacia (Bucharest) vol. 47 (5), 1999, pp. 43-58 (Abstract in English).Applicant
Millar, R.P. et al., “Diversity of actions of GnRHs mediated by ligand-induced selective signaling,” Frontiers in Neuroendocrinology (2008) 29, 17-35.Applicant
Millikan, L.E., “Treatment of alopecia,” J. Clin. Pharmacol. (1987) 27(9):715.Applicant
Millikan, L.E., “Treatment of male pattern baldness,” Drug Therapy (1989) 19(3):62-73.Applicant
Mishima, H.K. et al., “A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension,” Arch. Ophthalmol. (1996) 114:929-932.Applicant
Mishima, S. et al., “Determination of tear volume and tear flow,” Invest. Ophthal. (1966) 5(3):264-276.Applicant
Miyamoto, T., et al., “A comparison in the Efficacy and Safety between Ramatroban (BAY u 3405) and Ozargrel HC1 for Bronchial Asthma: A Phase III, Multi-Center, Randomized, Double-Blind, Group Comparative Study,” 13, 1997, pp. 599-639 Abstract (in English).Applicant
Mori, S. et al., “Effects of prostaglandin E2 on production of new cancellous bone in the axial skeleton of overlectomized rats,” Bone (1990) 11:103-113.Applicant
Morris, C.L. et al., “The role of bimatoprost eyelash gel in chemotherapy-induced madarosis: an analysis of efficacy and safety,” Int. J. Trichology (2011) 3, 84-91.Applicant
Murakami, T. et al., “Effect of isocarbacyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease,” Arzheim.-Forsh/Drug Res. (1995) 45(Ii)(9):991-994.Applicant
Narumiya, S., “Roles of prostanoids in health and disease, lessons from receptor-knockout mice,” Int. Congr. Ser. (1999) 1181:261-269.Applicant
Neau, S.H., “Pharmaceutical salts,” Water-Insoluble Drug Formulation, Rong Liu editor, CRC Press (2008) 15:417-435.Applicant
Negishi, M. et al., “Molecular mechanisms of diverse actions of prostanoid receptors,” Biochimica et Biophysica Acta (1995) 1259:109-120.Applicant
Ng, G.Y.K., “Phosphorylation and palmitoylation of the human D2L dopamine receptor in Sf9 cells,” J. Neurochem. (1994) 63:1589-1595.Applicant
Norridin, R.W. et al., “The role of prostaglandins in bone in vivo,” Prostaglandins, Leukotrienes and Essential Fatty Acids (1990) 41:139-149.Applicant
Ohashi, P.S. et al., “Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer,” Nature (1985) 316:606-609.Applicant
Olsen, E.A. et al., “Transdermal viprostol in the treatment of male pattern baldness,” J. Amer. Acad. Dermatol. (1990) 23(3 Part 1):470-472.Applicant
Orlicky, D.J., “Negative regulatory activity of a prostaglandin F2a receptor associated protein (FPRP),” Prostaglandins, Leukotrienes and Essential Fatty Acids (1996) 54(4):247-259.Applicant
Ortonne, J-P. et al., “Hair melanin's and hair color: ultrastructural and biochemical aspects,” J. Soc. Inv. Derm. (1993) 82S-89S.Applicant
Ota, T. et al., “The effects of prostaglandin analogues on IOP in prostanoid FP receptor-deficient mice,” Invest. Ophthal. Vis. Sci. (2005) 46, 4159-4163.Applicant
Ota, T. et al., The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor deficient mice, Invest. Ophthal. Vis. Sci. (2006) 47, 3395-3399.Applicant
Ozawa, A. et la., “Deorphanization of novel peptides and their receptors,” Am. Assc. Pharm. Sci. (2010) 12(3):378-384.Applicant
Patton, T.F. et al., “Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes,” J. Pharm. Sci. (1976) 65:1295-1301.Applicant
Pfeiffer, N., “New developments in glaucoma drug therapy,” Ophthalmologist (1992) 89:W1-W13.Applicant
Phamaprojects, No. 6321, Merck & Co. (2006) 1 page.Applicant
Physician's Desk Reference (2001) Supplement A, “Lumigan” (Mar. 2001) 3 pages.Applicant
Pierce, K.L. et al., Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor, J. Biol. Chem. (1997) 272, 883-887.Applicant
Pierce, K.L. et al., “Prostanoid receptor heterogeneity through alternative mRNA splicing,” Life Sci. (1998) 62:1479-1483.Applicant
Pin, J-P et al., “Alternative splicing generates metabotropic glutamate receptors inducing different patterns of calcium release in Xenopus oocytes,” Proc. Natl. Acad. Sci. (1992) 89, 10331-10335.Applicant
Powell, W.S. et al., “Prostaglandin F2alpha receptor in ovine Corpora lutea,” Eur. J. Biochem. (1974) 41:103-107.Applicant
Poyer, J.F. et al., “Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle,” Invest. Ophthalmol. Vis. Sci. (1995) 36(12):2461-2465.Applicant
Preparation of '404 patent documents for European Patent Office; Defendant Peter Thomas Roth Labs LLC and Peter Thomas Roth, Inc.,'s Invalidity Contentions Pursuant to Patent Local Rule 3-3 (Jun. 26, 2009).Applicant
Preparation of '404 Patent Documents for European patent Office; Defendants Metics LLC, Product Innovations LLC; Stella International LLC; and Nutra-Luxe, M.D. LLC's; Local Patent rule 3-3 Preliminary Invalidity Contentions (Jun. 26, 2009).Applicant
Rampton, D.S., Carty, E., Van Nueten, L., Anti-Inflammatory Profile in Vitro of Ridogrel, a Putative New Treatment for Inflammatory Bowel Disease, Gastroenterology, 1999, (116) G3477, p. 801.Applicant
Ramsey, D. et al., “Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): Hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences,” Biochem. J. (2002) 365:429.Applicant
Rath, C.M. et al., “Meta-omic characterization fo the marine invertebrate microbial consortium that produces the chemotherapeutic nature product ET-743,” ACS Chem. Biol. (2011) 6, 1244-1256.Applicant
Regan, J.W. et al., “Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype,” Mol. Pharm. (1994) 46, 213-220.Applicant
Response from the Food and Drug Administration to Pfizer's Citizen Petition and a Supplement (Aug. 31, 2010) at 23 (Exhibit 5), 26 pages.Applicant
Resul, B. et al., “Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents,” J. Med. Chem. (1993) 36(2):243-248.Applicant
Roenigk, H.H., “New topical agents for hair growth,” Clinics in Dermatology (1988) 6(4):119-121.Applicant
Romano, M.R., “Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle,” Invest. Opthal. Vis. Sci. (2007) 48(8):3677-3682.Applicant
Roof, S.L. et al., “mRNA expression of prostaglandin receptors EP1, EP2, EP3 and EP4 in human osteoblast-like cells and 23 human tissues,” J. Bone Min. Res. (1996) 11:S337.Applicant
Rouzer, C.Z. et al., “Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways,” Chem. Rev. (2011) 111:5899-5921.Applicant
Ruel, R. et al., “New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor,” Bioorg. Med. Chem. Left. (1999) 9:2699-2704.Applicant
Saito, O. et al., “Expression of the prostaglandin F receptor (FP) gene along the mouse genitourinary tract,” AJP-Renal Physiol. (2003) 284:F1164-1170.Applicant
Sakuma, Y. et al., “Crucial involvement of the PE4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide,” J. Bone Min. Res. (2000) 15(2):218-227.Applicant
Salim, K. et al., “Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation,” J. Biol. Chem. (2002) 277:15482-15483.Applicant
Satoh, T. et al., “The mammalian carboxylesterases: from molecules to functions,” Ann. Rev. Pharmacol. & Toxicol. (1998) 38:257-288.Applicant
Sauk, J.J. et al., “Influence of prostaglandin E-1 prostaglandin E-2 and arachidonate on melanosomes in melanocytes and keratinocytes of anagen bulbs in-vitro,” J. Invest. Dermatol. (1975) 64(5):332-337.Applicant
Scarselli, M. et al., “Reconsitution of functional dopamine D2s receptor by co-expression of amino- and carboxyl-terminal receptor fragments,” Eur. J. Pharma. (2000) 397, 291-296.Applicant
Schaaf, T.K. et al., “Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues,” J. med. Chem. (1979) 22:1340-1346.Applicant
Schachtsschabel, U. et al., “The mechanism of action of prostaglandins on oveosclerol outflow,” Curr. Op. Ophthal. (2000) 11, 112-115.Applicant
Shanbhag, V.r. et al., “Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity,” J. Pharm. Sci. (1992) 81, 149-154.Applicant
Sharif, N.A. et al., “3H AL-5848 ([3H]9 beta-(+)-fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor,” J. Phar. Pharmacol. (1999) 51(6):685-694.Applicant
Sharif, N.A. et al., “Agonist activity of Bimatoprost, Tavoprost, Latanoprost, Unoprosone, Isopropyl Ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor,” J. ocular Pharmacol. Therap. (2002) 18, 313-324.Applicant
Sharif, N.A. et al., “Bimatoprost (Lumigan) is an agonist at the cloned human ocular FP prostaglandin receptor: real-time FLIPR-based intracellular Ca2+ mobilization studies,” Prostaglandin Leukotrienes & Essential Fatty Acids (2003) 68:27-33.Applicant
Sharif, N.A. et al., “Bimatoprost and its free acid are prostaglandin FP receptor agonists,” Eur. J. Pharmacol. (2001) 432(2-3):211-213.Applicant
Sharif, N.A. et al., “Cat iris sphincter smooth-muscle contraction: comparison of FP-class prostaglandin analog agonist activities,” J. Ocul. Pharmacol. Ther. (2008) 24(2):152-163.Applicant
Sharif, N.A. et al., “Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation,” J. Ocul. Pharmacol. Ther. (2003) 19:437-455.Applicant
Sharif, N.A. et al., “Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues,” Invest. Ophthalmol. Vis. Sci. (2003) 44:715-721.Applicant
Sharif, N.A., “Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells,” J. Ocular Pharm. Thera. (2003) 19(6):501-515.Applicant
Sharif, N.A., “Update and commentary on the pro-drug bimatoprost and a putative 'prostamide receptor',” Expert Rev. Ophthalmol. (2009) 4(5):477-489.Applicant
Sheerer, P. et al., “Crystal structure of opsin in its G-protein-interacting conformation,” Nature (2008) 455, 497-502.Applicant
Shell, J.W., “Ophthalmic drug delivery systems,” Survey Ophthal. (1984) 29(2):117-128.Applicant
Shell, J.W., “Pharmacokinetics of topically applied ophthalmic drugs,” Surv. Ophthal. (1982) 26(4):207-218.Applicant
Sherwood, M. et al., “Six-month comparison of bimatoprost once-daily and twice-daily with timomol twice-daily in patients with elevated intraocular pressure,” Surv. Ophthal. (2001) 45(4):5361-5368.Applicant
Shih, M.S. et al., “PGE2 induces regional remodeling changes in Haversian envelope: a histomorphometric study of fractured ribs in beagles,” Bone and Mineral (1986) 1:227-234.Applicant
Shimazaki, A., et al. “New Ethacrynic Acid Derivatives as Potent Cytoskeletal Modulators in Trabecular Meshwork Cells,” Biol. Pharm. Bull. vol. 27, No. 6, 2004, pp. 846-850.Applicant
Shimazaki, A., et al., “Effects of the New Ethacrynic Acid Derivative SA9000 on Intraocular Pressure in Cats and Monkeys,” Biol Pharm. Bull. vol. 27, No. 7, 2004, pp. 1019-1024.Applicant
Singer, I.I. et al., “CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells,” J. Virol. (2001) 75(8):3779-3790.Applicant
Sjoquist, B. et al., “Ocular and systemic pharmacokinetics of latanoprost in humans,” Surv. Ophthalmol. (2002) 47(Supp 1):S6-12.Applicant
Sjoquist, B. et al., “Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography, Glacoma research laboratories,” Arzneimittelforschung (1999) 49:240-249.Applicant
Sorbera, L.A. et al., “Travoprost” Drugs of the Future (2000) 25(1):41-45.Applicant
Souillac, P. et al., “Characterization of delivery systems, differential scanning calorimetry,” Encyclopedia of Controlled Drug Delivery, John Wiley & Sons (1999) 212-227.Applicant
Spada, C.S. et al., “Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells,” Exp. Eye Res. (2005) 80(1):135-145.Applicant
Sredni, B. et al., “The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models,” Int. J. Cancer (1996) 65(1):97-103.Applicant
Stahl, P.H. et al., editors, Handbook of Pharmaceutical Salts, Properties, Selection and Use, Wiley-Vch (2008) Chapter 12, 265-327.Applicant
Stamer, W.D. et al., “Cellular basis for bimatoprost effects on human conventional outflow,” Invest. Ophthalmol. Vis. Sci. (2010) 51(10):5176-5181, Epub Apr. 30, 2010.Applicant
Stern, F.A. et al., “Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes,” Invest. Ophthal & Vis. Sci. (1982) 22, 588-598.Applicant
Stjernschantz et al., “Preclinical pharmacology of Latanoprost, a phenyl-substituted PGF2alpha analogue,” Adv. Prostagldin Thromboxane & Leukotriene Res. (1995) 23:513-518.Applicant
Stjernschantz, J. et al., “Phenyl substituted prostaglandin analogs for glaucoma treatment,” Drugs of the Future (1992) 17(8):691-704.Applicant
Stjernschantz, J., “Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment,” Exp. Eye Res. (2004) 78(4):759-766.Applicant
Stjernschantz, J.W., “From PGF2alpha-isopropyl ester to latanoprost: a review of the development of Xalatan: the Proctor lecture,” Invest. Ophthalmol. Vis. Sci. (2001) 42(6):1134-1145.Applicant
Stulting, R.D. et al., “Diagnosis and management of tear film dysfunction,” in Corneal Disorders; Clinical Diagnosis and Management (Leibowitz et al. eds) (1998) Chapter 16, 482-500.Applicant
Svensson, et al., “The design and bioactivation of presystemically stable prodrugs,” Drug Metabolism Rev. (1988) 19(2):165-194.Applicant
Swarbrick, J. et al., editors, Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc. (1988) 13:453-499.Applicant
Tauchi, M. et al., “Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle and anagen prolongation by bimatoprost,” Br. J. Derm. (2010) 162, 1186-1197.Applicant
Tereda, N. et al., “Effect of a thromboxane A2 receptor antagonist, ramatroban (BAY U3405), on inflammatory cells, chemical mediators and non-specific nasal hyperactivity after allergen challenge in patients with perennial allergic rhinitis,” Allergology Int. (1998) 47(1):59-67.Applicant
The Newsletter of the Glaucoma Foundation, Fall 2000, vol. 11, No. 2, 11 pages.Applicant
Thomas, W. et al., “Stable expression of a truncated AT1A receptor in CHO-K1 cells,” J. Biol. Chem. (1995) 270:207-213.Applicant
Tomasz, M., “Mitomycin C: small, fast and deadly (but very selective),” Chem. Biol. (1995) 2, 575-579.Applicant
Tomita, Y. et al., “Melanocyte-stimulating properties of arachidonic acid metabolites: possible role in postinflammatory pigmentation,” Pigm. Cell Res. (1992) 5(5, Pt. 2):357-361.Applicant
Toris, C.B. et al., “Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction,” Surv. Ophthal. (2008) 53, S107-S120.Applicant
Travatan (Travoprost Opthalmic Solution) 0.04% Product Insert (Published Mar. 16, 2001), 7 pages.Applicant
Trinkaus-Randall, V. et al., “Corneal structure and function,” in Corneal Disorders: Clinical Diagnosis and Management, Howard M. Leibowitz et al. eds., (1998) 2nd Edition, p. 2-31.Applicant
Trueb, R.M., “Chemotherapy—induced alopecia,” Seminars Cutaneous Med. & Surg. (2009) 28, 11-14.Applicant
Ueda, K. et al., “Brief clinical and laboratory observations: coritical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease,” J. Pediatrics (1980) 97:834-836.Applicant
Ungrin, M.D. et al., “Key structural features of prostaglandin E2 and prostanoid analogs involved in binding and activation of the human EP1 prostanoid receptor,” Mol. Pharm. (2001) 59, 1446-1456.Applicant
Van Alphen, G.W.H.M. et al., “The effect of prostaglandins on the isolated internal muscles of the mammalian eye, including man,” Documenta Ophthalmologica (1977) 42(2):397-415.Applicant
Van Santvliet, L. et al., “Determinants of eye drop size,” Surv. Ophthal. (2004) 49(2):197-213.Applicant
Vandenburgh, A.M. et al., “A one-month dose-response study of AGN 192024, a novel antiglaucoma agent, in patients with elevated intraocular pressure,” IOVS (1999) 40(4):4373-B176, p. S830.Applicant
Vandenburgh, A.M., reply to Alan L. Robin, “An accurate comparison of Bimatoprost's efficacy and adverse effects,” Arch. Ophthal. (2002) 120:1000.Applicant
Vassilatis, D. et al., “The G protein-coupled receptor repertoires of human and mouse,” Proc. Natl. Acad. Sci. USA (2003) 100, 4903-4908.Applicant
Vayssairat, M., Preventive Effect of an Oral Prostacyclin Analog, Beraprost Sodium, on Digital Necrosis in Systemic Scierosis, J. of Rheumatol., 1999, 26(10), pp. 2173-2178.Applicant
Vengerovsky, A.I. et al., “Hepatoprotective action of prostaglandins,” Eksp. Klin. Farmakof. (1997) 60(5):78-82.Applicant
Verbeuren, T., et al., “The TP-Receptor Antagonist S 18886 Unmasks Vascular Relaxation and Potentiates the Anti-Platelet Action of PGD2,” Journal of the International Society Thrombosis and Haemostasis, Jun. 6-12, 1997, p. 693.Applicant
Vielhauer, G.A. et al., “Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor,” Arch. Biochem. Biophys. (2004) 421(2):175-185.Applicant
Villumsen, J. et al., “Prostaglandin F2alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma,” Br. J. Ophthalmol. (1989) 73:975-979.Applicant
Vincent, J.E., “Prostaglandin synthesis and selenium deficiency a hypothesis,” Prostaglandins (1974) 8(4):339-340.Applicant
Vippagunta, “Crystalline solids,” Adv. Drug Del. Rev. (2001) 48:3-26.Applicant
Voss, N.G. et al., “Induction of anagen hair growth in telogen mouse skin by topical latanoprost application,” IOVS (1999) 40:3570-B428, p. S676.Applicant
Waddell, K. A., et al., “Combined Capillary col. Gas Chromatography Negative Ion Chemical Ionization Mass Spectrometry of Prostanoids,” Biomed. Mass Spectrom., vol. 10, No. 2, pp. 83-88 (1983).Applicant
Walsh, D.A. et al., “Anti-inflammatory agents, syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid,” J. Med. Chem. (1990) 33:2296-2304.Applicant
Wan, Z. et al., “Bimatoprost, prostamide activity, and conventional drainage,” Invest. Ophthal. Vis. Sci. (2007) 48, 4107-4115.Applicant
Wand, M., “Latanoprost and hyperpigmentation of eyelashes,” Archives of Ophthalmology (1997) 115(9):1206-1208.Applicant
Wang, Y. et al., “The design and synthesis of 13, 14-dihydro prostaglandin F1a analogs as potent and selective ligands for the human FP receptor,” J. Med. Chem. (2000) 43(5):945-952.Applicant
Warne, T. et al., “Expression and purification of truncated, non-glycosylated Turkey beta-adrenergic receptors for crystallization,” Biochimica et Biophysica Acta—Biomembranes (2003) 1610, 133-140.Applicant
Warne, T. et al., “Structure of a betal-adrenergic G-protein-coupled receptor,” Nature (2008) 454:486-491.Applicant
Watson et al., “A six-month, randomized, double-masked study in comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension,” Ophthalmology (1996) 103:126-137.Applicant
Weber, A. et al., “Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry,” J. Lipid Res. (2004) 45, 757-763.Applicant
White, J.H. et al., “Heterodimerization is required for the formation of a functional GABA(B) receptor,” Nature (1998) 396(6712):679-682.Applicant
Whitson, J.T., “Travoprost—a new prostaglandin analogue for the treatment of glaucoma,” Exp. Op. Pharmacotherapy (2002) 3(7):965-977.Applicant
Wilson, S.J. et al., “Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation,” J. Biol. Chem. (2004) 279(51):53036-53047.Applicant
Winfield, A.J. et al., “A study of the causes of non-compliance by patients prescribed eyedrops,” Br. J. Ophthal. (1990) 74:477-480.Applicant
Witkowski, A. et al., “Head-to-head coiled arrangement of the subunits of the animal fatty acid synthase,” Chem. Biol. (2004) 11, 1667-1676.Applicant
Woodward, D., “Replacement of carboxylic acid group of prostaglandin F2a with a hydroxyl or methoxy substituent provides biologically unique compounds,” Br. J. Pharma. (2000) 130(8):1933-1943.Applicant
Woodward, D.F. et al., “Bimatoprost effects on aqueous humor dynamics in monkeys,” J. Ophthalmol. (2010) Article ID 926192, 5 pages.Applicant
Woodward, D.F. et al., “Bimatoprost: a novel antiglaucoma agent,” Cardiovasc. Drug Rev. (2004) 22(2):103-120.Applicant
Woodward, D.F. et al., “Emerging evidence for additional prostanoid receptor subtypes,” Curr. Top. Pharmacol. (1998) 4:153-163.Applicant
Woodward, D.F. et al., “Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris,” Br. J. Pharmacol. (2007) 150:342-352.Applicant
Woodward, D.F. et al., “Molecular characterization and ocular hypotensive properties of the prostanoid EP2 receptor,” J. Oc. Pharm. Therap. (1995) 11(3):447-454.Applicant
Woodward, D.F. et al., “Pharmacological characterization of a novel anti-glaucoma agent,” J. Pharmacol. Exp. Ther. (2003) 305:772-785.Applicant
Woodward, D.F. et al., “Prostaglandins F2alpha (PGF2alpha) 1-ethanolamide: a pharmacologically unique local hormone biosynthesized from anandamide,” 11th Int. Conf. Advances Prostaglandin & Leukotrine Res: Basic Sci and New Clinical Applications—abstract book (2000) 27.Applicant
Woodward, D.F. et al., “Studies on the ocular effects of a pharmacologically novel agent prostaglandin F2 alpha 1-OCH3 (AGN 191129) N-S,” Arch. Pharmacol. (1998) 358(1):P1713.Applicant
Woodward, D.F. et al., “The pharmacology of bimatoprost (Lumigan),” Surv. Ophthalmol. (2001) 45(Suppl 4):S337-45.Applicant
Xalatan (Latanoprost Opthalmic Solution) 0.005% product insert (Published Jun. 6, 2001), 5 pages.Applicant
Yamaji, K. et al., “Prostaglandins El and E2, but not F2alpha or latanoprost, inhibit monkey ciliary muscle contraction,” Curr. Eye Res. (2005) 30(8):661-665.Applicant
Yang, W. et al., “Enzymatic formation of prostamide F2alpha from anandamide involves a newly identified intermediate metabolite, prostamide H2,” J. Lipid Res. (2005) 46, 2745-2751.Applicant
Yoshida, K. et al., “Synthesis and pharmacological activities of the new TXA2 receptor antagonist Z-335 and related compounds,” AFMC (1995) 95:53.Applicant
Yuan, X. et al., “Quantitative proteomics: comparison of the macular bruch membrane/choroid complex from age-related macular degeneration and normal eyes,” Mol. Cell Proteomics (2010) 9:1031-1046.Applicant
Zeigler, T., “Old drug, new use: new research shows common cholesterol-lowering drug reduces multiple sclerosis symptoms in mice,” Natl. Institute of Neurological Disorders and Stroke (2003) 2 pages.Applicant
Zimbric, M.L. et al., “Effects of latanoprost of hair growth in the bald scalp of stumptailed macaques,” IOVS (1999) 40:3569-B427, p. S676.Applicant
Zioptan (Tafluprost Opthalmic Solution) 0.0015% product insert (Published Feb. 10, 2012), 12 pages.Applicant
International Search Report for Application No. PCT/US00/05301 (WO 00/51980) dated Jul. 21, 2000 (3 pages).Applicant
Written Opinion for Application No. PCT/US00/05301 (Wo 00/51980) dated Oct. 20, 2000 (7 pages).Applicant
International Preliminary Examination Report for Application No. PCT/US00/05301 (WO 00/51980) dated Mar. 16, 2001 (6 pages).Applicant
International Search Report for Application No. PCT/US00/20851 (WO 01/10873) dated Nov. 7, 2000 (4 pages).Applicant
Written Opinion for Application No. PCT/US00/20851 (WO 01/10873) dated Jul. 10, 2001 (9 pages).Applicant
International Preliminary Examination Report for Application No. PCT/US00/20851 (WO 01/10873) dated Oct. 12, 2001 (8 pages).Applicant
International Search Report for Application No. PCT/US98/18339 (WO 99/12895) dated Dec. 3, 1998 (2 pages).Applicant
International Preliminary Examination Report for Application No. PCT/US98/18339 (WO 99/12895) dated Jun. 28, 1999 (4 pages).Applicant
International Search Report for Application No. PCT/US98/18340 (WO 99/12896) dated Dec. 8, 1998 (3 pages).Applicant
Written Opinion for Application No. PCT/US98/18340 (WO 99/12896) dated Aug. 2, 1999 (7 pages).Applicant
International Preliminary Examination Report for Application No. PCT/US98/18340 (WO 99/12896) dated Dec. 6, 1999 (7 pages).Applicant
International Search Report for Application No. PCT/US98/18594 (WO 99/12898) dated Dec. 3, 1998 (3 pages).Applicant
Written Opinion for Application No. PCT/US98/18594 (WO 99/12898) dated May 25, 1999 (5 pages).Applicant
International Preliminary Examination Report for Application No. PCT/US98/18594 (WO 99/12898) dated Sep. 7, 1999 (5 pages).Applicant
International Search Report for Application No. PCT/IB99/00478 (WO 99/50241) dated Jul. 12, 1999 (3 pages).Applicant
Written Opinion for Application No. PCT/IB99/00478 (WO 99/50241) dated Feb. 21, 2004 (4 pages).Applicant
International Preliminary Examination Report for Application No. PCT/IB99/00478 (WO 99/50241) dated Jun. 23, 2000 (5 pages).Applicant
International Search Report for Application No. PCT/IB99/00480 (WO 99/50242) dated Jun. 25, 1999 (3 pages).Applicant
Written Opinion for Application No. PCT/IB99/00480 (WO 99/50242) dated Jan. 18, 2000 (6 pages).Applicant
International Search Report for Application No. PCT/US00/05299 (WO 99/51979) dated Jul. 28, 2000 (3 pages).Applicant
Written Opinion for Application No. PCT/US00/05299 (WO 99/51979) dated Oct. 20, 2000 (7 pages).Applicant
International Preliminary Examination Report for Application No. PCT/US00/05299 (WO 99/51979) dated Mar. 16, 2001 (7 pages).Applicant
International Search Report for Application No. PCT/US01/10368 (WO 01/74313) dated Nov. 7, 2001 (3 pages).Applicant
International Preliminary Examination Report for Application No. PCT/US01/10368 (WO 01/74313) dated Jun. 14, 2002 (2 pages).Applicant
International Search Report for Application No. PCT/US01/10369 (WO 01/74314) dated Nov. 7, 2001 (3 pages).Applicant
International Preliminary Examination Report for Application No. PCT/US01/10369 (WO 01/74314) dated Jun. 14, 2001 (3 pages).Applicant
International Search Report for Application No. PCT/US01/10370 (WO 01/74315) dated Nov. 7, 2001 (3 pages).Applicant
International Preliminary Examination Report for Application No. PCT/US01/10370 (WO 01/74315) dated Jun. 14, 2002 (2 pages).Applicant
International Search Report for Application No. PCT/US01/10547 (WO 01/74307) dated Jan. 2, 2002 (2 pages).Applicant
International Preliminary Examination Report for Application No. PCT/US01/10547 (WO 01/74307) dated Jun. 14, 2002 (2 pages).Applicant
Invitation to Pay Additional Fees and Partial International Search for Application No. PCT/US2009/062590 (WO 2010/096123) dated Aug. 19, 2010 (5 pages).Applicant
International Search Report and Written Opinion for Application No. PCT/US2009/062590 (WO 2010/096123) dated Nov. 16, 2010 (16 pages).Applicant
Invitation to Pay Additional Fees and Partial International Search for Application No. PCT/US2010/43701 dated Sep. 28, 2010 (2 pages).Applicant
International Search Report and Written Opinion for Application No. PCT/US2010/43701 dated Dec. 7, 2010 (10 pages).Applicant
International Search Report and Written Opinion for Application No. PCT/US2010/27831 (WO 2010/108012) dated Apr. 26, 2010 (8 pages).Applicant
Chinese Office Action dated Jun. 22, 2007 (7 pages) for Chinese Application No. 01807355.7, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315) filed Mar. 30, 2001 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
Chinese Office Action dated Feb. 4, 2005 (9 pages) for Chinese Application No. 01807355.7, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315) filed Mar. 30, 2001 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
Canadian Office Action dated Nov. 28, 2005 (2 pages) for Canadian Application No. 2401731, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315) filed Mar. 30, 2001 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
Canadian Office Action for Canadian Application No. 2401731 dated Oct. 1, 2004 (3 pages) , claiming priority to International Application No. PCT/US01/10370 (WO 01/74315) filed Mar. 30, 2001 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
Chinese Patent Office Action dated Nov. 13, 2009 (9 pages) for Chinese Application No. 200810081548.8, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315) filed Mar. 30, 2001 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
Chinese Patent Office Action dated May 23, 2011 (13 pages) for Chinese Application No. 201010193487.1, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315) filed Mar. 30, 2011 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
Chinese Patent Office Action dated Jul. 6, 2012 (6 pages) for Chinese Application No. 201010193487.1, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315) filed Mar. 30, 2011 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
Chinese Patent Office Action dated Feb. 6, 2013 (12 pages) for Chinese Application No. 201010193487.1, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315) filed Mar. 30, 2011 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
European Patent Office Action dated May 13, 2004 (4 pages) for European Application No. 01926506.5, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315) filed Mar. 30, 2001 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
Japanese Patent Office Action dated Jun. 7, 2011 (10 pages) for Application No. 2001-572061, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315 filed Mar. 30, 2001 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
Japanese Patent Office Action dated Apr. 30, 2013 (10 pages—Including English Translation) for Application No. 2011-262344, claiming priority to International Application No. PCT/US01/10370 (WO 01/74315 filed Mar. 30, 2001 and U.S. Appl. No. 60/193,645, filed Mar. 31, 2000.Applicant
Complaint for Patent Infringement, U.S. District Court for Middle District of North Carolina, Allergan, Inc. et al., v. Hi-Tech Pharmacal Co., Inc., Case No. 1:11-CV-650, filed Aug. 17, 2011 (11 pages).Applicant
Hi-Tech Pharmacal Co., Inc.'s Answer to Allergan, Inc.'s and Duke University's Complaint Against Hi-Tech for Patent Infringement, U.S. District Court for Middle District of North Carolina, Allergan, Inc. et al. v. Hi-Tech Pharmacal Co., Inc., Case No. 1:11-CV-650, filed Oct. 7, 2011 (18 pages).Applicant
Allergan, Inc. and Duke University's Answer to Counterclaims of Hi-Tech Pharmacal Co., Inc., U.S. District Court for Middle District of North Carolina, Allergan, Inc. et al. v. Hi-Tech Pharmacal Co., Inc., Case No. 1:11-CV-650, filed Oct. 31, 2011 (8 pages).Applicant
Defendant Hi-Tech Pharmacal Co., Inc's Responses to Plaintiffs First Set of Interrogatories, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al., v. Hi-Tech Pharmacal Co., Inc., Case No. 1:11-CV-650 dated Feb. 21, 2012 (14 pages).Applicant
Complaint for Patent Infringement, U.S. District Court, North Carolina Middle District, Allergan, Inc. et al v. Sandoz, Inc., Case No. 1:11-cv-00298-CCE -WWD, filed Apr. 15, 2011 (12 pages).Applicant
Defendant Sandoz Inc.'s Answer, Affirmative Defenses and Counterclaim, U.S. District Court, North Carolina Middle District, Allergan, Inc. et al v. Sandoz, Inc., Case No. 1:11-cv-00298-CCE -WWD, filed May 27, 2011 (29 pages).Applicant
Allergan, Inc. and Duke University's Answer to Counterclaims of Sandoz Inc., U.S. District Court, North Carolina Middle District, Allergan, Inc. et al v. Sandoz, Inc., Case No. 1:11-cv-00298-CCE -WWD, filed Jun. 20, 2011 (6 pages).Applicant
Defendants Apotex Inc., Apotex Corp., Sandoz, Inc. and Hi-Tech Pharmacal Co., Inc.'s Supplemental Joint Submission Concerning Inquiry by the Court During the Claim Construction Hearing, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Aug. 2, 2012 (7 pages).Applicant
Defendant Sandoz Inc.'s First Set of Supplemental Responses to Plaintiffs' First Set of Interrogatories (Nos. 5, 6, and 11), U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. v. Apotex Inc. et al. and Allergan, Inc. et al. v. Sandoz, Inc., Case Nos. 1:10-CV-681-CCE-PTS and 1:11-CV-298-CCE-PTS dated Feb. 7, 2012 (39 pages).Applicant
Expert Report of Dr. David H. Sherman, Ph.D., Pursant to Federal Rule of Civil Procedure 26(a)(2)(B), U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Apr. 27, 2012, redacted (81 pages).Applicant
Expert Report of Howard M. Leibowitz, M.D., Pursant to Federal Rule of Civil Procedure 26(a)(2)(B), U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Apr. 27, 2012, redacted (43 pages).Applicant
Reply Expert Report of Vesna Petronic-Rosic, M.D., Pursant to Federal Rule of Civil Procedure 26(a)(2)(B), U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Jun. 19, 2012, redacted (10 pages).Applicant
Reply Expert Report of Dr. David H. Sherman, Ph.D., Pursant to Federal Rule of Civil Procedure 26(a)(2)(B), U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Jun. 19, 2012, redacted (79 pages).Applicant
Apotex's Fifth Supplemental and/or Amended Responses and Objections to Allergan, Inc.'s and Duke University's First Set of Interrogatories to Defendants Apotex Inc. and Apotex Corp. (Interrogatory Nos. 5 and 6), U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al., v. Apotex Inc. et al., Case No. 1:10-CV-681 dated Aug. 24, 2012, redacted (46 pages).Applicant
Defendant Sandoz Inc.'s Second Set of Supplemental Responses to Plaintiffs' First Set of Interrogatories (Nos. 5 and 6), U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Sep. 10, 2012, redacted (80 pages).Applicant
Defendant Hi-Tech Pharmacal Co., Inc.'s Supplemental Responses to Plaintiffs First Set of Interrogatories, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650, redacted, dated Sep. 13, 2012 (44 pages).Applicant
Plaintiffs' Opening Brief in Support of Plaintiffs' Motion in Limine No. 1 to Exclude Expert Opinions on Anticipation and Obviousness Not Disclosed in Expert Reports, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Sep. 10, 2012 (13 pages).Applicant
Deposition Transcript of Howard M. Leibowitz, M.D. taken Jul. 26, 2012, portions thereof, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650, filed Sep. 10, 2012 (7 pages).Applicant
Defendants Apotex, Sandoz, and Hi-Tech's Brief in Opposition to Plaintiffs' Motion in Limine No. 1, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Oct. 4, 2012 (18 pages).Applicant
Deposition of Howard M. Leibowitz, M.D., taken Jul. 26, 2012, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 submitted Oct. 4, 2012, (332 pages).Applicant
Stipulated Facts, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Oct. 26, 2012 (9 pages).Applicant
Plaintiffs' Brief in Opposition to Defendants' Motion in Limine No. 1 on the Alleged Invention Dates for the Patents-in-suit, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Nov. 1, 2012 (14 pages).Applicant
Excerpts of Transcript of Deposition of Timothy L. MacDonald dated Aug. 22, 2012, pp. 1, 26-27, 34-36, and 164-166 in Allergan, Inc. v. Apotex, Inc., Case No. 1:10CV681 (M.D. North Carolina).Applicant
Trial Transcript Day 5—Nov. 9, 2012—Testimony of Howard Leibowitz, and Dr. David Howard Sherman in Allergan, Inc. v. Apotex, Inc., Case No. 1:10CV681 (M.D. North Carolina).Applicant
Trial Transcript Day 6—Nov. 13, 2012—Testimony of Dr. David Howard Sherman, Robert Noecker, Robert Rhatigan, Dr. John Regan, in Allergan, Inc. v. Apotex, Inc., Case No. 1:10CV681 (M.D. North Carolina).Applicant
Trial Transcript Day 7—Nov. 19, 2012—Testimony of Dr. John Regan, Dr. Valerie Randall, Dr. Timothy MacDonald, in Allergan, Inc. v. Apotex, Inc., Case No. 1:10CV681 (M.D. North Carolina).Applicant
Trial Transcript Day 8—Nov. 20, 2012—Testimony of Dr. Timothy MacDonald, David H. Sherman, Harry Charles Boghigian, in Allergan, Inc. v. Apotex, Inc., Case No. 1:10CV681 (M.D. North Carolina).Applicant
Defendants' Memorandum in Support of Their Motion for Partial Judgment Under Federal Rule of Civil Procedure 52(c) that Plaintiffs Have Failed to Prove Alleged Conception Dates Earlier Than the Priority Filing Dates for the Patents-in-Suit, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Nov. 25, 2012 (21 pages).Applicant
Claim Construction Order, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Nov. 27, 2012 (3 pages).Applicant
Designated Excerpts From Brandt Deposition Submitted by Defendants at Trial (DTX 1035), U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (29 pages).Applicant
Plaintiffs' Brief in Opposition to Defendants' “Motion for Partial Summary Judgment Under Federal Rule of Civil Procedure 52(c) that Plaintiffs have Failed to Prove Alleged Conception Dates Earlier than the Priority Filing Dates for the Patents-in-Suit,” U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (23 pages).Applicant
Defendants' Opening Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (61 pages).Applicant
Appendix A of Defendants' Opening Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (2 pages).Applicant
Appendix B of Defendants' Opening Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (7 pages).Applicant
Appendix C of Defendants' Opening Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (10 pages).Applicant
Appendix D of Defendants' Opening Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (6 pages).Applicant
Appendix E of Defendants' Opening Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (11 pages).Applicant
Appendix F of Defendants' Opening Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al.,v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (3 pages).Applicant
Appendix G of Defendants' Opening Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (8 pages).Applicant
Appendix H of Defendants' Opening Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (12 pages).Applicant
Appendix I of Defendants' Opening Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (17 pages).Applicant
Defendants' Findings of Fact and Conclusions of Law, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (89 pages).Applicant
Defendants' Responsive Post-Trial Brief, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 10, 2012 (33 pages).Applicant
Defendants' Reply Memorandum in Support of Their Motion for Partial Judgment Under Federal Rule of Civil Procedure 52(c) that Plaintiffs have Failed to Prove Alleged Conception Dates Prior to the Priority Filing Dates for the Patents-in-Suit, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Dec. 21, 2012 (14 pages).Applicant
Judgment, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Jan. 25, 2013 (2 pages).Applicant
Memorandum Opinion and Order Upholding Validity of Parent U.S. Patent No. 7,388,029, U.S. District Court for the Middle District of North Carolina, Allergan, Inc. et al. vs. Apotex Inc. et al., Case No. 1:10-CV-681; Allergan, Inc. et al., v. Sandoz Inc., Case No. 1:11-CV-298; and Allergan, Inc. et al., v. Hi-Tech Pharmacol Co., Inc., Case No. 1:11-CV-650 dated Jan. 24, 2013, (25 pages).Applicant
Complaint for Patent Infringement, U.S. District Court, Middle Court of North Carollina, Allergan, Inc. et al., v. Apotex Inc. et al., Case No. 1:10-CV-681, Document 1, filed Sep. 8, 2010, 12 pages.Applicant
Answer, Defenses and Counterclaims of Defendants Apotex Inc. And Apotex Corporation, U.S. District Court, Middle Court of North Carolina, Allergan, Inc. et al., v. Apotex Inc. et al., Case No. 1:10-CV-681, Document 24, filed Nov. 22, 2010, 20 pages.Applicant
Allergan, Inc. and Duke University's Answer to Counterclaims of Apotex, Inc. and Apotex Corporation, U.S. District Court, Middle Court of North Carolina, Allergan, Inc. et al. v. Apotex Inc. et al., Case No. 1:10-CV-681, Document 26, filed Jan. 7, 2011, 6 pages.Applicant
Complaint for Patent Infringement, Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 1, Filed Apr. 27, 2009 (126 pages).Applicant
Defendant Metics, LLC's Answer to Complaint for Patent Infringement, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 25, Filed Apr. 7, 2009 (13 pages).Applicant
Defendant Peter Thomas Roth Labs LLC's Answer to Complaint for Patent Infringement, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 48, Filed Apr. 27, 2009 (12 pages).Applicant
Answer and Counterclaims of Defendants Athena Cosmetics, Inc. to Plaintiffs Allergan, Inc., Murray A. Johnstone, and Duke University's Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 54, Filed Apr. 27, 2009 (170 pages).Applicant
Answer and Counterclaims of Defendant Pharma Tech International., Inc. to Plaintiffs Allergan, Inc., Murray A. Johnstone, and Duke University's Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 55, Filed Apr. 27, 2009 (19 pages).Applicant
Answer and Counterclaims of Defendant Pharma Tech International, Inc. to Plaintiffs Allergan, Inc., Murray A. Johnstone, and Duke University's Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 56, Filed Apr. 28, 2009 (19 pages).Applicant
Answer and Counterclaims of Defendants Athena Cosmetics, Inc. to Plaintiffs Allergan, Inc., Murray A. Johnsone, and Duke University's complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 57, Filed Apr. 28, 2009 (170 pages).Applicant
Defendants Peter Thomas Roth Labs LLC and Peter Thomas Roth, Inc.'s first Amended Answer to Complaint for Patent Infringement, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 61, Filed May 7, 2009 (13 pages).Applicant
Answer of Defendants Lifetech Resources LLC and Rocasuba Inc. to Complaint for Patent Infringement, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 64, Filed May 8, 2009 (13 pages).Applicant
First Amended Answer and Counterclaims of Defendant Athena Cosmetics, Inc., to Plaintiffs Allergan, Inc., Murray A. Johnstone, and Duke University's Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv00328-JVS-RNB, Document 65, Filed May 7, 2009 (65 pages).Applicant
First Amended Complaint for Patent Infringement, Violation of California Business and Professions Code Section 17200 et seq., and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 86, Filed Aug. 10, 2009 (129 pages).Applicant
Answer of Defendants Lifetech Resources, LLC and Rocasuba, Inc. to First Amended Complaint for Patent Infringement, Violation of California Business and Professions Code Section 17200 et seq., and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 89, Filed Sep. 8, 2009 (18 pages).Applicant
Answer of Defendants Cosmetic Alchemy, LLC; Metics, LLC; Product Innovations, LLC; and Stella International, LLC to Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 90, Filed Sep. 11, 2009 (14 pages).Applicant
Answer of Defendant Nutra-Luxe MD to Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 91, Filed Sep. 11, 2009 (14 pages).Applicant
First Amended Complaint for Patent Infringement, Violation of California Business and Professions Code Section 17200 et seq., and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 95, Filed Oct. 22, 2009 (128 pages).Applicant
Order Entering Final Judgment Pursuant to Federal Rule of Civil Procedure 54(b) on Plaintiff Allergan, Inc.'s Fourth Claim for Relief in Favor of Defendants and Stay of Trial Court Proceedings Pending Appeal, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Athena Cosmetics Inc. et al., Case No. 8:09-cv-00328-JVS-RNB, Document 101, filed May 5, 2010 (2 pages).Applicant
Complaint for Patent Infringement and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 1, Filed Nov. 7, 2007 (12 pages).Applicant
First Amended Complaint for Patent Infringement and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 7, Filed Dec. 20, 2007 (8 pages).Applicant
Defendant Jan Marini Skin Research Inc.'s Answer to Plaintiff Allergan, Inc.'s Second Amended Complaint for Patent Infringement, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 75, Filed Apr. 2, 2008 (11 pages).Applicant
Answer and Counterclaims of Defendant Athena Cosmetics, Inc. to Plaintiffs Allergan, Inc. and Murray A. Johnstone's Second Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 79, Filed Apr. 2, 2008 (15 pages).Applicant
Second Amended Complaint for Patent Infringement and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 87, Filed May 8, 2008 (38 pages).Applicant
Third Amended Complaint for Patent Infringement and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 90, Filed May 15, 2008 (52 pages).Applicant
Answer to Third Amended Complaint and Additional Defenses of Defendant Photomedex, Inc., U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 91, Filed May 23, 2008 (8 pages).Applicant
Answer to Third Amended Complaint by Beauty Society, Inc., Formerly Intuit Beauty, Inc. and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 92, Filed May 23, 2008 (11 pages).Applicant
Defendant Jan Marini Skin Research Inc.'s Answer to Plaintiff Allergan, Inc.'s Third Amended Complaint for Patent Infringement, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 94, Filed May 23, 2008 (12 pages).Applicant
Answer and Counterclaims of Defendant Athena Cosmetics, Inc. to Plaintiffs Allergan, Inc. and Murray A. Johnstone's Third Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 98, Filed May 23, 2008 (20 pages).Applicant
Amended Answer and Counterclaims of Defendant Athena Cosmetics, Inc. to Plaintiffs Allergan, Inc., and Murray A. Johnstone's Third Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 111, Filed Jun. 12, 2008 (20 pages).Applicant
Defendant Cosmetic Alchemy, LLC's Answer to Third Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 116, Filed Jul. 2, 2008 (10 pages).Applicant
Allergan, Inc. and Murray A. Johnstone, M.D.'s Answer to Amended Counterclaims by Defendant Athena Cosmetics, Inc., U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 118, Filed Jul. 3, 2008 (10 pages).Applicant
Response of Procyte Corporation to the Third Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 122, Filed Jul. 14, 2008 (5 pages).Applicant
Defendant Cayman Chemical Company's Answer and Counterclaim to Third Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 126, Filed Jul. 24, 2008 (19 pages).Applicant
Joint Claim Construction and Prehearing Statement Under Patent Local Rule 4-3, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 175, Filed Nov. 13, 2008 (45 pages).Applicant
Allergan, Inc. and Murray A. Johnstone, M.D.'s Opening Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 185, Filed Dec. 15, 2008 (622 pages).Applicant
Defendant Athena Cosmetics, Inc.'s Opening Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 188, Filed Dec. 15, 2008 (84 pages).Applicant
Plaintiffs Allergan, Inc. and Murray A. Johnstone, M.D.'s Opening Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNb, Document 229, Filed Feb. 13, 2009 (594 pages).Applicant
Defendant Athena Cosmetics, Inc.'s Opening Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 233, Filed Feb. 13, 2009 (135 pages).Applicant
Fourth Amended Complaint for Patent Infringement and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 248, Filed Mar. 11, 2009 (54 pages).Applicant
Plaintiffs Allergan, Inc. and Murray A. Johnstone, M.D.'s Opposition Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 252, Filed Mar. 13, 2009 (34 pages).Applicant
Amended Answer and Counterclaims of Defendant Athena Cosmetics, Inc. to Plaintiffs Allergan, Inc., and Murray A. Johnstone's Fourth Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 273, Filed Mar. 24, 2009 (26 pages).Applicant
Defendant Cosmetic Alchemy, LLC's Answer to Fourth Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 275, Filed Mar. 31, 2009 (11 pages).Applicant
Plaintiffs Answer to Counterclaims by Defendant Athena Cosmetics, Inc. to Plaintiffs' Fourth Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 280, Filed Apr. 2, 2009 (11 pages).Applicant
Answer and Counterclaims of Defendant Pharma Tech International, Inc. to Plaintiffs Allergan, Inc. et al. and Murray A. Johnstone's Fourth Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 290, Filed Apr. 13, 2009 (25 pages).Applicant
Plaintiffs' Answer to Counterclaims by Defendant Pharma Tech International, Inc. to Plaintiffs' Fourth Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 291, Filed Apr. 16, 2009 (11 pages).Applicant
Answer of Defendants Lifetech Resources LLC and Rocasuba Inc. to Complaint for Patent Infringement, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 298, Filed May 8, 2009 (13 pages).Applicant
Defendant Nutra-Luxe M.D.'s Answer to Complaint for Patent Infringement filed in Case No. SACV09-328-JVS, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 310, Filed May 26, 2009 (13 pages).Applicant
Second Amended Answer and Counterclaims of Defendant Athena Cosmetics, Inc. to Plaintiffs Allergan, Inc., Murray A. Johnstone, and Duke University's Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 328, Filed Jul. 13, 2009 (56 pages).Applicant
Supplemental Joint Claim Construction and Prehearing Statement Regarding the ′105 and the ′404 Patents Under Patent Local Rule 4-3, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 355, Filed Aug. 24, 2009 (17 pages).Applicant
Defendants Peter Thomas Roth Labs LLC and Peter Thomas Roth, Inc.'s Answer to Plaintiffs' First Amended Complaint for Patent Infringement, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 370, Filed Sep. 8, 2009 (15 pages).Applicant
Answer of Defendants Lifetech Resources, LLC and Rocasuba, Inc. to First Amended Complaint for Patent Infringement, Violation of California Business and Prfessions Code Section 17200 et seq., and Demand for Jury Trial filed in Case No. SACV09-328-JVS, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 371, Filed Sep. 8, 2009 (18 pages).Applicant
Answer and Counterclaims of Defendant Pharma Tech . Johnstone, and Duke University's First Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 374, Filed Sep. 8, 2009 (21 pages).Applicant
Answer and Counterclaims of Defendant Northwest Cosmetic Laboratories, LLC to Plaintiffs Allergan, Inc., Murray A. Johnstone, and Duke University's First Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 376, Filed Sep. 8, 2009 (28 pages).Applicant
Answer and Counterclaims of Defendant Athena Cosmetics, Inc. to Plaintiffs Allergan, Inc., Murray A. Johnstone, and Duke University's First Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 377, Filed Sep. 8, 2009 (161 pages).Applicant
Lifetech Defendants' Opening Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 379, Filed Sep. 14, 2009 (24 pages).Applicant
Declaration of Elizabeth A. Zidones in Support of Lifetech Defendants' Opening Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 380, Filed Sep. 14, 2009 (314 pages).Applicant
Plaintiffs Allergan, Inc., Murray A. Johnstone, M.D. and Duke University's Supplemental Opening Claim Construction Brief Regarding the ′105 and the ′404 Patents, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 381, Filed Sep. 14, 2009 (195 pages).Applicant
Defendants Peter Thomas Roth, Inc. and Peter Thomas Roth Labs LLC's Opening Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 382, Filed Sep. 14, 2009 (22 pages).Applicant
Declaration of Dr. Brian M. Stoltz in Support of Ptr Defendants' Opening Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 383, Filed Sep. 14, 2009 (221 pages).Applicant
Declaration of Bryan J. Sinclair in Support of PTR Defendants' Opening Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 384, Filed Sep. 14, 2009 (31 pages).Applicant
Opening Markman Brief of Defendants Metics, LLC; Product Innovations, LLC; and Stella International, LLC, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 385, Filed Sep. 14, 2009 (11 pages).Applicant
Opening Markman Brief/Joinder of Defendant Nutra-Luxe, MD, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 386, Filed Sep. 14, 2009 (12 pages).Applicant
Supplemental Claim Construction Brief of Cosmetics Alchemy, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 387, Filed Sep. 14, 2009 (33 pages).Applicant
Athena Cosmetics, Inc.'s Supplemental Claim Construction Brief Re U.S. Patent No. 6,262,105 and U.S. Patent No. 7,351,404, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 388, Filed Sep. 14, 2009 (145 pages).Applicant
First Amended Answer of Defendants Lifetech Resources, LLC and Recasuba, Inc. to First Amended Complaint for Patent Infringement, Violation of California Business and Professions Code Section 17200 et seq. and Demand for Jury Trial filed in Case No. SACV09-328-JVS, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 401, filed Sep. 29, 2009 (17 pages).Applicant
Defendants Peter Thomas Roth, Inc. and Peter Thomas Roth Labs LLC's First Amended Answer to Plaintiffs' First Amended Complaint for Patent Infringement, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 405, Filed Oct. 1, 2009 (18 pages).Applicant
Amended Answer and Counterclaims of Defendant Northwest Cosmetic Laboratories, LLC to Plaintiffs Allergan, Inc., Murray A. Johnstone, and Duke University's First Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 411, filed Oct. 6, 2009 (34 pages).Applicant
First Amended Answer and Counterclaims of Defendant Athena Cosmetics, Inc. to Plaintiffs Allergan, Inc., Murray A. Johnstone, and Duke University's First Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 412, Filed Oct. 6, 2009 (56 pages).Applicant
Amended Answer and Counterclaims of Defendant Pharma Tech International, Inc. to Plaintiffs Allergan, Inc., Murray A. Johnstone, and Duke University's First Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 413, Filed Oct. 6, 2009 (22 pages).Applicant
First Amended Answer of Defendants Cosmetic Alchemy, LLC; Metics, LLC; Product Innovations, LLC; and Stella International, LLC to Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 416, Filed Oct. 9, 2009 (14 pages).Applicant
First Amended Answer of Defendant Nutra-Luxe MD to Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 417, Filed Oct. 9, 2009 (16 pages).Applicant
Plaintiffs Allergan, Inc. and Murray A. Johnstone, M.D.'s Reply Claim Construction Brief Regarding the ′105 and the ′404 Patents, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 418, Filed Oct. 13, 2009 (290 pages).Applicant
Defendants Peter Thomas Roth, Inc. and Peter Thomas Roth Labs LLC's Reply Claim Construction Brief, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 419, Filed Oct. 13, 2009 (15 pages).Applicant
Lifetech Defendants' Reply Brief in Opposition to Plaintiffs' Opening and Supplemental Claim Construction Briefs, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 423, Filed Oct. 13, 2009 (32 pages).Applicant
Declaration of Ryan J. Fletcher in Support of Lifetech Defendants' Brief in Opposition to Plaintiffs' Opening and Supplemental Claim Construction Briefs, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 424, Filed Oct. 13, 2009 (59 pages).Applicant
Plaintiffs' Answer to Counterclaims by Northwest Cosmetic Laboratories, LLC to Plaintiffs' First Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 432, Filed Oct. 23, 2009 (8 pages).Applicant
Plaintiffs' Answer to Counterclaims by Pharma Tech International, Inc. to Plaintiffs' First Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 433, Filed Oct. 23, 2009 (6 pages).Applicant
Plaintiffs' Answer to Counterclaims by Defendant Athena Cosmetics, Inc. To Plaintiffs' First Amended Complaint and Demand for Jury Trial, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 434, Filed Oct. 23, 2009 (21 pages).Applicant
Joint Claim Construction and Prehearing Statement Regarding U.S. Pat. No. 7,388,029 Under Patent Local Rule 43, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 435, Filed Oct. 23, 2009 (4 pages).Applicant
Second Amended Answer of Defendant Nutra-Luxe MD to Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 439, Filed Oct. 30, 2009 (17 pages).Applicant
Second Amended Answer of Defendants Cosmetic Alchemy, LLC; Metics, LLC; Product Innovations, LLC; and Stella International, LLC to Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document Filed Oct. 30, 2009 (14 pages).Applicant
Second Amended Answer of Defendants Lifetech Resources, LLC and Recasuba, Inc. To First Amended Complaint for Patent Infringement, Violation of California Business and Professions Code Section 17200 et seq. and Demand for Jury Trial Filed in Case No. SACV09-328-JVS, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document Filed Oct. 30, 2009 (18 pages).Applicant
Minutes of Markman/Claim Construction Hearing, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document Filed Oct. 26, 2009 (1 page).Applicant
Minutes of in Chambers Final Order re Claim Construction, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 446, Filed Nov. 16, 2009 (49 pages).Applicant
Stipulation for Defendants Cosmetic Alchemy, LLC; Metics, LLC; Product Innovations, LLC; Stella International, LLC; and Nutra-Luxe MD to Amend Their Second Amended Answers to Plaintiffs' First Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 448, Filed Dec. 7, 2009 (3 pages).Applicant
Third Amended Answer of Defendant Nutra-Luxe Md to Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 449, Filed Dec. 7, 2009 (17 pages).Applicant
Third Amended Answer of Defendants Cosmetic Alchemy, LLC; Metics, LLC; Product Innovations, LLC; and Stella International, LLC to Amended Complaint, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 450, Filed Dec. 7, 2009 (15 pages).Applicant
Plaintiffs Allergan, Inc. and Duke University's Opening Claim Construction Brief Regarding U.S. Patent No. 7,388,029, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 451, Filed Dec. 7, 2009 (241 pages).Applicant
Athena Cosmetics, Inc., Pharma Tech International, Inc. and Northwest Cosmetic Laboratories, LLC's Opening Claim Construction Brief Ref U.S. Patent No. 7,388,029, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 452, Filed Dec. 7, 2009 (213 pages).Applicant
Plaintiffs' Allergan, Inc. and Duke University's Reply Claim Construction Brief Regarding U.S. Patent No. 7,388,029, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 454, Filed Dec. 21, 2009 (72 pages).Applicant
Athena Cosmetics, Inc., Pharma Tech International, Inc. and Northwest Cosmetic Laboratories, LLC's Reply Claim Construction Brief Re U.S. Patent No. 7,388,029, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 455, Filed Dec. 21, 2009 (24 pages).Applicant
Minutes from Markman/Claim Construction Hearing on the '029 Patent, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 462, Filed Jan. 11, 2010 (1 page).Applicant
Minutes in Chambers Order re Claim Construction on the ′029 Patent, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 463, Filed Jan. 12, 2010 (16 pages).Applicant
Order Entering Final Judgment Pursuant to Federal Rule of Civil Procedure 54(b) on Plaintiff Allergan, Inc.'s Fourth Claim for Relief in Favor of Defendants and Stay of Trial Court Proceedings Pending Appeal, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, Document 526, filed May 5, 2010 (2 pages).Applicant
Defendants' Invalidity Contentions Pursuant to Patent Local Rule 3-3, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, dated Sep. 22, 2008 (315 pages).Applicant
Defendants Athena Cosmetics, Inc., Pharma Tech International, Inc., and Northwest Cosmetic Laboratories, Inc.'s Preliminary Invalidity Contentions Pursuant to Patent Local Rule 3-3, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, dated Aug. 24, 2009 (102 pages).Applicant
Defendant Athena Cosmetics, Inc.'s Supplemental Invalidity Contentions Pursuant to Patent Local Rule 3-3, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, dated Feb. 9, 2009 (38 pages).Applicant
Defendant Athena Cosmetics, Inc.'s Supplemental Invalidity Contentions Pursuant to Patent Local Rule 3-3, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, dated Feb. 20, 2009 (320 pages).Applicant
Plaintiffs' Responses to Athena Cosmetics, Inc.'s Second Set of Interrogatories (Nos. 3-7), U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, dated Feb. 1, 2010 (14 pages).Applicant
Defendants Athena Cosmetics, Inc., Pharma Tech International, Inc., and Northwest Cosmetic Laboratories, Inc.'s Supplemental Invalidity Contentions Pursuant to Northern District Patent Local Rules 3-3 and 3-7, U.S. District Court, Central District of California (Southern Division), Allergan, Inc. et al. v. Cayman Chemical Company et al., Case No. 8:07-cv-01316-JVS-RNB, dated Mar. 18, 2010 (25 pages).Applicant
Brief of Defendant-Appellants Apotex Inc., Apotex Corp., Sandoz, Inc., and Hi-Tech Pharmacal Co., Inc. in the United States Court of Appeals for the Federal Circuit, Case No. 2013-1245, -1246, -1247, filed May 13, 2013 (198 pages).Applicant
Appellees' Responsive Brief in the United States Court of Appeals for the Federal Circuit, Case No. 2013-1245, -1246, -1247, filed Jul. 29, 2013 (80 pages).Applicant
B. W. Griffin et al., FP Prostaglandin Receptors Mediating Inositol Phosphates Generation and Calcium Mobilization in Swiss 3T3 Cells: A Pharmacological Study, J. Pharmacol. Exp. Ther. (1997) 281(2):845-854.Applicant
C.S. Harmon et al., Protein Kinase C Inhibits Human Hair Follicle Growth and Hair Fibre Production in Organ Culture, Br. J. Derm. (1995) 133:686-693.Applicant
Carl B. Camras, Mechanism of the Prostaglandin-Induced Reduction of Intraocular Pressure in Humans, in Advances in Prostaglandin, Thromboxane, and Leukotriene Res. 519-525 (B. Samuelsson et al., eds., vol. 23, 1995).Applicant
Charles Mark Ensor and Hsin-Hsiung Tai, 15-Hydroxyprostaglandin Dehydrogenase, J. Lipid Mediators Cell Signalling (1995) 12: 313-319.Applicant
Gerald R. Zins, The History of the Development of Minoxidil, Clinics in Derm. (1988) 6(4):132-147.Applicant
Gerd Linder et al., Involvement of Hepatocyte Growth Factor/Scatter Factor and Met Receptor Signaling in Hair Follicle Morphogenesis and Cycling, 14 FASEB J. 313-319 (2000).Applicant
Hiroyuki Toh et al., Molecular Evolution of Receptors for Eicosanoids, 361 Fed. Eur. Biochem. Soc. 17:21 (1995).Applicant
International Publication No. WO 92/02496 (Feb. 20, 1992).Applicant
J. Chen et al., AGN 191129: A Neutral Prostaglandin F2α (PGF2α) Analog That Lacks the Mitogenic and Uterotonic Effects Typical of FP Receptor Agonists, 40 IOVS S675 (Abstract 3562-B420) (1999).Applicant
J.L.Burton & A. Marshall, Hypertrichosis Due to Minoxidil, 101 Br. J. Derm. 593-595 (1979).Applicant
J.W. Regan et al., Cloning of a Novel Human Prostaglandin Receptor with Characteristics of the Pharmacologically Defined EP2 Subtype, 46 Molecular Pharm. 213-220 (1994).Applicant
James P. Bennett, Jr., Methods in Binding Studies, in Neurotransmitter Receptor Binding, (H.I. Yamamura et al., eds., 1978) 57-90.Applicant
Jonathan Hadgraft, Prodrugs and Skin Absorption, in Design of Prodrugs (H. Bungaard ed., 1985) 271-289.Applicant
K.S. Stenn & R. Paus, Controls of Hair Follicle Cycling, 81 Physiol. Rev. 449 (Jan. 2001).Applicant
L.E. Anderson et al., Prostaglandin Moieties that Determine Receptor Binding Specificity in the Bovine Corpus Lutem, 116 J. Reproduction Fertility 133-141 (1999).Applicant
Laszlo Z. Bito, Prostaglandins: A New Approach to Glaucoma Management with a New, Intriguing Side Effect, 41(2):S1-14 Sur. Ophthalmol. (1997).Applicant
Marianne Nelson O'Donoghue, Eye Cosmetics, 18 Derm. Aspects Cosmetics 633-639 (2000).Applicant
Masayuki Nakajima et al., Effects of Prostaglandin D2 and its Analogue, BW245C, on Intraocular Pressure in Humans, 229 Graefe'S Arch. Clin. Exp. Ophthalmol. 411-413 (1991).Applicant
Michael R. Goldberg, Clinical Pharmacology of Pinacidil, A Protype for Drugs That Affect Potassium Channels, 12(Supp 2):541-547 J. Cardio. Pharm. (1988).Applicant
Per J. Wistrand et al., The Incidence and Time-Course of Latanoprost-Induced Iridial Pigmentation as a Function of Eye Color, 41(2):S129-138 Sur. Ophthalmol.(1997).Applicant
Peter J. Koblenzer & Lester Baker, Hypertrichosis Lanuginosa Associated with Diazoxide Therapy in Prepubertal Children: A Clinicopathologic Study, 150 Annals NY Acad. Sci. 373-382 (1968).Applicant
Richard B. Silverman, Drug Metabolism, in The Organic Chemisty of Drug Design and Drug Action 277 (1992).Applicant
Richard B. Silverman, Prodrugs and Drug Delivery Systems, in the Organic Chemisty of Drug Design and Drug Action 352 (1992) 352-401.Applicant
Richard A. F. Dixon et al., Cloning of the Gene and cDNA for Mammalian β-Adrenergic Receptor and Homology with Rhodopsin, 321 Nature 75-79 (1986).Applicant
Shuh Narumiya et al., Prostanoid Receptors: Structures, Properties, and Functions, 79 Physiol. Rev. (1999) 1193-1226.Applicant
Yasumasa Goh et al., Prostaglandin D2 Reduces Intraocular Pressure, 72 Br. J. Ophthalmol. 461-464 (1988).Applicant
Yukihiko Sugimoto et al, Failure of Parturtion in Mice Lacking the Prostaglandin F Receptor, 277 Science 681-683 (1997).Applicant
Khidhir, K.G. et al., “The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias,” The FASEB J. (2013) 27:11p.Applicant
Opinion of the United States Court of Appeals for the Federal Circuit, Allergan, Inc. et al. v. Apotex Inc. et al., Case No. 13-1245, decided Jun. 10, 2014 (41 pages).Applicant
Notice of Entry of Judgment of the United States Court of Appeals for the Federal Circuit, Allergan, Inc. et al. v. Apotex Inc. et al., Case No. 13-1245, decided Jun. 10, 2014 (1 page).Applicant
Corrected Combined Petition of Plaintiffs-Appellees Allergan, Inc. And Duke University for Panel or Enbanc Rehearing, United States Court of Appeals of the Federal Circuit, Allergan, Inc. et al. v. Apotex Inc. et al., Case No. 13-1245, filed Aug. 12, 2014 (62 pages).Applicant
Joint Status Report in the United States District Court for the Middle District of North Carolina, Allergan, Inc. et al. v. Apotex Inc. et al., Case No. 1:10-CV-681 dated Jul. 21, 2014 (13 pages).Applicant